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ABSTRACT  
Invariant natural killer T (iNKT) cells are endowed with features of both innate and 
adaptive immunity. They are activated by the recognition of glycolipid agonists 
presented by CD1d which makes them excellent candidates for cellular therapies.  
In order to investigate the ability of iNKT cells to suppress experimental acute Graft 
versus host disease (GVHD), iNKT cells were first expanded in vitro, which is likely to 
be required prior to their use as a cellular therapeutic. Interestingly, the expanded 
cells showed increased frequencies of IL-10, IL-13 and IL-17 producing cells and 
were found to robustly suppress alloreactive T cell proliferation in vitro compared to 
freshly isolated cells. However, in a model of acute GVHD induced by alloantigen-
reactive TCR-transgenic T cells neither freshly isolated nor expanded iNKT cells 
suppressed GVHD, although some survival benefit was seen following the activation 
of host iNKT cells.  
These data indicate that iNKT cells can be expanded ex vivo, that they can acquire 
different functional properties and that such cells robustly suppress alloreactive T cell 
proliferation in vitro. Therefore, further investigation into the suppressive behaviour of 
these cells is warranted despite a failure to suppress acute GVHD in the current 
study.   
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Mb megabase 
MCMV murine cytomegalovirus  
MCP Methyl-accepting chemotaxis protein  
MDSCs myeloid derived suppressor cells  
MFI Median Fluorescence intensity  
mHC Minor histocompatibility antigens  
MHC Major histocompatibility complex 
MIG Monokine induced by gamma interferon  
min minutes 
MIP Macrophage inflammatory protein 
MLN Mesenteric lymph node 
MS Multiple Sclerosis  
MSCs mesenchymal stem cells  
mTEC medullary thymic epithelial cells  
mTOR mammalian target of rapamycin 
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells  
NK Natural killer 
NKR Natural killer receptor 
NKT cells Natural killer T cells 
NKTFH Follicular helper Natural Killer T  
NLRs Node like receptors 
NO nitric oxide 
NOD non-obese diabetic  
nTreg natural (thymically derived) Treg  
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OCH 2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-N-tetracosanoyl-2-
amino-1,3,4-nonanetriol 
OCT optimum cutting temperature cryopreservation media  
PAMPs Pathogen associated molecular patterns 
PBS Phosphate-buffered saline 
PD1 Programmed cell death protein 1  
PDL-1 Programmed cell death protein ligand 1  
PIP2 phosphatidylinositol bisphophate  
PKC protein kinase c  
PLC-γ  phospholipase C-γ  
PLZF  promyelocytic leukaemia zinc finger  
PMA para-Methoxyamphetamine 
PRRs Pathogen recognition receptors 
r Recombinant  
r.t. room temperature 
RA Rheumatoid arthritis  
RAG lymphoid specific recombinase  
RLRs RIG-like receptors 
RNA Ribonucleic acid 
RORγ Retinoic acid receptor-related orphan receptor gamma  
RORγT RAR-related orphan receptor gamma thymus  
ROS reactive oxygen species  
RSS recombination signals sequence  
SAP signalling lymphocytic-activation molecule -associated 
protein 
sec seconds 
SI  Small intestine 
siRNA Small interfering Ribonucleic acid 
SLAM signalling lymphocytic-activation molecule  
SLP-76 SRC-homology 2 (SH2)-domain containing leukocyte protein 
75kD 
STAT signal transducer of activation  
TALENs Transcription activator-like effector nucleases 
T-bet T-box transcription factor  
TBI total body irradiation 
TCD BM T cell depleted bone marrow  
TCF1 T Cell Factor 1  
Tcon conventional T cells  
TCR t cell receptor 
TGF-β Transforming growth factor beta-1  
Th T helper 
TIGIT T cell immunoglobulin and immunoreceptor tyrosine-based 
inhibition motif domain 
TIM-3 immunoglobulin and mucin domain 3  
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TLRs Toll like receptors 
TNF Tumour necrosis factor 
Tr1 type 1 regulatory T cells  
Treg Regulatory T cells 
VDJ variable, diversity and joining  
WT wild type 
ZAP-70  PTK zeta chain-associated protein  
αGal alpha galactosylceramide 
β2M Beta 2 microglobulin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
 
CHAPTER 1 INTRODUCTION 
 
 
 
 
 
 
 
 
1.1. The Immune system 
1.1.1. The innate Immune system  
The immune system has evolved to protect organisms against infectious agents and 
maintain homeostasis. It is generally regarded to be made up of two arms; namely 
the innate immune system and the adaptive immune system. The innate immune 
system is the first line of defence against invading microbes. Pathogen recognition 
receptors (PRRs) are expressed by innate immune cells, such as macrophages and 
dendritic cells (DCs) and recognise conserved microbial antigens known as pathogen 
associated molecular patterns (PAMPs). In addition, some PRRs can be triggered by 
the products of cellular damage known as damage-associated molecular patterns 
(DAMPs), which are endogenous stress-induced self-molecules (1, 2).  
There are several families of PRRs, such as Toll Like Receptors (TLRs), NOD-like 
receptors (NLRs), C-type lectin like receptors (CLRs) and RIG-I like receptors (RLRs) 
20 
 
(3). PRR activation leads to activation of downstream signalling molecules which 
initiate the innate immune response and leads to the upregulation of Major 
histocompatibility (MHC) molecules and co-stimulatory molecules on antigen-
presenting cells (APCs). In response to their activation APCs also produce cytokines 
such as Interleukin (IL)-12 and IL- 18 and the cytokine milieu which they provide 
directs the differentiation of T cells. Once they have been activated by the binding of 
PAMPs to PRRs, the APCs are then regarded as mature, and have the capacity to 
not only present antigen but also to provide the co-stimulatory signals and cytokines 
that are necessary for a productive T cell response (2).  
 
1.1.2. The Adaptive Immune system  
The adaptive immune system is characterised by highly-specific antigen recognition, 
the generation of a huge repertoire of antigen receptors and the formation of memory 
cells that rapidly respond on secondary encounter of an antigen, resulting in a 
prophylactic response and faster clearance of antigen. The main cellular constituents 
of the adaptive immune system are T and B cells which bear receptors (T cell 
receptor (TCR) and B cell receptor (BCR)) that enable recognition of antigens in their 
native form or in the case of T cells as a peptide presented in the context of MHC (4). 
In contrast, following recognition of native antigen by the BCR, activated B cells 
develop into plasma cells which secrete antibodies with the same specificity as the 
BCR to, for example, neutralise the antigen, or enhance opsonisation of antigen-
bearing cells (5). Conventional alpha beta (αβ) T cells can be divided into two broad 
categories Cluster of differentiation (CD)8+ effector T cells and CD4+ Helper T cells 
(Th cells). The main function of CD8+ T cells is to kill pathogen-infected or cancer 
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cells (6). Th cells can be further divided into four main classes Th1, Th2, Th17 and 
regulatory T cells (Treg) (7). 
 
1.1.3. Major histocompatibility complex (MHC) 
In humans the MHC region includes a series of genes on chromosome 6p21.31, 
which spans 3.75 Megabase (Mb) and codes more than 120 genes (8, 9). 
Approximately 40% of these genes have a function in the immune system (9). Among 
these are the class I and class II Human leukocyte antigens (HLA). HLA class I 
antigens are divided into classical HLA class I (HLA-A, B, C) and non-classical (HLA-
E, F, G) and HLA class II molecules (classical HLA DP, DQ and DR) and non-
classical (HLA-DO and HLA-DM)) (10) (Table 1). As HLA mismatching is amongst 
the strongest risk factors for the development of both acute and chronic Graft versus 
host disease (GVHD), HLA matching has become a cornerstone in pre-transplant 
donor evaluation (11). While the norm in clinical practice is to HLA match donors and 
recipients where possible, minor histocompatibility complex (mHC) antigens may also 
lead to GVHD (12). mHC antigens are polymorphic peptides which may lead to 
recognition by T cells in the context of allogeneic transplantation and can therefore 
act as alloantigens.    
In mice MHC molecules are called H-2 and are located on chromosome 17 (13). 
Similarly to humans they can be divided into class I (or MHCIa and MHCIb) and MHC 
class II (MHCIIa and MHCIIb) (14) (Table 1). MHC-Ia (classical-MHC class I) is made 
up of H-2D, H-2K and H-2L molecules and MHCIb (non-classical MHC class I) 
contains H-2Q, H-2M and H-2T molecules (14) (Table 1). MHC-IIa (classical MHC 
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class II) comprises H-2A (I-A) and H-2E (I-E), and finally MHC-IIb (non-classical MHC 
class II) contains H-2M and H-2O (14) (Table 1). MHC molecules in mice and 
humans are highly polymorphic and many laboratory strains of mice have a specific 
haplotype readily available (13).   
Table 1 Mouse and Human MHC  
MHC Class I MHC class II MHC Class I MHC class II 
Human HLA Human HLA Mouse H2 Mouse H2 
Classical 
HLA- A, B, C 
Classical 
HLA- DP, DQ, DR 
H2Ia (Classical) 
H-2D, H-2K, H-2L 
 
H2IIa (Classical) 
H-2A(I-A), H-2E(I-E) 
Non-Classical 
HLA- E,F,G 
Non-classical 
HLA- DO, DM 
H2Ib (non-classical) 
H-2Q, H-2M and H-2T 
H2IIb (non-classical) 
contains H-2M, H-2O. 
 
The primary function of MHC molecules is to present peptide antigens to T cells 
following processing of the native protein. The process of antigen processing varies 
depending on whether it is to be loaded on MHC class I or class II molecules. MHC 
class I is expressed by all nucleated cells and primarily presents intracellular 
antigens to CD8+ T cells. Some DCs can also present exogenously-derived antigen 
through the process of cross-presentation (15). MHC class II is constitutively 
expressed on professional APCs and additionally can be upregulated in response to 
Interferon (IFN)-γ (16, 17). MHC class II typically presents exogenously-acquired 
peptides to CD4+T cells.  
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1.1.4. T cell development in the thymus  
T cells originate in the bone marrow (BM), however their commitment to the T cell 
lineage occurs in the thymus. The process of variable, diversity and joining (VDJ) 
recombination is a process that involves the random splicing of different VDJ genes 
in order to generate a vast repertoire of TCR capable of recognising a panoply of 
antigens. The T cells then undergo an ordered selection process which favours the 
selection of potential useful TCRs, whilst avoiding the selection of potentially self-
reactive TCRs. This enables the adaptive immune system to eradicate a vast array of 
pathogens whilst preventing the unwanted activation by self-reactive T cells and 
ensuing autoimmune disease. 
Common lymphoid progenitor cells enter the thymus at the corticomedullary junction. 
Such immature thymocytes then migrate to the outer cortex where they undergo a 
series of well-established differentiation processes. At this point the thymocytes are 
committed to the T cell lineage but lack TCR and CD4 and CD8 expression and are 
referred to double negative (DN) (18-20). The DN thymocytes progress through 4 
stages of differentiation from DN1 to DN4 (21).  
β-chain rearrangement occurs between the DN2 and DN4 stages. The variable (V), 
diversity (D) and joining (J) gene segments are recombined to make a functional 
gene in the process of VDJ recombination. Specific sequence motifs called 
recombination signals sequence (RSS) flank gene segments that can be 
recombined. The products of the recombinase genes lymphoid specific recombinase 
(RAG)-1 and lymphoid specific recombinase RAG-2 form the lymphoid specific 
recombinase which bind to the RSS and bring together the specific gene segments 
that are to be recombined and cleave the Deoxyribonucleic acid (DNA) (22). The 
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individual gene segments to which the lymphoid specific recombinase binds are 
selected at random from a number of copies that are present at each gene locus and 
thus are responsible for the highly diverse TCR repertoire of conventional T cells.(23)  
TCR-β recombination occurs during the DN2 and DN3 stages of thymocyte 
development (24, 25). First the Dβ-is recombined to Jβ and then Vβ is recombined to 
DβJ (26). A process called allelic exclusion occurs, which means that only one of two 
possible alleles is expressed at a time, meaning each individual cell only expresses 
one TCR-β chain (27). Following rearrangement of the TCR-β chain is expressed 
with a non-rearranged pre-Tα which is necessary for allelic exclusion (28-30). 
 TCR-α gene rearrangement occurs differently as approximately 30% of mature αβ T 
cells express two productive TCRα gene rearrangements (31). TCR-α gene 
segments recombines the V and J segments in a non-random manner (32, 33). 
Theoretically, there are 1015 possible TCR combinations in humans (34, 35), however 
this is 1000 fold higher than actual human T cell repertoires. The newly rearranged α-
chain replaces the pre α-chain which leads to the cells being expressing αβTCR. 
Such cells are CD4+CD8+ double positive (DP). 
 DP thymocytes then undergo positive selection, in which cortical epithelial cells 
present self-peptide in the context of MHC class I and MHC class II molecules. The 
outcome of this interaction is dependent on the strength of the signal, too weak a 
signal leads to cell “death by neglect”, while too strong a signal leads to death via 
apoptosis (negative selection) (36, 37). This mechanism which is critical to central 
tolerance is a means by which strongly self-reactive T cells do not enter the 
periphery. 
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Thymocytes that recognise self-peptide present on MHC class I become committed 
CD8+ T cells and thymocytes that recognise self-peptide presented on MHC class II 
become committed CD4+ T cells (38). During negative selection, autoimmune 
regulator (AIRE) expressing medullary thymic epithelial cells (mTECs) and thymic 
DCs present tissue specific antigens which helps to negatively select T cells that 
would be autoreactive in the periphery (39-41). The medulla is also where factor 
forkhead box P3 (FOXP3) Treg are produced in response to antigens presented on 
mTEC (42). Thymocytes further mature for several days in the medulla before thymic 
egress occurs and the cells migrate to the periphery as fully functional mature 
thymocytes (43).  
T cells undergo this lengthy process of T cell development in the thymus in which 
they are positively and negatively selected. However, notwithstanding this, mature T 
cells exhibit a high frequency of cross-reactivity or alloreactivity to foreign peptide-
MHC complexes despite the fact that they have not previously encountered the MHC 
variant of antigen. This is a result of the inherent ability of T cells to recognise peptide 
MHC complexes (44, 45).  
 
1.1.5. The T cell receptor (TCR) and T cell activation  
T Cells are activated in the periphery to become functional mature T cells which can 
elicit damage during GVHD. This process is initiated by the presentation of antigen 
by MHC class I or MHC class II molecules on APCs. In order to be successfully 
activated T cells require three signals. The first signal is provided by the peptide in 
the context of an MHC molecule (46, 47). CD4 or CD8 molecules then stabilise the 
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complex (48). The second signal is provided by co-stimulatory molecules which are 
upregulated on APCs in response to infection or tissue injury (49-51). The best 
characterised interaction occurs between CD28 on the T cell and CD80 and CD86 on 
the APC (49-52).The third signal is provided by cytokines, the nature of which leads 
to the differentiation of Th cells into particular subsets, for example IL-12 promotes 
differentiation into Th1 cells (53). These external signals lead to the recruitment of 
intracellular effector molecules and adaptor proteins which lead to the activation, 
differentiation and proliferation of effector T cells.  
 
1.1.6. TCR intracellular signalling  
The term immunological synapse is used to refer to interface between the APC and T 
cells (54). In the case of GVHD the APC presents alloantigen. The interactions which 
occur at the immunological synapse lead to intracellular signalling leading to the 
activation and proliferation of T cells. The TCR receptor is composed of either an α 
and β chain or a γ and a δ chain (55, 56). The 2 TCR chains are bound together by 
disulphide bond subunits (55). The αβ TCR complex also includes a CD4 or CD8 co-
receptor with the tyrosine kinase Lck (57, 58), as well as the CD3 complex which 
consists of two ε chains, a γ chain, δ chain and two ζ chains (59, 60). Each of the 
CD3 chains has at least one copy of the immunoreceptor tyrosine-base motif (ITAM) 
in the cytoplasmic domain (61-65). CD45 which contains a tyrosine phosphatase 
enzyme in its cytoplasmic domain is also involved (66).  
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The signalling is initiated by triggering of the TCR, leading to the activation of 
intracellular src family kinase enzymes such as fyn. Upon activation fyn kinase 
phosphorylates the ITAMS of the CD3 subunits, which can then act as binding sites 
for a second kinase PTK zeta chain-associated protein (ZAP-70) (67). ZAP-70 binds 
the phosphorylated zeta chain (67). In addition the co-receptor can bind to the same 
peptide MHC complex (58). This results in lck coming into close proximity with ZAP-
70, which leads to lck phosphorylating and hence activating Zap70 (68). Upon 
activation ZAP-70 can bind to and activate a number of intracellular adaptor proteins. 
which in turn can activate other signalling pathways within the cell (69). ZAP-70 
phosphorylates linker for activation of T cells (LAT) and SRC-homology 2 (SH2)-
domain containing leukocyte protein 75kD (SLP-76) (69, 70). This leads to the 
activation of phospholipase C-γ (PLC-γ) and Ras (71-74).  
PLC-γ cleaves phosphatidylinositol bisphophate (PIP2) into inositol triphosphate (IP3) 
and diacylglycerol (DAG), which act as second messengers required for intracellular 
Ca2+ release and protein kinase c (PKC) activation (75). These second messengers 
lead to the activation of transcription factors Nuclear factor of activated T cells 
(NFAT), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and 
Activator protein-1 (AP-1), which translocate to the nucleus and promote the 
expression of genes required for proliferation, IL-2 production and T cell survival and 
differentiation (76, 77).   
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1.1.7. T cell subsets 
T cells can be divided into two broad subsets based on the expression of CD4 and 
CD8 co-receptors (78). CD4+ T cells can be further divided according to transcription 
factor and cytokine expression. Each subset of Th cells arises when naïve T cells 
encounter antigen in a certain local microenvironment in terms of the cytokine milieu 
and the availability of co-stimulatory molecules (2). This endows Th cells with the 
capacity to mount a response appropriate to the perceived threat. Th cells mainly 
elicit their effector functions through cytokine production.  
Mossman and Coffman were the first to describe Th1 and Th2 cells according to 
cytokine production (79). Th1 cells primarily produce IFN-γ and express the cytokine 
T-box transcription factor (T-bet), while Th2 cells express GATA Binding Protein 3 
(GATA3) and produce the signature cytokine IL-4 (80-82). Later cells that express 
RAR-related orphan receptor gamma thymus (RORγT) which predominantly produce 
IL-17 were discovered, which were subsequently termed Th17 cells (83, 84). This 
has culminated as a model in which proinflammatory Th cells are divided into the 
subsets based on cytokines and transcription factor expression. There is growing 
evidence for plasticity between the subsets, for example Th17 cells can develop the 
ability to produce IFN-γ (85, 86).  
CD8+ T cells are also known as cytotoxic T cells and they play an important role in 
killing virally infected cells and cancer cells (6). Upon recognition of cognate peptide 
presented by MHC class I, CD8+ T cells undergo clonal expansion to increase the 
frequency of T cells specific for the target antigen (87). Activated CD8+ T cells 
typically lyse target cells by inducing apoptosis by perforin and granzyme or through 
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FAS-FAS Ligand (FAS-L) interactions (88). Both CD4+ and CD8+ T cells contribute to 
the effector mechanisms that occur in GVHD.  
 
1.1.8. Immune regulation and tolerance induction  
As discussed previously, central tolerance takes place in the thymus and leads to the 
deletion of self-reactive T cells. However, this process is incomplete and therefore 
additional peripheral mechanisms are required to suppress autoreactive T cells in 
order to prevent autoimmune diseases. These include but are not limited to induction 
of anergy, autocrine feedback loops and suppression with regulatory cell populations 
such as Treg.  
T cell anergy occurs in vitro upon the activation of T cells with their cognate antigen-
MHC complex in the absence of co-stimulation (89). This leads to a state of active 
unresponsiveness where T cells do not respond to subsequent exposure to antigen 
even in the presence of co-stimulation (90-93). Anergic T cells have been shown to 
have an altered transcriptional programme with enhanced expression of genes such 
as Cbl-b and Gene related to anergy in lymphocytes (GRAIL) that target various 
signalling molecules used by TCR and co-stimulatory molecules for degradation by 
the proteasome via targeted ubiquitination (94, 95). There is also an immunological 
state commonly referred to as immunological ignorance in which self-reactive 
lymphocytes coexist with self-antigen without reacting. This is as a result of the 
antigen in question either being present at too low a concentration to induce a 
response or binding too weakly to induce a response or indeed being inaccessible to 
lymphocytes (4).  
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Inducing apoptosis in autoreactive cells has also been shown to be a mechanism of 
suppression employed against autoreactive and alloreactive T cells and this has 
been shown to occur in Experimental autoimmune encephalomyelitis (EAE; a mouse 
model for multiple sclerosis (MS)), a mouse model of oral tolerance and in transgenic 
mice capable of recognising the influenza virus hemagglutinin (HA) (96-98). In these 
cases apoptosis occurs as a result of repeat high dose stimulation with antigen, for 
example, repeat administration of myelin basic protein in EAE (96). Apoptosis as a 
result of a potent antigenic signal is thought to be a homeostatic mechanism that 
prevents the immune response causing collateral damage due to excessive 
inflammation caused by the unrestricted expansion of a particular clonotype or 
chronic antigen stimulation (99). Apoptosis can also be induced in the absence of co-
stimulation, as co-stimulation leads to the production of anti-apoptotic genes such as 
B-cell lymphoma-extra large (BCL-XL) and enhances the production of growth factors 
such as IL-2, and their receptors (100).  
Autoreactive T cells in the periphery can also be prevented from causing 
autoimmune disease by a process termed immune deviation. For example in the 
case of Anterior Chamber Associated Immune Deviation (ACAID) inhibition of 
activation and differentiation of T cells into Th1 cells occurs (101). Transforming 
growth factor beta-1  (TGF-β) produced by peritoneal exudate cells and acting on 
APCs, causes T cells to secrete IL-4 and not IFN-γ (101).  
Treg play a major immunosuppressive function in the periphery. Treg were first 
discovered in 1972, when they were termed suppressor cells (102). Much 
controversy surrounded the existence of such cells (103) and it wasn’t until 1995 that 
they were rediscovered by Sakaguchi et al. (104). Sakaguchi showed that CD4+ T 
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cells which expressed the IL-2 receptor (IL-2r) α chain (CD25) had the capacity to 
prevent T cell mediated autoimmune diseases when adoptively transferred from 
naïve adult mice (104, 105). Treg function was later shown to be under the control of 
lineage specific transcription FOXP3 (106, 107). FOXP3 has been shown to be 
necessary for the conversion of naïve Th cells into Treg, and mutations in the foxp3 
gene results in defective thymic generation of Treg and importantly rampant 
autoimmune disease (106, 107). Scurfy mice lack functional CD4+FOXP3+ Treg and 
develop a lymphoproliferative disease which affects multiple organs especially the 
skin, lung and liver (108, 109). In addition, the human disease immune dysregulation, 
polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome occurs as a result of 
mutations in the FOXP3 gene and results in Treg dysfunction and severe 
autoimmunity (110, 111) 
Treg are usually divided into two broad categories, those which are differentiate in 
the thymus derived (natural Treg (nTreg) or thymus-derived (tTreg)) and those that 
differentiate from naïve T cells in the periphery (inducible Treg (iTreg) or peripheral-
derived (pTreg) (112, 113). nTreg develop in the thymus and required recognition of 
self-antigens on mTEC (114). On the other hand, iTreg are generated in the 
periphery following antigen-recognition in the presence of TGF-β (115-117). In 
addition to FOXP3+ Treg it is worth noting that a number of other T cells with 
regulatory activity have been identified such as type 1 regulatory T cells (Tr1) cells 
which make IL-10 and Th3 cells that make TGF-β (118). Furthermore, CD8+ 
regulatory T cells that produce IL-10 and TGF-β have also been identified (119, 120).  
In addition to regulatory populations of T cells, innate cells can also be 
immunosuppressive. One such population is myeloid derived suppressor cells 
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(MDSCs). MDSCs were originally described as CD11b+Gr1+ in mice (121, 122). 
However the term now covers a heterogeneous population of cells, involving both 
monocytic and granulocytic cells, which have been extensively characterised in 
contributing to the suppressive microenvironment of tumours (123). While they can 
produce immunosuppressive cytokines such as IL-10 and TGF-β, in a pathological 
context they can also induce nitric oxide (NO) and reactive oxygen species (ROS) 
through inducible nitric oxide synthase (iNOS) and arginase-1 (ARG 1) respectively 
(118). Such molecules can induce apoptosis in alloreactive T cells (124). In addition 
they can mediate suppression indirectly by recruiting Treg as has been shown in 
models of heart transplant and GVHD (125, 126).  
The Holy Grail in transplant research is to achieve operational tolerance. Operational 
tolerance is a state in which the immune system is unresponsive to the transplant 
while simultaneously maintaining the ability to mount an immune response against 
infection and cancer. It is important to understand the various forms of immune 
mediated suppression in order to design better therapies to combat GVHD in 
Haematopoietic stem cell (HSC) transplant.   
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1.2.  Pathways of allorecognition 
Mismatched MHC molecules are a significant risk factor for the occurrence of GVHD 
and transplant related mortality following BM or HSC transplantation (127). There are 
two ways in which T cells within BM grafts can recognise alloantigen in GVHD. The 
first is the direct antigen recognition in which donor T cells directly recognised 
recipient MHC-peptide complexes on recipient APCs (128, 129) (Figure 1.1). The 
second is indirect recognition of alloantigen whereby T cells recognise recipient 
derived peptides from MHC molecules that have been phagocytosed and processed 
and presented in the MHC of donor APCs (128, 129) (Figure 1.1). A third pathway, 
namely the semi-direct pathway has more recently been described in solid organ 
transplantation whereby donor cells may sequester intact recipient MHC+peptide 
complexes via either exosome uptake or trogocytosis (130, 131) (Figure 1.1). 
The TCR has a propensity to bind MHC molecules (44, 45). While T cells undergo 
maturation in the thymus and hence are selected on their ability to form low avidity 
interactions with MHC+peptide complexes, a proportion of T cells exhibit cross-
reactivity to other MHC alleles (132). In addition, memory T cells primed against a 
particular peptide presented by the MHC on which they were selected have also 
been shown to be able to respond to allo-MHC-peptides complexes presenting a 
different peptide (133, 134). Humans and mice usually have a high precursor 
frequency of alloreactive T cells of between 1 and 10% (135-138).  
There are two models of peptide-MHC complex recognition to explain the cross-
reactivity. The first is peptide-dominant binding in which the peptide presented in the 
allo-MHC is tightly bound in the TCR even if the interaction between the TCR and the 
MHC molecule is a weak interaction (139). The second is MHC dominant binding 
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when the MHC molecule provides a stronger interaction with the TCR and the 
peptide presented by the allo-MHC is a less important factor (139). Molecular mimicry 
has been suggested as the reason that T cells can recognise foreign MHC at all, 
although crystal structures have revealed that TCRs recognise self and allo-MHC by 
divergent mechanisms and thus cross reactivity can occur in the absence of 
molecular mimicry (140). At the heart of transplant rejection is the concept that it is 
mediated by T cells that recognise allogeneic MHC molecules.  
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Figure 1.1 Pathways of MHC recognition following HSC transplantation  There are three 
methods of recognition of alloantigen by alloreative T cells. A). Peptide can be recognised by 
direct methods in which donor T cells directly recognised MHC-peptide complexes on 
recipient APCs cells. B). Indirect recognition occurs when donor T cells recognised recipient 
derived peptides from MHC molecules that have been phagocytosed and processed and 
presented in the MHC of donor APCs. C). In semi-direct recognition donor cells obtain 
recipient MHC molecules via either exosome uptake or trogocytosis which are recognised by 
donor T cells.  
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1.3. Bone Marrow (BM) and Haematopoietic stem cell (HSC) transplantation  
1.3.1. Bone marrow transplantation (BMT) as a curative treatment for 
leukaemia, lymphoma and myeloma 
As outlined previously the immune system is essential to recognise and fight disease 
whilst maintaining homeostasis. Therefore it is not surprising that medical procedures 
that involve perturbing immune homeostasis have a profound effect and are strongly 
influenced by the immune system, as is the case with HSC transplantation. HSC 
transplantation is a curative treatment for leukaemia, lymphoma and myeloma. The 
first HSC transplant was performed in 1959 (141). Prior to HSC transplantation, the 
patient receives myeloablative conditioning generally in the form of lethal irradiation 
and chemotherapy. High dose irradiation leads to increased clearance of tumour 
cells, and additionally results in the loss of a patient’s haematopoietic cells, and 
therefore the patient requires a HSC transplant to reconstitute the hematopoietic 
system. 
HSCs are administered via intravenous (i.v.) infusion and are often from a genetically 
distinct donor. HSC can be derived from BM, peripheral blood or umbilical cord blood 
(142-144). As well as reconstituting the patient with a healthy haematopoietic system, 
the use of an allogeneic transplant has the added benefit of mediating anti-tumour 
effects (referred to as the graft versus leukaemia effect (GVL) or graft versus tumour 
(GVT) effect). These anti-tumour effects are mediated by contaminant donor T cells 
present within the HSC preparation, and are associated with decreased disease 
relapse (145-148). However, the same cells responsible for the GVT effect are also 
responsible for the induction of GVHD.  
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1.3.2. The immunobiology of Graft versus host disease (GVHD) 
Acute GVHD is defined as GVHD which occurs in the first 100 days after 
transplantation, as opposed to chronic GVHD which is observed greater than 100 
days post-transplant. It is a major cause of mortality and morbidity amongst the 
30,000 recipients transplanted annually, worldwide. 
 
1.3.2.1. Initiation 
The classical description of GVHD begins with the activation of PRRs and the 
release of chemokines, microbial products and other PAMPs (Figure 1.2). This leads 
to the activation of innate immune cells, including APCs, upregulation of MHC 
molecules and production of proinflammatory cytokines such as IL-1, IL-6, and 
Tumour necrosis factor (TNF)-α (149, 150). Total body irradiation (TBI) also induces 
endothelial apoptosis in the gastrointestinal tract (GI) tract, which leads to epithelial 
cell damage, this also leads to the release of PAMPs such as lipopolysaccharide 
(LPS), which are usually sequestered away, to be released into circulation which 
further perpetuates the inflammatory response (151, 152). HSC transplants which 
contain monocytes and macrophages which are resistant to LPS but are otherwise 
normal have been shown to produce significantly less TNF-α, accompanied by 
reduced GVHD in the GI (153). Disruption of the intestinal epithelia can also lead to 
commensal bacteria translocating into deeper tissue where they can cause infection 
and septicaemia (154). Furthermore, the intensity of the conditioning regime 
positively correlates with the severity of GVHD further emphasising the impact of 
radiation induced damage (155, 156). 
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1.3.2.2. T cell activation 
Activated recipient APCs present self-antigen to donor T cells which leads to 
activation of alloreactive donor T cells and subsequent release of additional 
proinflammatory cytokines, which contribute to the cytokine storm and further 
proliferation of the T cells (157) (Figure 1.2). Although direct presentation is critical in 
the case of a fully MHC mismatched transplant, mHC mismatched antigens can also 
occur where they are presented in the context of recipient MHC through the indirect 
pathway (157-159). In one model of GVHD, intestinal myofibroblasts have been 
shown to be responsible for the initiation of GVHD although it is generally accepted 
that DCs are the most potent APCs capable of initiating GVHD responses (160, 161). 
The inflammatory environment with elevated inflammatory cytokines, PAMPs, 
DAMPs and gut commensals can all activate DCs, causing them to exhibit a more 
mature phenotype capable of activating T cells. 
The second signal of T cell activation, namely co-stimulation is also required to 
activate alloreactive T cells. Indeed co-stimulatory molecule blockade has proven to 
be an effective strategy to reduce GVHD in some models (162). In mouse models of 
GVHD the nature of the T cell response is dependent on the alloantigen presented. 
Alloantigen presented by MHC class I cells leads to a CD8 driven model, while 
alloantigen presented by MHC class II leads to a CD4 driven model (163).  
In terms of the polarity of the Th response, Th1 cytokines are predominantly 
produced and are implicated in the pathology of GVHD. IFN-γ is a crucial cytokine in 
the initiation of GVHD and it is markedly elevated in mice with GVHD (154). IFN-γ 
can lead to the upregulation of MHC molecules, which leads to pathology in the skin 
and GI and a reduction in the amount of LPS which is required to induce NO 
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production by macrophages (164-167). It should be noted that Th1 cells are not the 
only cells with the capacity to produce IFN-γ. While Th1 have classically been shown 
to induce GVHD, Th17 cells also play a role. Until relatively recently, the role of Th17 
cells was disputed. However a study by Yu et al. using T-bet-/- and RORγT-/- mice 
showed that while RORγT-/- mice had little impact on the systemic occurrence of 
GVHD, double knock-out (KO) mice produced less severe GVHD than T-bet-/- mice 
(168). The one drawback to this study is that the KO mice were not cell specific, and 
as such the gene was knocked out in all cells not just Th1 or Th17 cells respectively. 
Chemokines and their cognate receptors play an important role in recruiting 
pathogenic T cells to the target tissues. A plethora of chemokines are known to be 
overexpressed in the target organs. Macrophage inflammatory protein (MIP)-1α and 
MIP-2 and C-X-C motif ligand (CXCL)-9 also known as Monokine induced gamma 
interferon (MIG) are overexpressed in the liver and spleen, while in the skin MIP-1α, 
MIP-2, Methyl-accepting chemotaxis protein 1 (MCP)-1 and MCP-3 are over 
expressed (169). Furthermore, there is an association between onset of liver GVHD 
and the recruitment of chemokine receptor (CCR)5+ T cells which are usually Th1 
cells (170). In terms of the recruitment of CD4+ T cells and CD8+ T cells to the lungs, 
liver and spleen, MIP-1α is important for increasing the recruitment of CD8+ T cells, 
but not CD4+ T cells (169, 171).  
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1.3.2.3. Effector Phase 
The activation of alloreactive T cells leads to further activation of innate cells which 
amplifies the cycle of inflammation. The end-stage result is organ damage with the 
skin, liver, lungs and gut being predominately targeted. The cellular effectors of 
GVHD are alloreactive T cells and Natural Killer (NK) cells (172). NK cells 
predominantly mediated their effect through the Fas-FasL and perforin and granzyme 
pathways but TNF-α and IFN-γ mediated cytotoxicity also plays a role (173). Perforin 
and granzyme mediated cytotoxicity is important in CD8+ T cell driven GVHD, while in 
CD4+ T cell mediated GVHD it appears to be less important than Fas/FasL mediated 
killing (173, 174). Furthermore, Fas-FasL mediated killing is thought to be more 
important in liver and skin damage (175).  
The effector cytokines IL-1 and TNF-α are also thought to play a major role in the 
pathophysiology of GVHD. TNF-α has a pathogenic role in both humans and mice 
(176, 177). In addition to activating DCs and recruiting inflammatory cells TNF-α is an 
important effector molecule in skin and lymphoid tissues (176, 178). Furthermore 
lung damage could be prevented by administration of anti-TNF-α antibodies (179). IL-
1 accumulates in the spleen and the skin during the effector phase (180). However, 
although anti-IL-1R blockade reduces mortality in animal models, unfortunately this 
has not translated to clinical trials (181-183).  
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Figure 1.2 Initiation and maintenance of GVHD  The process of GVHD is initiated by the 
conditioning regime, which usually consists of chemotherapy and irradiation. This causes tissue 
damage, which leads to the release of PAMPs, chemokines and gut commensals. This in turn leads to 
the activation of PRRs and hence the activation of innate immune cells including APCs. This results in 
the production of proinflammatory cytokines. The activated APCs can then go on to present host 
antigen to donor T cells. This results in alloactivation of the donor T cells. The donor T cells produce 
further cytokines and perpetuate the process. The end stage result is tissue damage to the skin, lungs, 
liver and gut. Adapted from Blazer et. al., 2012, Nature Reviews Immunology 12, 443-458.  
1.3.3. GVHD manifestations and clinical occurrence 
Clinically, acute GVHD is classified from grade 0-IV according to number and severity 
of organ involvement (184). The first symptom to appear is generally skin GVHD, 
which is characterised by a maculopapular rash and often occurs contemporaneously 
with the engraftment of donor cells. The GI pathology occurs later and includes 
diarrhoea, nausea, vomiting, cramping and failure to thrive (185). Additionally, liver 
GVHD manifests as hyperbilirubinemia, which presents in the form of jaundice (186). 
Clinical GVHD is graded according the degree of severity from Grade I (mild) GVHD 
to Grade IV (very severe) GVHD according to the modified Seattle Glucksberg 
42 
 
criteria (187-190). The occurrence of GVHD is directly related to the degree of MHC 
mismatch (191). Disease prognosis is related to the severity of GVHD with 5-year 
survival of 25% for grade III and 5% for grade IV disease (192, 193). 
 
1.3.4. Utilising the mechanisms of tolerance to self-antigens to prevent GVHD  
Peripheral mechanisms of immune regulation and tolerance induction can be utilized 
to suppress GVHD. For example inducing apoptosis has been shown to be an 
effective way to suppress GVHD. Targeting heat shock protein 90 using Small 
interfering Ribonucleic acid (siRNA), and hence causing apoptosis of activated T 
cells has also been shown to be effective in preventing GVHD (194). Another 
effective way to prevent GVHD is by blocking co-stimulation, indeed it has been 
shown in a primate model of GVHD that blocking CD28 can control T cell activation, 
thus attenuating GVHD (195).  
Treg have the ability to profoundly affect GVHD, indeed the balance of CD4+CD25+ 
Treg and inflammatory Th cells can determine the outcome of GVHD (196). Their 
ability to suppress GVHD has been shown to be partly dependent on IL-10 and 
partially on CD28 (196, 197). Adoptively transferred Treg have been shown to 
suppress GVHD (196, 198-203). The concern is that Treg may inhibit the anti-tumour 
effect of conventional T cells (Tcon). In some models of GVHD, Treg have been 
shown to suppress GVHD while maintaining the anti-tumour response (200-202). 
However, in non-GVHD mice following vaccination to a rare tumour antigen Treg 
have been shown to suppress the GVT effect (204, 205). The reason for this disparity 
has been postulated to relate to the relatively high precursor frequency of allospecific 
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T cells in many models of GVHD. In this context the expansion of cytotoxic T 
lymphocytes (CTLs) is less important for the anti-tumour effect. While in the tumour 
vaccination setting, the CTL precursor frequency is low and therefore expansion is 
important for CTLs to mediate their anti-tumour effect. Effectively this means that the 
maintenance of the anti-tumour effect in some models of GVHD is due to the 
suppressive effect of Treg inhibits proliferation, but not activation.  
The encouraging results observed in mouse models have led to several clinical trials 
investigating the ability of Treg to suppress GVHD as a potential new therapy. The 
results of a phase 1 clinical trial have shown that early infusion of freshly isolated 
Treg followed by Tcon, prevented GVHD and improved immunity to infection and 
maintained the anti-tumour effect (206). Although this is only a phase 1 trial the 
results are promising. Furthermore, a clinical trial that is currently recruiting for a 
phase 1 trial plans to look at the potential of ex vivo expanded allo specific Treg cells 
to prevent GVHD (207).  
 
1.3.5. Current Methods of GVHD prevention and treatment and mechanisms of 
action 
According to the National Health Service (NHS) protocol, many patients who are at a 
high risk of developing GVHD are treated prophylactically with immunosuppressive 
drugs (187). The first line treatment upon development of GVHD usually includes 
systemic corticosteroids or calcineurin inhibitors (187). However, it has been reported 
that steroid refractory GVHD occurs in 50% of patients (208). Patients that develop 
steroid refractory GVHD have a mortality rate of as high as 95% (209). Second line 
therapies are dependent on the clinical presentation of GVHD and is highly 
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individualised based on the immune response of the patients (187). Table 2 shows 
some of the therapeutic strategies employed to treat GVHD and their mechanisms of 
action as further illustrated in Figure 1.3. The problem with many of these therapies is 
that as well as suppressing GVHD they also dampen down the anti-tumour response, 
which is required for progression free survival. Such therapies also increase 
susceptibility to infection (210).  
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
Table 2 Current treatments for GVHD  
Drug Main mechanism of action References 
Steroids Broad non-specific anti-inflammatory (211) 
Ciclosporin 
(aka Cyclosporine) 
Inhibits calcineurin pathway (212) 
Tacrolimus 
 
FKB506 binding protein (FKBP) thus inhibiting 
calcineurin 
(213) 
Light treatment 
(ECP) 
 
During Extracorporeal photopheresis 
apoptosis is induced in lymphocytes which  
causes processing of these cells and the 
subsequent immune response is likely 
responsible for the protective effect 
(214) 
Monoclonal 
antibodies: 
a). Alemtuzumab 
(Campath) 
b). Infliximab 
(Remicade) 
c). Rituximab 
(Mabthera) 
 
a). Anti-CD52, binds CD52 which is expressed 
on mature lymphocytes, targeting them for 
destruction 
b).Anti-TNF-α, block proinflammatory 
cytokineTNF-α 
c). Anti-CD20. Likely works through leading to 
the depletion of Programmed cell death 
protein ligand (PDL) 1hi B cells and T follicular 
helper cells 
(215) 
(216) 
(217) 
Mammalian target of 
rapamycin (mTOR) 
inhibitors: 
a).Sirolimus 
(Rapamune) 
b).Everolimus 
 
 
a, b). Bind to FKBP12 which inhibits mTOR 
signalling thus preventing IL-2 mediated signal 
transduction and hence arrested cell cycle 
progression 
(218) 
(219) 
Tyrosine kinase 
inhibitors 
 
Inhibits the Janus kinase (JAK)/ signal 
transducer of activation (STAT) signalling 
pathway with is essential for lymphocyte 
function 
(220) 
Etanercept 
 
TNF receptor II-Fc fusion protein, blocks 
proinflammatory cytokineTNF-α 
(216) 
Thaliodomide 
 
Allows antigen specific suppressor cells to 
develop but inhibits precursor cytotoxic cell 
development 
(221) 
Mycophenolate 
mofetil 
 
Inhibits inhibitor of inosine monophosphate 
dehydrogenase (IMPDH) an enzyme that is 
required for guanine synthesis which B and T 
cells are very dependent on 
(222) 
Pentostatin 
 
Purine analogue, 
reduces DNA synthesis 
(223) 
Methotrexate 
 
Antiproliferative (224) 
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Figure 1.3 Current treatments for GVHD Current methods of treating GVHD are mainly non-specific 
and risk dampening the anti-tumour response. They can be broken down into several categories 
namely mTOR inhibitors, monoclonal antibodies, cell cycle inhibitors, tyrosine kinase inhibitors, anti-
proliferative agents, broadly acting anti-inflammatory drugs, calcineurin inhibitors and other treatments 
such as light treatment. The exact mechanisms of action of these drugs are described in Table 2.     
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1.3.6. Graft versus leukaemia effect 
A caveat with the use of current therapies for GVHD is that as well as suppressing 
GVHD, they also inhibit the anti-tumour effect. Donor derived T lymphocytes are 
thought to be the main mediators of the GVT effect in both experimental models and 
in the clinic (145-148). The impact of the GVT effect in the context of haematological 
malignancies is clearly evident from the improved outcome of patients suffering from 
leukaemia and lymphomas which are generally incurable by means of standard 
chemotherapy and radiation alone. These patients show more robust remission when 
they receive a HSC transplant in addition to chemotherapy and/or irradiation. For 
example, patients with acute myeloid leukaemia (AML), have a long term prognosis 
of ~10% with conventional chemotherapy, compared to 30-50% following allogeneic 
stem cell transplantation (225).  
 
1.3.7. Mouse models of GVHD 
There are multiple mouse models of GVHD; some are fully MHC mismatched while 
others are driven by mHC mismatches. The severity and clinical signs of GVHD can 
vary depending on a variety of factors including but not limited to the age and sex of 
the mice, the number and type of T cells used to mediate GVHD (202, 226, 227), 
variations in environmental pathogens and gut microflora (which can be affected by 
the animal supplier and local animal facilities) and genetic differences between donor 
and recipient (228). In addition, GVHD can vary according to the dose of irradiation 
which influences the extent of tissue damage and therefore alloreactive T cell 
activation (229). Where there is a full MHC-mismatch, GVHD is induced due to 
differences in MHC class I and MHC class II (H2) molecules, which can be 
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recognised either directly (as intact recipient MHC + peptide complexes) or indirectly 
(following processing and presentation of recipient MHC molecules in the context of 
donor MHC). This leads to the activation of CD8+ and CD4+ T cells. Mouse models of 
GVHD will be discussed further in Chapter 3.  
The use of such mouse models of GVHD has provided much key information on the 
mechanisms of GVHD and has enabled the efficacy of potential new therapies for 
GVHD to be tested. One exciting area of therapeutic potential is the use of immune 
cells to modulate the unwanted immune responses that lead to GVHD whilst sparing 
the GVT or GVL response. For example, as previously mentioned Treg were shown 
to suppress GVHD in a number of mouse models (196, 198-203). This has resulted 
in Treg being used in clinical trials for the treatment of GVHD (206, 207). Our own 
interest lies predominantly with another type of immune cell that has been 
demonstrated to have immunomodulatory properties; iNKT cells (230). It has 
previously been demonstrated that iNKT cells can act in an immunosuppressive 
manner following solid organ transplantation (231-233). Indeed, it has now been 
shown that iNKT cells decrease the risk and severity of GVHD in multiple mouse 
models (126, 234-238), whilst maintaining the GVT effect (126, 234, 238).  
 
1.4. Natural Killer T cells; at the interface between innate and adaptive 
immunity  
Natural Killer T (NKT) cells, are postulated to bridge innate and adaptive immunity. 
They are endowed with features of both the innate and adaptive immune system and 
they can facilitate and sculpt the subsequent adaptive response.  
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1.4.1. Invariant (i)NKT cells  
Over the last 20 years the term NKT cells has evolved considerably and now 
encompasses any CD1d restricted T cell. NKT cells are further classified into 
subpopulations, namely type 1 NKT cells which express a semi-invariant TCR, type 2 
NKT cells which express a more diverse TCR repertoire and finally NKT-like cells 
which is a broad term referring to MHC-restricted T cells which possess some or the 
properties of type 1 and type 2 NKT cells (Table 3). Type 1 or invariant (i) NKT cells 
are the most well characterised subset of NKT cells and are thought to be the main 
immunosuppressive subset in transplantation. 
The process of TCR gene rearrangement takes place in the thymus, and while 
conventional T cells can form approximately 1015 possible variations of αβTCR, iNKT 
express a semi-invariant TCR Vα14Jα18 in mice and Vα24Jα18 in humans (239, 
240). This is paired with a limited Vβ chain repertoire (Vβ2, Vβ7, Vβ8, Vβ8.2 or Vβ8.3 
in mice and Vβ11 in humans) (241-245). iNKT cells are a rare population of cells, 
which vary in their frequency in different anatomical site. The exceptions are the the 
adipose tissue where they constitute 10-25% of T cells (or 2-8% of lymphocytes) in 
mice and the liver where they they make-up up to 50% of intrahepatic lymphocytes in 
mice (246-254). Despite their relative paucity they have been shown to be able to 
profoundly influence immunity as they are able to respond to the same glycolipid 
antigens due to the expression of the semi-invariant TCR.  
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Table 3 NKT cell subtypes  
 Type 1 NKT Type 2 NKT NKT-like 
Other names Classical NKT 
Invariant NKT 
(iNKT) 
Non-classical 
NKT 
Diverse NKT 
NK1.1+ T 
cells 
CD3+ CD56+ 
T cells 
Restriction CD1d CD1d MHC, other? 
α-Gal 
reactivity 
+ - - 
TCR repertoire Restricted: 
Vα14 iNKT 
(mouse) 
Vα24 iNKT 
(human) 
Diverse Diverse 
 
1.4.2. Discovery  
iNKT cells were first identified in several independent studies, which culminated in 
the designation of iNKT cells as a separate lineage of T lymphocytes (18, 255-259). 
Initially a small subset of DN thymocytes which were capable of differentiating into all 
other subsets were discovered (18). Subsequently it was reported that this population 
of CD4-CD8- T cells in the thymi of mice favoured the use of Vβ8 (255, 256, 259). 
Shortly after this, Taniguchi et al. cloned an invariant TCR Vα14-Jα18 from keyhole 
limpet hemocyanin-specific suppressor T cell hybridomas (257, 258). Furthermore, 
around the same time the first allotypic monoclonal antibody (mAb) to the TCR was 
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developed, which as serendipity would have it, was specific for the Vβ8 TCR, which 
is over-represented among iNKT cells. 
It was later noted that there was a subset of cells in the spleen and liver which 
expressed NK and T cell markers and moreover this was shown to be in the case in 
the Vβ8-biased thymocytes (260). Such cells were later shown to have a lineage 
relationship with Vβ8 iNKT cells in the liver (261). Finally, in 1994 this was all brought 
together by the observation of cells which express NK receptors and highly biased 
TCR expression and rapidly secrete cytokines and they were designated iNKT cells 
(239, 262). Around the same time human iNKT cells were also discovered (244, 
263).  
 
1.4.3. iNKT cell ligands  
Following the discovery of iNKT cells the search began for the iNKT cell ligand. Initial 
studies assessed the selection of such cells in MHC class I and II deficient mice 
(264-266). These studies suggested that MHC class I or Beta 2 microglobulin (β2M) 
was involved in ligand recognition. However, in mice lacking the transporter required 
for loading peptides on the class-I complexes during antigen processing, NKT cells 
developed normally (267). This suggested that MHC molecules other than MHC class 
I that used β2M were potential restriction elements for these cells. Bendelac et al. 
provided robust functional evidence that CD1d was required to select and activate 
NKT cells (268). This was later proven when the CD1d-/- mouse was generated (269). 
CD1d is a non-polymorphic MHC class-I like molecule which presents glycolipids to 
NKT cells and is highly conserved between humans and mice (270). However, it was 
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not yet clear whether CD1d alone was enough to activate NKT cells and this was not 
formally proven until Koezuka, Taniguchi and colleagues discovered that a synthetic 
version of α-galactosylceramide (αGal), which had originally been isolated from 
marine sponge (Agelas maurititianus), could activate iNKT cells in a CD1d dependant 
manner (271). αGal is now regarded as the prototypical agonist for iNKT cells. The 
discovery that αGal was an exogenous ligand for iNKT cells also brought about the 
development of the PBS-57 (an αGal analogue) tetramer which had a significant 
impact on the advancement of the field.  
Later, many microbial ligands were discovered which were α-anomeric glycolipid 
antigens and could be recognised by iNKT cells (272, 273). However, the 
identification of the endogenous glycolipid responsible for selecting iNKT cells in the 
thymus proved difficult and controversial. Several weak self-reactive antigens were 
suggested (274, 275) and to further complicate things the dogma was that mammals 
could not synthesize α-anomeric glycolipid antigens. This lead to the search for a β-
anomeric glycolipid and one study suggested that β-glucosylceramide (β-GluCer) 
was indeed the endogenous antigen (275). However, further research by Kain et al. 
showed that it was in fact contaminating α-anomers in the β-GluCer prep, which were 
causing the reactivity (276). Using a CD1d-α-GalCer antibody (L363) in functional 
iNKT experiments they showed that the iNKT cell reactivity was indeed related to 
CD1d presentation of an α-anomer.  
The chemical nature of the glycolipids is also thought to sculpt the subsequent 
adaptive response through driving iNKT cells to produce different sets of cytokines. 
For example αGal leads to the production of predominantly Th1 type cytokines such 
as IFN-γ, whereas the glycolipid 2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-N-
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tetracosanoyl-2-amino-1,3,4-nonanetriol (OCH) leads to preferential production of IL-
4 and other Th2 type cytokines (271, 277, 278).  
 
1.4.4. Glycolipid and CD1d structure and loading  
In terms of structure, glycolipids consist of an oligosaccharide chain and a linked lipid 
component (Figure 1.4). αGal is glycosphingolipid, which is a glycolipid containing 
ceramide. A ceramide is composed of an amino alcohol, which contains a 
sphingosine (a carbon chain containing an amino alcohol) and a fatty acid. In αGal 
the sphingosine chain contains 18 carbons and the longer fatty acid chain is 26 
carbons, while in contrast OCH has a 9 carbon sphingosine chain and a 24 carbon 
fatty acid chain and C20.2 has an 18 carbon sphingosine chain and a 20 carbon fatty 
acid chain (271, 277, 278) (Figure 1.4).  
CD1d is encoded by the CD1d genes located on chromosome 1 in humans and 
chromosome 3 in mice (279-282). Structurally, they are similar to MHC class I as 
they consist of two heavy chains, non-covalently bound to a β2M to require 
processing, however in order to interact with the TCR αGal requires removal of 
terminal sugars (283). 
Self or exogenous glycolipids that require processing in order to be presented require 
localisation to the late endosome and lysosomal subcellular compartments (283, 
284). The glycolipid enzymes (including α-galactosidase A) and lipases process the 
lipid or glycolipid antigens and a set of lipid transfer proteins load the processed 
antigen into CD1d (283, 284). CD1d has large antigen binding groove which is found 
between the α1 and α2 helices which lie on top of 6 β strands. X-ray crystallography 
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has shown that the lipid portion of αGal fits tightly into the binding groove creating a 
stable interaction (285, 286).  
It has been suggested that there is a relationship between the length of the lipid 
chain and the biological activity of the glycolipid. The strength of the signal seems to 
be determined by its stability is the CD1d complex, which determines its cytokine 
profile. Glycolipids such as αGal with longer fatty acid chains are most effective at 
stimulating iNKT cells, suggesting that the long fatty acid chain may be required for 
the glycolipid to stably bind in the CD1d molecule (271). Furthermore, another study 
showed that the length and saturation of both alkyl chains both contribute to the 
stability of binding in the CD1d binding groove, which leads to altered binding affinity 
(287). 
As previously mentioned, activation of iNKT cells by OCH has been shown to lead to 
a type 2 response. This has been suggested to be due to its shorter carbon chains 
leading to lower affinity binding than αGal (288). C20.2 also has a shorter fatty acid 
chain, which leads to a mainly type 2 response, the presence of a double bond at 
carbon 11 and carbon 14 in the C20.2 fatty acid chain has been shown to increase 
the potency of the C20.2 (278). It should be noted that while the stability of the 
glycolipids is considered to be an important factor responsible for the bias in cytokine 
production, the nature of the APCs presenting the glycolipid may also play a role in 
an in vivo setting, as may the site of lipid loading (289-291). 
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Figure 1.4 Glycolipid structures  In terms of structure, glycolipids consist of an oligosaccharide and 
a linked lipid component A). αGal has a sphingosine chain contains 18 carbons and a longer fatty acid 
chain containing 26 carbons. B). OCH has a 9 carbon sphingosine chain and a 24 carbon fatty acid 
chain. C). C20.2 has an 18 carbon sphingosine chain and a 20 carbon fatty acyl chain.  
1.4.5. iNKT cell development 
Like conventional T cells, iNKT cell development takes place in the thymus. However, 
limited pairings of Vα genes and Vβ genes occur in the TCR. In mice Vα14-Jα18 is 
coupled with a limited Vβ repertoire (Vβ8, Vβ7, or Vβ2) (239-242), while in humans 
iNKT TCR are Vα24-Jα18/Vβ11 (239, 243-245). β-chain rearrangement occurs at the 
DN3 and DN4 stage, while α-chain rearrangement occurs during the immature single 
positive (ISP) stage and the DP stage (292, 293). 
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iNKT cells diverge from conventional αβ T cells at the DP stage of development 
(292). Positive selection is mediated by CD4+CD8+ thymocytes which present 
glycolipid antigens to iNKT cell precursors (268, 294). RAR-related orphan receptor 
gamma (RORγ) has been shown to be required for the generation of iNKT cells as it 
promotes the survival of immature iNKT cells through regulating the expression of 
anti-apoptotic protein BCL-xL and thus enabling successful T cell rearrangement to 
occur (292, 293, 295). Furthermore, E protein transcription factor (HEB) plays a role 
in promoting immature iNKT cell survival as it regulates both RORγT and BCL-xL 
(296).  
In addition, the transcription factor c-Myb also plays a role in regulating the 
development of iNKT cells as it facilitates Vα14 to Jα rearrangement by supporting 
the long half-life of DP thymocytes (297-299). In the absence of c-Myb expression 
iNKT cells are not generated (299). Using Nur77 green fluorescent protein (GFP) 
mice (which is an immediate-early gene upregulated by TCR stimulation), iNKT cells 
have been shown to require a strong TCR signal during selection (300). However, 
iNKT cells also require an additional signal from signalling lymphocytic-activation 
molecule (SLAM)F receptors which are expressed on DP thymocytes (301). Further 
to its role supporting the half-life of DP thymocytes, c-Myb has been shown to 
promote the expression of CD1d and SLAM family members and the adapter 
molecule signalling lymphocytic-activation molecule-associated protein (SAP) (299, 
301). 
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Subsequent to positive selection, precursor iNKT cells are referred to as stage 0 
iNKT cells. They are CD1d-glycolipid tetramer positive, CD44-, CD24+, CD69+ (302, 
303). Historically, the model for development in C57BL/6 (B6) mice was linear, 
progressing from stage one to three based on CD44 and NK1.1 expression (302). 
More recently, the lineage diversification model has been proposed in which CD24 is 
downregulated and promyelocytic leukaemia zinc finger (PLZF) is upregulated (304). 
PLZFhigh cells then relocate from the cortex to the medulla, in a process likely to be 
mediated by CCR7 (305-308). Based on CD1d tetramer and immunofluorescence 
staining, the subsets of iNKT cells namely NKT1, NKT2 and NKT17 cells have been 
found to be predominantly located in the medulla (309).  
NKT1 cells express T-bet and low levels of PLZF and produce IFN-γ when stimulated 
and low amounts of IL-4 (310). NKT2 cells are PLZFhigh and upon stimulation produce 
high amounts of IL-4 (310). NKT17 cells express intermediate levels of PLZF, RORγT 
and when stimulated produce IL-17 (310).  
It has recently been reported that the TCR signal strength is responsible for the 
subtype of iNKT cells that is generated, with strong signalling leading to the 
promotion of NKT2 and NKT17 development (311). ETS-related gene (Erg) 1 and 
Erg 2 are transcription factors that are important at stage 0 for the further 
development of iNKT cells, as they are required for the induction of transcription 
factor PLZF (312). Erg2 expression can be influenced by the strength of the TCR 
signal, with decreased signalling effecting Erg-2 expression and hence the 
upregulation of PLZF (311).  
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Another transcription factor Kruppel-like factor 2 (KLF) 2 negatively regulates 
differentiation into NKT2 cells, while KLF13 a member of the same family of 
transcription factors plays the opposite role (313, 314). The transcription factor Hobit 
also plays a role in the differentiation of iNKT cells (315). Its highest expression 
occurs in CD44high NK1.1+ iNKT cells which are mainly NKT1 cells, the number of 
which is significantly reduced in Hobit KO mice. This suggests that Hobit promotes 
the development or thymic retention of NKT1 cells (308). T Cell Factor 1 (TCF1) and 
Lymphoid Enhancer Factor 1 (LEF1) also play key roles in development. Deleting 
TCF1 led to defects in all three subsets of NKT cells, while LEF1 was necessary for 
survival and proliferation particularly during the NKT0 stage in which NKT cells 
numbers expand significantly (316, 317). 
Cytokines are also important for iNKT effector cell differentiation. IL-15 production 
has been shown to be required for development in NKT1 cells (318). Similarly, TGB-
β has been shown to be necessary for differentiation into NKT17 cells (319). IL-17RB 
the IL-25 receptor is expressed on both NKT2 and NKT17 cells and has been shown 
to be required for the production of αGal-induced IL-9, IL-10, IL-13 and IL-17 (320). 
The cytokines that mature iNKT cells produce on activation are diverse and help 
delineate the subsets of iNKT cells. It is these subsets that are partially responsible 
for the diverse roles that iNKT cells play in immunity.  
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1.4.6. iNKT cell activation 
iNKT cells are activated during a plethora of infections and inflammatory conditions 
(321-325). Under physiological conditions, TCR signals and cytokine signals are 
required for iNKT cell activation (Figure 1.5). Unlike conventional T cells which 
recognise processed peptide antigens presented by MHC molecules, iNKT cells 
recognise lipid antigens and antigen processing is not an absolute requirement. Two 
models of iNKT cells activation have been proposed; the first involves a dominant 
TCR signal provided by a high affinity lipid binding to the TCR and to a lesser extent 
APC-derived cytokine, the second comprises dominant cytokine mediated signals 
along with a weak TCR-CD1d-lipid interaction (Figure 1.5).  
There is also evidence that iNKT cells can be activated independently of TCR 
signalling in some models of infection (321, 326). Furthermore, solely innate 
activation is also thought to be possible through natural killer receptors (NKRs). 
Crosslinking NKR NK1.1 with an antibody can directly activate iNKT cells and NKR 
NKG2D ligation can also activate iNKT cells in the absence of lipid antigens (327, 
328). In contrast, inhibitory NKRs may negatively regulate activation (329).  
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Figure 1.5 Models of iNKT cells activation Two models of iNKT cell activation have been proposed. 
The first involves a dominant T cell receptor signal provided by a high affinity lipid binding to the TCR 
and to a lesser extent APC-derived cytokine. The second comprises a predominantly cytokine 
mediated signals along with a weak TCR-lipid interaction.. Adapted from Brennan et al., 2013, Nature 
Reviews Immunology 13, 101-117.  
1.4.7. iNKT cell subtypes    
Rapid production of cytokines upon activation is a hallmark of iNKT cells. In B6 mice 
the majority of iNKT cells in the liver and spleen are described as Th1-like (or NKT1) 
cells, like Th1 cells they express T-bet and produce mainly IFN-γ but they can also 
produce low amounts of IL-4 (310, 320, 330, 331) (Figure 1.6). NKT1 cells can be 
either CD4+ or CD4- and can be NK1.1+, or NK1.1- (320). iNKT cells are most 
frequent in the liver where the can constitute up to 50% of intrahepatic lymphocytes 
(249-254).  
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Conversely, Th2-like NKT cells (NKT2 cells) produce large amounts of IL-4 as well as 
IL-9, IL-10 and IL-13 (310, 332, 333) (Figure 1.6). Thymic NKT cells predominantly 
produce IL-4 when activated with thymic DCs (334). However, the outcomes of iNKT 
cell activation are strongly influenced by the context in which the iNKT cells are 
activated. When thymic iNKT cells are co-cultured with APCs from the spleen in the 
presence of αGal, there is a significant increase in IFN-γ expression, compared to 
when they are co-cultured with APCs from the thymus (334).  
Yet another subset of iNKT cells analogous to CD4+ T cells are Th17-like iNKT cells 
(or NKT17 cells), which are most commonly contained within the CD4-NK1.1- 
subpopulation (335). Like Th17 cells they express the transcription factor RORγT, 
CCR6 and primarily produce IL-17 (Figure 1.6). 
More recently a regulatory subset of iNKT cells has been identified, which have been 
named regulatory iNKT cells (or NKT10 cells; Figure 1.6) (336, 337). These cells are 
enriched in the adipose tissue and produce IL-10 and IL-2. While other iNKT cells 
express the transcription factor PLZF, NKT10 cells express E4BP4, which is required 
for their IL-10 production (Figure 1.6), NKT10 cells can also be generated in 
response to repeated activation with αGal. (336, 337). Follicular helper NKT (NKTFH) 
are another subset of iNKT cells and are analogous to T follicular helper cells in that 
they have a role in promoting affinity maturation and antibodies in the germinal 
centres of spleens (338, 339). 
In humans the subsets of iNKT cells are not definitively defined. However, CD4-CD8- 
iNKT cells and CD8+ iNKT cells produce IFN-γ are exhibit cytotoxic function when 
activated and are thought to be similar to NKT1 cells (340, 341). Understanding the 
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subtypes of iNKT cells, at what point they diverge and identifying lineage specific 
markers is essential for unravelling the contrasting roles of iNKT cells in the immune 
response. Furthermore, it is of fundamental importance if iNKT cells are to be 
isolated and manipulated for cell based therapies, such as in the treatment of GVHD.  
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Figure 1.6 iNKT cell subtypes  iNKT cells can be divided into subtypes based on their transcription 
factor and cytokine expression NKT1 cells express T-bet and low levels of PLZF and produce IFN-γ 
when stimulated and low amounts of IL-4. They are associated with anti-viral and anti-tumour 
immunity. NKT2 cells are PLZF
high
 and upon stimulation produce high amounts of IL.-4 and IL-13. 
NKT2 cells are increased in asthma. NKT17 cells express intermediate levels of PLZF, RORγT and 
when stimulated produce IL-17. They are increased in skin graft rejection. NKT10 cells express 
E4BP4 and produce IL-10.and are decreased in obesity.    
 
 
64 
 
1.4.8. iNKT cells in disease 
iNKT cells have been shown to be involved in a wide variety of immune responses 
showing both protective and pathogenic roles in disease due to their ability to act in 
both a proinflammatory and anti-inflammatory manner. Moreover, iNKT cells are not 
a homogenous population and their frequencies vary depending on the anatomical 
site in which they are located as well as the local microenvironment and cytokine 
milieu. Furthermore, the bidirectional activation between DCs and iNKT cells 
contributes to the sculpting of iNKT cells responses.  
 
1.4.8.1. iNKT cells in viral infection  
In the context of viral infection iNKT cells have been shown to possess both 
protective and pathogenic roles depending on the virus involved. iNKT cell deficient 
mice show exacerbated phenotypes in infections such as herpes simplex virus type 
(HSV)-1 and HSV-2 (342-344). In addition, studies of patients with defects in iNKT 
cell development have shown that iNKT cells are protective in Epstein-Barr virus 
(EBV) in humans (345-347). Furthermore, treatment with αGal leads to enhanced 
viral immunity in a number of infections including human immunodeficiency virus 
(HIV), hepatitis B virus (HBV) and murine cytomegalovirus (MCMV) (348-350). These 
effects are often not mediated directly by iNKT cells as is the case with MCMV in 
which NK cells mediate the effect through perforin and IFN-γ (350).  
However, iNKT cells have been shown to contribute to pathology in some viral 
infection for example they promote chronic lung disease in mice infected with Sendai 
virus (351). Despite the absence of a known microbial glycolipid some viruses 
including HSV-1 possess strategies to evade the immune system via disruption of 
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CD1d-mediated antigen presentation, suggesting that iNKT cells may be protective 
following CD1d-glycolipid activation in some viral infections (352). iNKT cells have 
also been shown to play an important role in promoting B cell immunity to viruses 
through the production of IL-4 at the interfollicular areas of LNs which allows for B 
cells to seed germinal centre reactions (353).  
While iNKT cells can play antithetic roles in viral infection, it is not clear whether this 
is driven by the primary site of infection, the lifecycle of the virus, the mode of 
activation or a combination of factors.  
 
1.4.8.2. iNKT cells in bacterial infection 
iNKT cells have primarily been mostly studied in the context of intracellular bacteria. 
They have been shown to be protective in a variety of infections including 
mycobacterium tuberculosis, Leishmania major and Streptococcus pneumoniae 
(354-356). For example, the transfer of wild type (WT) or Jα18−/− splenocytes to mice 
that received sub-lethal irradiation and infection with mycobacterium tuberculosis 
resulted in a reduction in the bacterial burden in mice that received WT splenocytes 
compared to KO cells, suggesting a role iNKT cells in the clearance of the bacteria 
(354).  
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1.4.8.3. iNKT cells in fungal infection  
iNKT cells can play a role in protection against fungal infections such as Cryptococus 
neoformans and Aspergillus fumigatus. In C.neoformans infection iNKT cells were 
shown to accumulate in the lungs in the early stages of infection and Jα18-/- mice 
show a reduced Th1 response and a delay in clearance of the pathogen (357). 
Similarly CD1dKO mice poorly control A.fumigatus, infection (358).  
 
1.4.8.4. iNKT cells in protozoan infection 
iNKT cells generally play a protective role in the context of protozoan infection. For 
example lipids extracted from mouse parasites can actually be loaded onto CD1d 
molecules and used to stimulate iNKT cells (359). iNKT cells have also been shown 
to be important for control of parasitic replication in vivo (360). However, when the 
immune response goes unchecked this can lead to collateral damage, as is the case 
in Visceral leishmaniasis in which iNKT cells lead to a chronic dermal complication 
called Post-kala-azar dermal leismaniasis (361, 362). There are also some cases in 
which iNKT cells play a pathogenic role in protozoan infection such is the case with 
Toxoplasma gondii. In Toxoplasma gondii iNKT cells are thought to produce IL-4, 
and suppress the production of heat shock protein by γδ T cells, which is required for 
protective immunity to the disease (363).  
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1.4.8.5. iNKT cells in autoimmune diseases 
iNKT cells have been shown to have contradictory roles in autoimmune disease. 
However, this can be partially explained by the use of different models, the dose of 
glycolipid, the timing of glycolipid administration, and the route by which it is delivered 
as well as the stage of the disease in question (364-366). In general low numbers of 
peripheral blood iNKT cells have been observed in autoimmune diseases such as 
rheumatoid arthritis (RA), Grave’s disease and type 1 diabetes (367-369). 
One example of an autoimmune disease in which iNKT cells have been shown to 
play both protective and pathogenic roles is MS. MS is a T cell mediated autoimmune 
disease of the central nervous system which leads to progressive paralysis. In 
relapsing remitting MS, which is associated with period of latency and relapse of the 
disease, there were decreased peripheral blood iNKT cells, which seems to correlate 
with onset of relapse (370). Remission periods meanwhile have been associated with 
Th2 biased NKT cells (371). Similarly in mice, SJL/J mice which are particularly 
susceptible to EAE, have a defect in Vβ8, the most common β-chain used in iNKT 
cells, and adoptively transferring NK1.1+, DX5+ T cells (which contain a high 
frequency of iNKT cells) to such mice confers protection and recovery from EAE 
(372). Additionally, overexpression of the Vα14-Jα18 TCR chain in non-obese 
diabetic (NOD) mice leads to reduced susceptibility to EAE (373).  
αGal administration has been observed to be protective in some models of EAE, 
whilst in other models its administration has been reported to exacerbate disease 
(364-366). Typically protection from disease was associated with a Th2-biased 
response (364-366). The aforementioned studies used cytokine blockade and 
cytokine KO mice to inform on iNKT cells function and it was shown that IL-4 and IL-
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10 are involved in protection from EAE, although one study found IFN-γ attenuated 
disease (364-366). Interestingly, OCH which is known to bias towards a type 2 
immune response was more protective than αGal and this protective effect was 
mediated by IL-4 (277). However, another model found no difference between the 
two glycolipids (374).  
Taken together these studies show that the role of iNKT cells in autoimmune disease 
is by no means fully understood and is clearly context dependent, and suggests that 
iNKT cells can play paradoxical roles even within the same disease.   
 
1.4.8.6. iNKT cells in allergy 
iNKT cells particularly NKT2 cells have been observed in allergic diseases. By far the 
best characterisation of iNKT cells in allergic disease exists for asthma. Asthma is a 
common long-term multifaceted and heterogeneous lung disease characterised by 
inflammation, bronchospasms and airway hyper-reactivity (AHR). The most common 
form of asthma is allergic asthma and type-2 cytokines are crucial for disease 
development, leading to the hypothesis that iNKT cells can promote AHR (375).  
A study in which iNKT cells were isolated from the lungs and bronchiolar lavage 
fluids of patients suffering from asthma showed that iNKT cells were the dominant T 
cells in the lung and solely produce NKT2 cytokines (376). Two later studies 
supported the hypothesis that iNKT cells are important for the development of 
asthma as they also observed increased numbers of iNKT cells in the lungs of 
patients with asthma (377, 378). However, one study showed that patients with 
severe asthma have higher numbers of iNKT cells compared to those with mild 
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asthma (379). Furthermore, it has been suggested that iNKT cells have a modulatory 
rather than a causative role in asthma (380, 381). It is possible that these 
discrepancies are due to different causative agents or the severity of disease. (379) 
Mouse studies have shown that Jα281-/- mice, which lack iNKT cells, do not develop 
AHR in response to stimulation (332). Furthermore, adoptive transfer of iNKT cells 
from WT but not IL-4-/- or IL-13-/- mice leads to the establishment of AHR (332). 
Conversely, skewing the immune response in asthma towards a Th1 dominant 
response has been shown to prevent asthma is several models. For example, 
administering αGal during the sensitization phase of allergic asthma suppressed the 
allergic type-2 response by means of IFN-γ production (382). Furthermore, adoptive 
transfer of BMDCs loaded with αGal has been shown to prevent the development of 
an allergic response in the lung via iNKT cell derived IFN-γ (383). Together these 
studies show that while iNKT cells may not initiate asthma, they are at least a key 
player in the progression of the disease through their production of NKT2 type 
cytokines such as IL-4 and IL-13, while iNKT cell derived IFN-γ appears to play a 
protective role in the context of asthma.   
 
1.4.8.7. iNKT cells in cancer 
iNKT cells have a well-established role in anti-tumour immunity (384-387). In mice 
treated with αGal iNKT cells have been found to be essential for NKT mediated anti-
tumour immunity (385, 387, 388). However, it should be noted that the Jα18-/- mice 
that were used for many of these studies had an inability to produce TCR Jα regions 
past Jα19 which may have impacted on the conventional T cell repertoire in addition 
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to preventing development of iNKT cells (385). Induction of tumours or transfer of 
tumour cells lines into mice deficient in iNKT cells lead to an increase in the 
occurrence of tumours compared to WT mice and this anti-tumour effect was found to 
be mediated by IFN-γ (389).  
In humans and mouse models iNKT cells can mediate their effects directly by killing 
CD1d expressing tumour cells, as can occur in many forms of cancer including AML 
and acute lymphoblastic leukaemia, myelomas, myeloid leukaemias and prostate 
cancer (390-393). Alternatively, iNKT cells can be activated by other CD1d 
expressing cells, such as tumour-associated macrophages (394).  
As well as activating iNKT cells via αGal, iNKT cells can be adoptively transferred in 
order to exploit their natural anti-tumour activity (395). Indeed, adoptive transfer of 
iNKT cells which have been activated with IL-12 has been shown to lead to the 
prevention of hepatic metastasis of B6 melanoma (395). Studies, of the anti-tumour 
properties of iNKT cells have led to a phase 1 clinical trial in which expanded iNKT 
cells are being investigated as a potential therapy for advanced melanoma which 
was found to be feasible and safe and the iNKT cells produced IFN-γ (396). The 
activation with αGal has also been investigated as a potential therapy for patients 
with solid tumours in phase 1 clinical trials and was deemed to be safe (397).  
 
1.4.8.8. iNKT cells in obesity 
In obesity adipose tissue can make up 50% of body mass. iNKT cells have been 
shown to be enriched in the adipose tissue in both humans and mice (249, 398). The 
environment in the adipose tissue in obesity is proinflammatory, and adipose tissue 
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iNKT cells can produce copious amounts of IL-10 (337). Lynch et al. showed that 
adipose tissue iNKT cells are depleted in obese patients compared to lean controls, 
as well as in diet-induced models of obesity (249, 398). This was confirmed by two 
other labs (246, 248). iNKT cell numbers fall in mice on high fat diets in a similar 
manner that occurs in human obesity and adoptively transferring WT iNKT cells into 
Jα18-/- or CD1d-/- mice leads to increased weight loss in obese mice (249). 
Furthermore, administration of αGal leads to rapid weight loss and reversal of 
glucose and insulin sensitivity in obese mice (248, 249). The protective role of iNKT 
cells is thought to be mediated through the production of regulatory cytokines such 
as IL-4 and IL-10 and their subsequent effect on the frequency and phenotype of 
macrophages (248, 249). Such cytokines promote M2 macrophages which suppress 
inflammation and indirectly influence adipose function leading to increased weight 
loss and improved fatty liver and insulin resistance (248, 249).   
 
1.4.8.9. iNKT cells in solid organ transplantation 
Mouse models have shown that the kinetics of organ rejection are not altered in the 
absence of iNKT cells in fully-mismatched skin, cardiac or islet (placed under the 
kidney capsule) allografts (399-401). However, this may be due to the high frequency 
of alloreactive T cells overshadowing any contribution of iNKT cells. Indeed, iNKT 
cells have been found to infiltrate skin and heart allograft prior to rejection and 
expanded numbers of iNKT cells are present in the peripheral lymphoid tissue post 
transplantation (402-404). 
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In certain contexts iNKT cells have been shown to be required for the facilitating the 
induction of tolerance. iNKT cells have been shown to be required for graft 
acceptance in cardiac transplant models in which tolerance is induced by blocking 
either co-stimulatory molecules, integrins or co-receptors (232, 399, 404). 
Furthermore, adoptive transfer of iNKT cells into iNKT cell deficient cardiac or skin 
transplant recipients being treated with such antibodies restores tolerance. This has 
been shown to be dependent on IFN-γ, IL-10 and/or CXCL16 (232, 399, 403, 404). 
iNKT cells have are also required for the induction of tolerance to corneal allografts 
(233, 405).   
However, iNKT cells can also play a role in promoting allograft rejection in 
transplantation as is the case in skin-graft transplantation (231). Islet transplanted 
into the liver via the portal vein has also been shown to promote rejection by 
activating iNKT cells and downstream triggering IFN-γ production by Gr-1+CD11b+ 
cells (400, 406). 
The role of iNKT cells in transplantation may be influenced by whether or not the 
transplanted organ or tissue is directly vascularised or not. Experimental skin 
transplants drain to the local lymph nodes (LNs) in mice where there is 
predominance of IL-17 secreting iNKT cells (407). Indeed, IL-17 produced by iNKT 
cells post skin transplantation has been shown to promote graft rejection (231). 
Furthermore, iNKT cells can be manipulated in order to promote allograft 
acceptance, multiple injections of αGal have been shown to promote skin graft 
survival (403).  
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1.4.8.10. iNKT cells in BM transplantation 
A decreased incidence of acute stage II-IV GVHD has been observed patients that 
receive above the median dose of iNKT cells contaminants in their bone marrow 
transplant (BMT) (408). In addition, an increased number of iNKT cells in the graft 
have been show to correlate with improved GVHD and progression free survival 
(409). Recovery of iNKT cells post-transplant has been shown to be associated with 
reduced non-relapse mortality without a risk of relapse and improvement in the 
overall survival rate (410). Furthermore, recent studies in mice have shown that 
adoptive transfer of iNKT cells can protect from GVHD in mice, which will be 
discussed in detail in chapter 6 (126, 234-238).  
 
1.4.8.11. iNKT cell summary 
iNKT cells are not a homogenous population of cells therefore they can be involved 
in dichotomous responses to immune perturbation. The same subtype of iNKT cells 
can be protective in one setting but not another, even within the same disease. 
Despite the regulatory effect of iNKT cells in the context of some forms of 
transplantation, they can have pathogenic roles in many contexts as outlined above. 
Other examples of pathogenic roles are in pregnancy wherein iNKT cells have been 
shown to induce preterm birth and early to mid-gestation pregnancy loss and in 
sterile hepatic injury they initiate hepatic reperfusion injury (411, 412). The role of 
iNKT cells is very much dependent on the local microenvironment, site of infection 
and or injury, stage of disease, dose of glycolipid (if any) and timing and route of 
administration all contributing to the nature of the response. Furthermore, discrete 
74 
 
differences between animal models of the same disease or between mice at different 
animal facilities may influence the nature of the iNKT cell response.  
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1.5. Thesis hypothesis and aims 
1.5.1. Hypothesis  
Subsets of iNKT cells have the potential to be used as cellular therapies for the 
treatment of GVHD.  
1.5.2. Global Aims  
Cell based therapies are an emerging area of therapeutics with the potential to treat 
a plethora of immune diseases by either enhancing or dampening down the immune 
response, depending on the nature of the disease being treated. Of particular interest 
to our lab is the ability of cellular therapies to promote immune regulation in the 
context of transplantation. iNKT cells possess the ability to facilitate and sculpt the 
adaptive immune response. They have been shown to be capable of suppressing 
GVHD in several models. We hypothesise that in order for this therapy to be clinically 
translatable the iNKT cells would require expansion and characterisation. The aims 
of this project were to: 
1.  Establish a mouse model of GVHD in which we can track alloreactive 
transgenic TEa T cells in vitro. 
2. Characterise the phenotype and function of freshly isolated and expanded 
splenic iNKT cells  
3. Investigate the immunomodulatory ability of freshly isolated and expanded 
iNKT cells in vitro  
4. Investigate the immunomodulatory ability of freshly isolated and expanded iNKT 
cells in the established mouse model of GVHD  
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CHAPTER 2 MATERIALS AND METHODS 
 
 
 
 
 
 
 
2.1. Mice  
Mice were either bred in house or sourced from Charles River and were between 8 
and 12 weeks at the time of first procedure (Appendix I). Mice from external sources 
were housed for a minimum of one week prior to the initiation of experiments under 
SPF conditions at the Biomedical Services Unit and the University of Birmingham. 
Animal studies were carried out in accordance with the UK Animals (Scientific 
Procedures) Act of 1986 under the appropriate project and personal licence 
(I14963778). On average 5 mice were housed per cage under alternating 12 hours 
(h) light/dark cycles at 23ºC. Mice were killed by cervical dislocation and all organs 
and tissues were removed by dissection under sterile conditions.  
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2.2. Cell isolations  
2.2.1. Isolation and culture of cells  
Spleens were mashed through a cell strainer (70 μm pore size) (Fisher), with 
complete Roswell Park Memorial Institute Medium (cRPMI) (Appendix II). Cells were 
centrifuged at 400 gravity (g) at 4 degrees Celsius (°C), for 5 minutes (min) and 
following this 1 ml of 1x red blood cell lysis buffer (BD) was added. The reaction was 
neutralised after ~1 min using cRPMI (Appendix II).   
 
2.2.2. Isolation of lymph node (LN) cells  
Fat was dissected from LNs prior to being mashed through a cell strainer (70 μm 
pore size), with cRPMI.  
2.2.3. Isolation of leukocytes from Liver  
Livers were mashed through a cell strainer (70 μm pore size), with cRPMI (Appendix 
II). Cells were centrifuged at 400 g, for 5 min and resuspended in 10 ml cRPMI. Each 
sample was then divided in two, and each half was layered on top of 7mL of room 
temperature (r.t.) Optiprep (1.09 g/ml) (Sigma Aldrich). The cells were centrifuged at 
1000 g (with no break), for 25 min, at r.t. Cells were removed from the interface that 
formed as a result of centrifugation and washed and resuspended in Fluorescence-
activated cell sorting (FACS) buffer (Appendix II) for FACS staining. 
  
2.2.4. Isolation of leukocytes from Small intestine (SI) 
Small intestine (SI) (end of the stomach to the cecum), was removed by dissection 
and placed in a petri dish containing ice cold CaMg free Hanks' Balanced Salt 
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solution (HBSS) (Sigma Aldrich) containing 2% Fetal calf serum (FCS) (Sigma 
Aldrich) HBSS 2% FCS (Sigma Aldrich) (Appendix II). The mesenteric fat and 
Peyer’s patches were carefully removed on tissue soaked in ice cold HBSS 2% FCS. 
The SI was sliced longitudinally opening it up and the contents removed by agitating 
it in the HBSS 2% FCS. Following this, the SI was cut into ~2 mm sections and 
placed in a 50 mL tube (Sarstedt) containing HBSS 2% FCS and shaken vigorously 
for 20 seconds (sec) before being placed on ice.  
The SI was filtered through mesh supported in a funnel, and placed in a 50 mL tube 
containing 20 mL HBSS with 2 mM Ethylenediaminetetraacetic acid (EDTA) 
(Corning) (Appendix II) and shaken vigorously for 20 sec. The SI was then incubated 
for 20 min in a shaker at the maximum speed at 37°C, which strips the epithelium of 
the SI. The SI was filtered again, placed in 20 mL HBSS with 2 mM EDTA and 
shaken vigorously for 20 sec and returned to the shaker for a further 20 mins. The SI 
was then filtered and shaken vigorously with HBSS (EDTA free) twice, before being 
placed in 15 ml of pre-warmed cRPMI containing collagenase VIII (1 mg/ml) (Sigma 
Aldrich), and shaken manually for 10 sec before being placed in the incubated shaker 
(Multitron Standard (Infors HT) ). After 10 min the SI was removed and shaken 
vigorously for 10 sec and then returned to the incubator for a further 5 min. The SI 
was then placed on ice, to stop the reaction and filtered through a 100 µm followed 
by a 70 µm strainer and centrifuged and resuspended in FACS buffer.  
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2.2.5. Isolation of bone marrow (BM) cells  
Bones from the femora and tibiae of mice were removed under sterile dissection. BM 
was flushed from the bone cavities of the femora and tibiae with cRPMI, using a 25 
gauge needle (Terumo). Cells were centrifuged at 400 g, for 5 min and following this 
1 ml of 1x red blood cell lysis buffer (BD) was added, followed by 10 ml of cRPMI.  
 
2.3. Cell enrichment by dynabeads, Magnetic Activated Cell Sorting (MACS®) 
and cell sorting  
2.3.1. Magnetic labelling and depletion of non-T cells using dynabeads  
Cells were suspended in 200 μl of Magnetic activated cellular sorting (MACS) buffer 
(Appendix II) per 5x107 cells. Subsequently, 100 μl of FCS (Gibco, Life technologies) 
and 50 μl CD4 enrichment cocktail (Life technologies), were added per 5x107 cells. 
The CD4 depletion cocktail contained non-T cell antibodies (cocktail contains biotin-
conjugated antibodies against CD8a, CD11b, CD11c, CD19, CD45R (B220), CD49b 
(DX5), CD105, Anti-MHC-class II, Ter-119 and TCRγ/δ), which were used to deplete 
non-T cells by means of negative selection. The cells were incubated for 20 min, at 
4°C. Cells were subsequently washed with 10 ml MACS buffer and resuspended in 4 
ml of buffer. The 4 ml cell suspension was then added to washed dynabeads 
(invitrogen) (250 μl of beads per 5x107 cells) and placed on a rotator for 20 min at 
4°C before being placed into the DynaMag magnet stand (Life technologies). The 
supernatant was removed into a new tube; this fraction contained enriched CD4+ 
cells. Cell purity was determined using flow cytometry, mean frequency post sort 
87%±0.08% (Appendix V). 
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2.3.2. Magnetic labelling and enrichment iNKT cells using Manual MACS® 
Separator  
The enriched CD4+ cells were washed with MACS buffer and resuspended in 200 μl 
of buffer per 7.5x107 cells, with 5 μl of Phosphate-buffered saline (PBS) 57-CD1d-
APC tetramer (1/40 dilution of 1.3-1.5 mg/ml; NIH Tetramer Core Facility) per 7.5x107 
cells, and incubated for 30 min, at 4°C. Cells were then washed with 10 ml of buffer 
and resusupended in 80 μl MACS buffer per 1x107 cells with 10 μl anti-APC beads 
(MACS®) per 1x107 cells and incubated for 20 min at 4°C. Cells were then washed 
with 10 ml of MACS buffer, and resuspended in 1 ml of MACS buffer. The MACS 
column was placed in the Manual MACS® Separator and primed by washing with 3 
ml of MACS buffer. The 1 ml cell suspension was then added to the primed column, 
and washed through by washing 3 times, with 3 ml of MACS buffer. The column was 
then removed from the magnet, 5 ml of MACS buffer were added to the column and 
the cells were eluted into a 15 ml tube using the plunger supplied with the column. 
The column purification was repeated in order to gain a purer sample. Mean 
frequency post sort 85%±11% (Appendix V).  
 
2.4. Preparation of glycolipids 
Prior to either the pulsing of BMDCs with αGal (Abcam/from Gurdyal S. Besra, 
School of Biosciences, University of Birmingham), or injection of αGal or C20.2 (from 
Gurdyal S. Besra, School of Biosciences, University of Birmingham) glycolipids were 
sonicated for 5 min using the ultrawave (Wolf Labs). Following this the glycolipid was 
heated for 5 min at 40°C. Following this glycolipids were either added to the BMDC 
culture, or diluted in PBS (Appendix II) for intraperitoneal (i.p.) injection.   
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2.5. iNKT cell sorting  
Isolation of specific iNKT cells from reporter mice was required in both in vitro and in 
vivo experiments, namely RORγT negative cells from RORγT reporter mice and IFN-
γ positive cells from IFN-γ reporter mice. In order to sort IFN-γ positive iNKT cells the 
mice first required injection with αGal. αGal was prepared as described in section 2.4 
Mice were given i.p. αGal (2 µg) before being sacrificed 48 h later, and splenocytes 
were isolated. In the case of sorting both RORγT negative and IFN-γ positive cells, 
cells were first enriched using micro-bead sorting as described in section 2.3. 
Following this cells were stained on ice for 30 mins. To sort RORγT negative cells 
from RORγT reporter mice, cells were stained on ice for 30 min, (for CD5 and PBS57 
tetramer). Cells were then sorted on expression of CD5 and PBS57 tetramer (iNKT) 
cells and GFP (negative cells sorted) using either the FACSAria Fusion (BD) or the 
Mo-Flow Astrios (Beckman). To sort IFN-γ positive cells from IFN-γ reporter mice, 
cells were stained on ice for 30 min, (for CD5 and PBS57 tetramer) and following this 
GFP positive (IFN-γ postive) iNKT cells were purified. For WT B6 mice Mean 
frequency post sort 85%±0%, for IFN-γ positive iNKT cells mean frequency post sort 
94%±6%, for RORγT negative iNKT cells Mean frequency post sort 87%±12% 
(Appendix V).   
 
2.6. Microarray 
IFN-γ reporter mice were injected i.p. with αGal or PBS-vehicle control and mice 
were sacrificed and spleens harvested after 48 h. iNKT cells were isolated as 
described in sections 2.3 and further sorted on expression of IFN-γ as described in 
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section 2.5 Ribonucleic acid (RNA) was then isolated from iNKT cells using a RNA 
micro kit (Qiagen). Cells were spun at 800 g for 5 min at 4°C and supernatant was 
removed and 350µl RLT (lysis buffer) containing β-mercaotoethanol (10ul per 1ml 
RLT) was added to each sample. Samples were added to RNA shredder column with 
collection tube which were spun at 20,000 g for 2 min at r.t. 350 µl of 70% ethanol 
was added to the flow through and samples were added to RNeasy Min Elute Spin 
column with collection tube. Samples were spun at 8000 g for 15 sec at r.t. To wash 
the column, 350 µl of RW1 was added to each column. Samples were spun at 8000 g 
for 15 sec at r.t. The DNAse solution (DNAse-I 10 µl and RDD buffer 70 µl) was 
added to each membrane on column and left at r.t. for 15 min to eliminate the 
genomic DNA. To wash the column, 350 µl of RW1 were added to the column. 
Samples were spun at 8000 g for 15 sec at r.t. Samples were placed into a new 
collection tube and 500 µl of RPE were added to each sample for further wash. 
Samples were spun at 8000 g for 15 sec. 500µl of 80% ethanol were added to each 
sample. Samples were spun at 8000 g at r.t. for 2 min and following this placed in a 
new collection tube. Samples were spun at 20,000 g at r.t. for 5 min to eliminate the 
residual ethanol on membrane in column. Samples were placed in new collection 
tubes and spun twice with 15 µl of RNase Free water at 20,000 g at r.t. for 5 min to 
elute the RNA. RNA purity (Ratio of 260/280, 260/230) and yield were determined 
using the thermos Scientific Nanodrop2000c spectrophotometer (Thermo Scientific). 
Purified RNA was sent to Aros applied biotechnologies who conducted the further 
RNA quality check (RNA pico chip) using a Bioanalyzer (Agilent Technologies) and 
the microarray (Affymetrics (GeneChip Mouse Transcriptome Assay 1.0 (MTA 1.0). 
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Microarray analysis was performed using Transcriptome Analysis Console 
(Affymetrix). 
 
2.7. Bone marrow dendritic cell (BMDC) culture  
BM cells were isolated as described in section 2.2.5. Isolated BM cells were 
centrifuged and resuspended at a concentration of 1x106 cells/ml, with a final 
concentration of 10 ng/ml granulocyte monocyte stimulating factor (GM-CSF) (R&D 
Systems) and 1 ng/ml IL-4 (Peprotech), and plated in a 24 well plate (Costar) with 1 
ml of cell suspension per well. Cells were cultured in carbon dioxide (CO2) incubator 
(Sanyo incubator (5% CO2)) for 1 week (Appendix V). 
2.8. In vitro expansion of iNKT cells  
2.8.1. In vitro expansion of iNKT cells with αGal pulsed BMDCs 
This protocol was based on the method described by Chiba et el. (413). BM cells 
were cultured as described in section 2.7. αGal (100 ng/ml) was added to the culture 
on day 6 and cells were harvested on day 7. The αGal pulsed BMDCs were washed 
with medium and irradiated at 3000Rad (~30 Gray (Gy.)) using the CIS bio 
international IBL 437c, and 2x105 BMDCs were plated with 2x106 purified iNKT cells 
in a flat bottomed 24 well plate in iNKT cell medium (Appendix II), in the presence of 
IL-2 and IL-7 (both 10 ng/ml final concentration). The iNKT cells were restimulated 
with irradiated αGal pulsed BMDCs on day 8 and fresh cytokines were added as 
required. Cells were harvested on day 14. Average fold expansion was 2.7. 
Estimated average purity at end of expansion was 71±12%.  
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2.8.2. In vitro expansion of iNKT cells with plate bound anti-CD3 and soluble 
anti-CD28 
This method was based on the protocol described by Govindarajan et al. (414). A flat 
bottomed 96-well plate (Sarstedt) was coated with purified anti-CD3 (3 µg/ml) in 
carbonate bicarbonate buffer (Sigma Aldrich), and incubated for 1 h at 37°C. The 
plate was washed twice with PBS and once with cRPMI. Purified iNKT cells (which 
were purified as described in section 2.3), at a concentration of 5x105/mL (or 1x105 
per well) were plated in cRPMI containing IL-2 (10 ng/ml), IL-12 (1 ng/ml) and soluble 
anti-mouse CD28 (5 µg/ml). Cells were incubated for 2 days at 37°C in a CO2 
incubator (BB15 Thermo Scientific). After 2 days cells were moved to fresh uncoated 
wells. In later experiments, cells were counted on day 2, and re-plated at 5x105/mL. 
On day 4, cells were re-plated at a concentration of 5x105/mL in cRPMI containing IL-
7 (5 ng/ml). Cells were monitored closely and plated with fresh IL-7 in cRPMI when 
required. On day 8, cells were restimulated with anti-CD3 and anti-CD28, and moved 
to fresh wells on day 10. On day 11 cells were re-plated in cRPMI containing IL-7 (5 
ng/ml) and monitored closely and plated with fresh IL-7 in cRPMI when required. 
Cells were harvested and counted on day 14, for use in in vitro and in vivo 
experiments. Estimated average purity at end of expansion was 74±11%. Average 
fold expansion was ~1.6 when calculated from day 0, but ~7 when calculated from 
day 2.  
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2.9. Flow Cytometry  
When cytokine staining was required, cells were stimulated with para-
Methoxyamphetamine (PMA) (Sigma Aldrich) (final concentration 500 ng/ml) and 
ionomycin (final concentration 500 ng/ml) (Sigma Aldrich) and incubated at 37°C for 
1h. After 1h, 1 μl of Brefeldin A (BFA) (e biosciences) (working concentration 3.0 
μg/ml), and 1 μl of monensin (2 μM) (ebioscience), were added to the culture and the 
cells were cultured for a further 4h. Cells were then transferred to FACS tubes (Alpha 
Labs) and washed by adding 1 mL of FACS buffer, at 400 g for 5 min. Supernatants 
were removed and cells were incubation with live/dead dye (Zombie dye (biolegend) 
in PBS or 7-AAD (ebioscience) in FACS buffer for 10 min at r.t. Following this cells 
werewashed with FACS buffer and stained with anti-CD16/32 (Biolegend) in FACS 
buffer (final concentration 1 μg/ml) for 10 min at r.t. and then washed twice with 2 ml 
of FACS buffer.  
 
2.9.1. Controls  
In order ensure the correct compensation was applied to each experiment, single 
colour staining was carried out, using cells and compensation was adjusted 
accordingly. Single colour staining was also used in order to determine the 
appropriate voltages used. The relevant antibody was added to each compensation 
control (Appendix) Isotype controls (Appendix III) were used for intracellular (IC) and 
intranuclear stains, which enabled the correct gating strategy to be applied. 
Fluorescence minus one (FMOs) were used for surface markers that are known to be 
expressed at low levels. Where cell number permitted, unloaded tetramer (Appendix 
III) (NIH Tetramer Core Facility) was used in order to gate iNKT cells.  
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2.9.2. Surface Staining  
The relevant antibodies (Appendix III) were diluted in FACS buffer, and 50 μl were 
added to each sample. The samples were incubated for 30 min at 4°C and 
subsequently washed twice with 1ml FACS buffer.  
 
2.9.3. Intracellular cytokine (IC) staining  
When intracellular staining was required 250 μl of IC fixation buffer (eBioscience) (or 
FOXP3 fixation buffer when intra-nuclear stains were required (eBioscience)), were 
added to the cells, and incubated for 20 min at 4ºC, and then washed twice with 1 ml 
pf permeabilization buffer. The IC antibodies (Appendix III) were then diluted in IC 
permeabilization buffer (eBioscience) (or FOXP3 fixation buffer for intra-nuclear 
antibodies (eBioscience), and 50 μl were added to each sample. Cells were 16 
incubated for 30 min at 4ºC and then washed twice with permeabilization buffer. 
Finally, cells were resuspended in 300 μl of FACs buffer, filtered before acquisition. 
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2.9.4. Alternative stimulation methods 
A 48 well plate was coated with carbonate bicarbonate buffer containing 10 µg/mL 
anti-CD3 at 37°C for 1 hr. The plate was washed twice with PBS and once with 
cRPMI. iNKT cells were purified as described in section 2.3, and purified cells were 
then plated in cRPMI containing 1 µg/ml anti-CD28, 500 µl were added to each 
coated well with a maximum concentration of 6x106 per well. Alternatively, cells were 
plated with BMDCs which had been pulsed with αGal 12 h previously, such that the 
number of BMDCs was a tenth of the number of the iNKT cells. Cells were incubated 
in a CO2  incubator at 37°C, after 2 hr BFA (working concentration 3.0 μg/ml), and 1 
μl of monensin (2 μM) and cells were incubated for a further 4 h. After 6 h cells were 
collected for flow cytometry.  
 
2.9.5. Stimulation of iNKT cells to examine the modulation of surface maker 
expression 
A 96 well plate was coated with carbonate bicarbonate buffer containing 10 µg/mL 
anti-CD3 at 37°C for 1 hr. The plate was washed twice with PBS and once with 
cRPMI. iNKT cells were purified as described in section 2.3, and purified cells were 
then plated in media containing 1 µg/ml anti-CD28, 5x103 were plated per well. 
Alternatively cells were plated in uncoated wells, or plated with BMDCs which had 
been pulsed with αGal 12 h previously or unpulsed BMDCs. The number of BMDCs 
(5x103/well) was such that the number of BMDCs was a tenth of the number of the 
iNKT cells (5x104/well). Cells were incubated in a CO2 incubator at 37°C. After 6 h 
cells were collected for flow cytometry.  
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2.10. Cell counting  
Cells numbers for flow cytometry experiments were determined using beads 
(Spherotech inc.), (1x104 particles/10 μl). Cell numbers for the purpose of tissue 
culture cell were enumerated using a light-microscope and dead cells were excluded 
using trypan blue.  
 
2.11. Confocal microscopy  
2.11.1. Sectioning tissues for confocal microscopy  
Following confirmation of cardiac death, organs were promptly isolated, frozen using 
dry ice or liquid nitrogen and stored at -80ºC. In order to section tissues, organs were 
mounted on optimum cutting temperature cryopreservation media (OCT) (Tissue 
Tek), frozen with cryospray (Bright) and cut in 7 μm sections using a cryostat (Bright).  
 
2.11.2. Staining  
Sections were blocked in anti-CD16/32 (Biolegend), diluted in PBS with 1% BSA 
(final concentration 1 μg/ml) for 10 min at r.t. Primary antibodies were diluted in PBS 
with 1% BSA (Appendix IV), 100 μl were added to each section and the sections 
were incubated for 1 hr at r.t. Slides were washed in PBS and secondary antibodies 
were diluted in PBS with 1% BSA (Appendix IV) and left to incubate for 1 hr at r.t. 
Slides were washed and then submerged in 4′,6-diamidino-2-phenylindole (DAPI) 
diluted in PBS(25 μg/ml) for 30 sec. Slides were washed again and antifade (Cell 
signalling technology) was applied to each section. Slides were covered with 
coverslips, sealed and analysed using the Zeiss 510 Meta confocal microscope.  
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2.12. In vitro TEa T cell suppression assay  
CD4+ TEa T cells were isolated as in section 2.3.1. BMDCs were removed from 
culture washed with RPMI and irradiated at 3000Rad (~30Gy 753 sec). The isolated 
TEa T cells were washed 3 times with 10 ml FCS free medium resuspended in FCS 
free RPMI with Carboxyfluorescein succinimidyl ester (CFSE) (final conc. 2.5 μM/ml) 
(eBioscience), and incubated for 10 min at 37ºC for 10 min in the dark. To neutralise 
the reaction, 10 ml of cRPMI were added to the suspension. αGal pulsed BMDCs 
were plated in a round bottomed 96 well plate at a concentration of 2.5x104/ml 
(5x103/well), with TEa T cells at a concentration of 2.5x105/ml (5x104/well) (10X the 
number of BMDCs). Purified freshly isolated (FI) or Expanded (Exp) iNKT cells were 
added at a ratio of 1:1 with the TEa T cells, and additional at ratios of 1:0.5 (TEa T 
cells:Exp iNKT cells),1:0.25,1:0.0125 and 1:0.1) were tested on some occasions. In 
addition to the basic assay as described above, this assay was also performed in the 
presence of anti-IL-10 receptor (IL-10r) (10 µg/ml), anti-IFN-γ (10µg/ml), anti- 
Programmed cell death protein 1 (PD1) (10µg/ml), anti-PDL1 (5 µg/ml) and anti-
PDL2 (5 µg/ml) and with excess IL-2 (10ng/ml). The cells were cultured for 4 days 
and the harvested for flow cytometry. 
 In some assays TEa T cells were stimulated with anti-CD3 and anti-CD28. A 96 well 
plate was coated with carbonate bicarbonate buffer containing 5 µg/mL anti-CD3 at 
37°C for 1 hr. The purified labelled TEa T cells were then plated in cRPMI containing 
anti-CD28 (2ug/ml) in the presence and absence of Exp iNKT cells and cultured for 4 
days, before being harvested for flow cytometry.    
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2.13. Establishing a mouse model of GVHD  
2.13.1. BM T cell depletion  
BM was flushed from W.T. B6 mice and the BM cells suspended in 200 μl of MACS 
buffer (Appendix II), per 5x107 cells, along with FCS (100 μl per 5x107) and Thy1.2 
antibody (10 μl per 5x107 cells) (Biolegend). The cells were incubated for 20 min, at 
4°C and then washed and resuspended in 4 ml of MACS buffer. The 4 ml cell 
suspension was then added to washed dynabeads (250 μl of beads per 5x107 cells; 
Life Technologies). The cell and bead suspension was then placed on a rotator for 20 
min at 4°C and then onto a DynaMag magnet (Life Technologies). The supernatant 
was then removed into a new tube; this fraction contained the T cell depleted BM 
(TCD BM). Mean frequency post sort of contaminating CD4+ T cells 0.4±0.7%. CD8+ 
T cells 0.2±0.1% (Appendix V).  
 
2.13.2. BM transplant  
CB6F1 recipient mice were given Baytril (Bayer) (0.16 mg/ml) in their water for 1 
week prior to BMT and for 14 days post-transplant. On Day 0, such mice were 
lethally irradiated with 2 doses of TBI, (2x550 centigray (cGy)), 4 h apart. Following 
irradiation, 5x106 B6 TDBM cells were i.v. injected via the tail vein.  
 
2.13.3. Cell isolations and TEa T cell and i.v. injection  
TEa T cells were isolated from the spleen as in section 2.3.1 and re-adjusted such 
that 200 μl contained 1x104 TEa T cells. TEa T cells were i.v. injected via dorsal or 
ventral tail vein (1x104 cells/mouse). Mice were closely monitored for clinical signs of 
weight loss (Appendix I), and weighed daily. 
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2.13.4. GVHD manipulation  
In order to investigate the ability of FI and Exp iNKT cells to suppress GVHD iNKT 
cells were injected i.v. Where FI iNKT cells were injected cells were isolated as 
described in section 2.3. Such cells were then injected i.v. on day 2, concomitantly 
with the TEa T cells, 1x105 FI iNKT cells were injected. When Exp iNKT cells were 
injected cells were expanded for 14 days. On day 2, 1x105 FI iNKT cells were 
injected per mouse, concomitantly with the TEa T cells. In some experiments 
glycolipids were used to activated iNKT cells. Glycolipids were prepared as described 
in section 2.4. Single or multiple doses of αGal (2 µg) or C20.2 (5 µg) were injected 
i.p. starting on day 2, as described in the individual experiments.  
 
2.13.5. GVHD scoring and mortality criteria  
Mice were weighed daily and monitored for clinical signs of GVHD (Appendix I).Mice 
were sacrificed prior to reaching reached 20% weight loss and/or if the animals’ 
clinical score was likely to exceed that stipulated within a moderate severity limit.  
 
2.14. Histology  
Organs were dissected from mice and liver and SI (short 5 mm sections), were fixed 
in formaldehyde 4% aqueous solution buffered (formalin 10%) (VWR chemicals). 
Tissues were processed by Royal Orthopaedic Hospital NHS Foundation Trust 
histology service. Briefly tissue was embedded in wax and sliced using a cryostat 
and sliced into 3 µm sections. Tissues were stained with haematoxylin and eosin. 
Photomicrographs were taken using ZeissAxio Scan.Z1 slide scanner (for the liver) 
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and using the Leica DM4000 B LED (for the SI). The magnification was x20 for the 
liver and x40 for the SI. Tissue was analysed for clinical signs of damage with the 
assistance of experts (Dr. Mona Elshafie, Consultant Histopathologist Queen 
Elizabeth Hospital and Dr. Scott Davies, University of Birmingham, Liver Labs). In the 
SI apoptotic bodies were signs of SI GVHD. In the liver bile duct damage, fibrotic 
tracts and perivascular infiltrates were sings of liver damage.  
 
2.15. Statistical analysis  
Student’s T test (unpaired; two-tailed) was used to determine the significance 
between two sets of related data. One-way ANOVA was used to compare 2 or more 
sets of data. Weight loss and clinical scores were compared with two-way ANOVA 
with post-hoc Bonferroni comparison (or Tukey comparison when comparing 5 or 
more groups). Survival curves were analysed using a log-rank test. Normality of data 
was investigated using the D'Agostino-Pearson omnibus normality test to choose 
whether a parametric or non-parametric test should be performed. Statistics were 
performed using GraphPad Prism 6 (GraphPad Software). P values <0.05 were 
interpreted as statistically significant. Data are presented as mean ± standard 
deviation unless otherwise stated. 
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2.16. Software 
Flow cytometry data was analysed using FlowJo (Treestar). Microarray analysis was 
performed using Transcriptome Analysis Console (Affymetrix). Statistics were carried 
out using Graphpad Prism 6 (Graph Pad Software, La Jolla California USA). 
Glycolipid structures were drawn using ChemDraw (online version). Modification of 
files from Servier Medical Art (licensed under a Creative Common Attribution 3.0 
Generic License) was used in some figures.  
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CHAPTER 3 ESTABLISHING AN IN VIVO MODEL 
OF GVHD 
 
 
 
 
 
 
 
3.1. Introduction 
GVHD is a disease that develops following HSC transplant as a result of 
contaminating donor T cells in the transplant recognising alloantigen leading to tissue 
destruction in the skin, lungs, liver and GI tract. Acute GVHD occurs in the first 100 
days after HSC transplantation and it is a major cause of mortality and morbidity in 
the 30,000 people who receive transplants worldwide every year. Numerous mouse 
models of acute GVHD have been developed with the aim of understanding the 
process of disease initiation and progression, in addition to possible methods of 
treatment. Indeed, much of what is known about the initiation of GVHD comes from 
studying mouse models. This research stemmed from the seminal murine studies of 
Korngold and Sprent, who first discovered that alloreactive T cells are the main 
mediators of GVHD (415, 416).  
95 
 
While effector T cells are essential for disease in all models of GVHD the nature of 
the T cells and their interactions with recipient and host cells varies. Models of GVHD 
can be either CD4+ T cell driven, CD8+ T cells driven or both. Some models are fully 
MHC mismatched, while others depend on mHC disparities. Where there is a full 
MHC-mismatch, GVHD is induced due to differences in MHC class I and MHC class 
II (H2) molecules, which can be recognised either directly (as intact recipient MHC + 
peptide complexes) or indirectly (following processing and presentation of recipient 
alloantigens by donor MHC). This results in the activation of both CD8+ and CD4+ T 
cells. In humans, high-resolution DNA typing is used to match transplants, which are 
major histocompatibility matched and usually only differ at mHCs, and as such mHC-
mismatched models represent clinical transplantation more closely.     
The first step in inducing GVHD in mice is generally TBI, although chemotherapy with 
cyclophosphamide, fludarabine, and busulfan may also form part of the conditioning 
regime (417). The irradiation dose required for lethal irradiation varies according to 
mouse strain. B6 mice are generally more resistant than BALB/c mice and F1 
progeny are generally more resistant than their parents (418). The conditioning 
regime initiates GVHD by causing damage to the host tissue and release of cytokines 
such as IL-1β and TNF-α which contribute to what is commonly referred to as the 
cytokine storm (149, 172, 419). In addition, PAMPs, DAMPs, chemokines and gut 
commensals are released (420). This leads to the activation of APCs (158, 160). The 
conditioning regime can be particularly damaging to the GI tract, where the release of 
LPS and other immunostimulatory microbial products can further perpetuate the 
cycle of inflammation (151, 153, 172, 421). Indeed the severity of GVHD can be 
correlated with the intensity of the treatment regime in both humans and mice (151, 
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154-156). Models which use irradiation doses of 1100 cGy are delivered in 
fractionated doses to decrease gut toxicity (163). Human conditioning regimes 
usually consist of chemotherapy with or without irradiation, and irradiation is usually 
fractionated.   
BM ablation provides a niche for the donor BM to engraft and reconstitute the 
immune system. This is reflective of what happens clinically when a patient is 
reconstituted with a healthy immune system, although HSCs in humans are now 
most commonly derived from mobilised stem cell products. Generally mice are given 
TCD BM, in order that alloreactive T cells can be added back in a controlled manner. 
This allows the GVHD-causing T cells to be added back at the time point, phenotype 
and number relevant to the biological question. Upon transplantation T cells traffic to 
the secondary lymphoid organs within 24 h (422, 423). This is thought to be critical 
for GVHD initiation. In the context of GVHD T cells produce further proinflammatory 
cytokines amplifying the cycle of inflammation. 
The release of cytokines such as IFN-γ leads to the activation and recruitment of 
additional effector cells such as NK cells, B cells, neutrophils and monocytes 
resulting in further T cell proliferation in an antigen independent manner (157, 419). 
Additionally, proinflammatory macorphages produce TNF-α, IL-1β and NO (153, 
167). Donor T cells exhibit a recently activated phenotype (CD62LlowCD44high) and by 
day 3 have upregulated the gut homing receptor α4β7 and migrate to the GI tract 
where they are activated in an antigen specific manner when they encounter 
alloantigen presented by myofibroblasts and epithelial cells within the GI tract (423, 
424). The initiation of gut GVHD precedes cell infiltration into the skin (423). The end 
result is that activated effector T cells traffic to all GVHD target organs, namely the GI 
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tract, skin, lung and liver, causing organ damage. Such damage is mediated through 
perforin and granzymes, TNF-α and Fas-FasL interactions (173, 425-428). 
Additionally Th17 cells may play a role in the pathophysiology of GVHD, although 
such cells have been shown to be sufficient but not an absolute requirement to cause 
GVHD (429).  
The severity and clinical signs of GVHD can vary depending on multiple factors such 
as the dose and type of T cells used to mediate GVHD (202, 226, 227), the age and 
sex of the mice, variations in environmental pathogens and gut microflora (which can 
be influenced by animal supplier and local animal facilities) and genetic disparity 
between donor and recipient (228). In addition, as previously mentioned, GVHD can 
vary according to the dose of irradiation which influences the extent of tissue damage 
and therefore alloreactive T cell activation (229).  
While mouse models can be very useful in understanding GVHD, it is important to be 
aware of the caveats associated with such models and the disparities between 
humans and mice. Factors such as the proportions of effector cells, differing 
condition regimes, differing sources of haematopoietic cells and differences in gut 
microflora between species all have the ability to influence the initiation and 
progression of the disease.  
Despite these caveats, much of what we know about GVHD was discovered from 
mice, and they continue to provide critical information that allows for significant 
innovations to reach the clinic. A recent example of this is the use of hypomethylating 
agents such as decitabine and azacitidine which can peripherally convert CD4+ T 
cells into FOXP3+ Treg which can abrogate GVHD in mice (430). This has led to 
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stage 1/2 clinical trials. Mouse models provide us with tools which allow us to dissect 
and manipulate GVHD in a way that is not possible in humans. For example, some 
mouse models of GVHD make use of transgenic and knockout mice as either donors 
or recipients. This can be extremely useful in enabling mechanistic dissection. In vivo 
imaging is also possible using CFSE, Bromodeoxyuridine (BRDU) or luciferase 
transgenic cells. In addition, the GVT effect can be investigated using transplantable 
tumour cell lines. Furthermore, newly developed humanised mouse models provide 
us with a system in which human T cell mediated GVHD can be studied and 
manipulated in vivo.    
It is evident that despite extensive research traditional therapies are less than perfect 
as at least half of patients develop some form of GVHD. An exciting area of 
therapeutic potential is the utilisation of immune cells to regulate the unwanted 
immune responses that result in GVHD whilst sparing the GVT or GVL response. For 
example, Treg have been shown to suppress GVHD in a number of mouse models 
(196, 202, 203) which has resulted in Treg being tested in clinical trials for the 
treatment of GVHD (206, 431). Our own interest lies predominantly with another type 
of immune cell that has been demonstrated to have immunomodulatory properties; 
the iNKT cell (230). This interest in iNKT cells as a therapy for GVHD originated in 
work on the immunosuppressive behaviour of iNKT cells following solid organ 
transplantation (231-233). Indeed, it has now been shown that iNKT cells decrease 
the risk and severity of GVHD in some mouse models (238, 408), whilst maintaining 
the GVT effect (234, 238).  
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3.2. Aims and hypothesis 
To enable us to investigate the ability of iNKT cells to influence GVHD we aimed to 
set up a model utilising alloreactive TCR-transgenic T cells. This model involves 
using CD4+ T cells isolated from the TEa line of mice (B6 background; H2b), which 
specifically recognises a 17-mer peptide of the BALB/c H2IEα-chain presented in the 
context of H2IAb (i.e., presented by B6 MHC class II via the indirect pathway) (432). 
CB6F1 mice (F1 progeny of B6 and BALB/c) endogenously produce and present the 
H2IEα peptide in the context of H2IAb enabling recognition by TEa T cells (Figure 
3.1). CB6F1 mice are CD45.2, whereas the GVHD-causing TEa T cells are CD45.1 
which enables identification of TEa T cells when injected into CB6F1 mice when 
combined with staining for the TEa TCR Vα chain (Vα2). TEa T cells have previously 
been shown to be capable of inducing GVHD (433). 
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Figure 3.1 Recognition of MHC-peptide complex by TEa T cellsTransgenic CD4
+
 TEa T cells (from 
B6 background mice; H2
b
), specifically recognise a 17-mer peptide of the BALB/c H2IEα-chain 
presented in the context of H2IA
b
 (i.e. presented by B6 MHC class II via the indirect pathway). CB6F1 
mice (F1 progeny of B6 and BALB/c) present this BALB peptides to TEa T cells, causing them to be 
alloactivated, proliferate and mediate GVHD. TEa T cells express CD45.1, whereas the host cells are 
CD45.2
+
. Additionally, they express a Vα2 TCR which further aids their identification.  
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3.3. Results  
3.3.1. TEa T cells induce weight loss, increased clinical signs of GVHD and 
death following transfer to lethally irradiated CB6F1 mice 
We first set-out to establish a model of GVHD where the GVHD-causing alloreactive 
T cell response could be followed in vivo. The model would then be employed to 
investigate the ability of iNKT cells to suppress GVHD. To this end, CB6F1 mice were 
lethally irradiated (1100 cGy split-dose) and were given 5x106 B6 TCD BM i.v. on day 
0. On day 2, CB6F1 mice received adoptive transfer of 5x104 TEa T cells i.v. and 
such mice were weighed daily and monitored for the development of clinical signs 
indicative of the development of GVHD. 
Mice that received TCD BM and 5x104 TEa T cells demonstrated significant weight 
loss compared to control mice that received TCD BM transplant only (Figure 3.2A). 
This loss of weight correlated with increased clinical scores which suggest that TEa T 
cells can induce GVHD in this model (Figure 3.2B). 2 out of 3 mice that received TEa 
T cells were sacrificed 10 days after transplant due to the loss of 20% body weight 
whereas all control mice survived with no significant weight loss or clinical signs of 
GVHD. 
To assess whether the weight loss observed in mice that received TEa T cells was 
related to the transfer of such cells, we investigated if TEa T cells were detectable in 
secondary lymphoid organs at the time of the appearance of symptoms of GVHD. 
The number of leukocytes and TEa T cells in the spleen and Mesenteric lymph node 
(MLN) of such mice were evaluated (Figure 3.2). There was an increase in the total 
number of leukocytes in the MLN compared to BM only controls (Figure 3.2G) and 
TEa T cells were detectable in the spleen and MLN of diseased mice (Figure 3.2F, 
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D). This suggests that that the induction of GVHD symptoms was caused by an anti-
recipient immune response that required TEa T cells.  
The kinetic of GVHD shown in Figure 3.2 was very acute which may impact any 
attempt to prevent this form of GVHD. Therefore, in order to slow the onset of the 
disease and increase the window in which it would be possible to manipulate GVHD 
in future experiments, the experiment was repeated with lower doses of TEa T cells. 
To this end, CB6F1 mice were lethally irradiated and given 5x106 TCD BM i.v. on day 
0 as well as 2.5x104 or 1x104 or no (control) TEa T cells via i.v. injection, on day 2. 
Mice were weighed daily and monitored for clinical signs of GVHD. Mice were 
sacrificed prior to 20% weight loss and/or if the animals’ clinical score exceeded that 
stipulated within the moderate severity limit.  
Mice that received either 2.5x104 or 1x104 TEa T cells experienced significant weight 
loss starting on day 9 compared to controls (Figure 3.3A). Furthermore, by day 10 
the mice that had received 2.5x104 had lost significantly more weight than mice 
injected with 1x104 TEa T cells. Similarly, mice that received 2.5x104 and 1x104 TEa 
T cells (Figure 3.3B) showed clinical signs of GVHD on day 9 and 10, which 
correlated with decreased survival compared to controls (Figure 3.3C). However, the 
survival of the mice that had received 1x104 TEa T cells was only extended by 1 day 
compared to those that received 2.5x104 (Figure 3.3C).  
Given that using 1x104 TEa T cells only increased survival by one day we examined 
the ability of 5x103, 2.5x103 and 1x103 TEa T cells to induce GVHD. While all groups 
except those that received 1x103 TEa T cells led to significant weight loss (Figure 
3.4A) and all groups induced clinical signs of GVHD (Figure 3.4B), the optimum 
survival that still resulted in complete penetrance was 1x104 TEa T cells (Figure 
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3.4C). Therefore, we decided to proceed with a dose of 1x104 TEa T cells in all future 
experiments.  
 
3.3.2. The onset of the symptoms of GVHD correlates with the presence of TEa 
T cells in CB6F1 recipients and an increase in proinflammatory cells 
In order to examine the various immune cells that participate in the induction of 
GVHD in this model, leukocytes were isolated from the spleens and MLN of mice that 
received 2.5x104 or 1x104 or no TEa T cells and analysed by flow cytometry. 
An examination of absolute cell numbers revealed that there was a significant 
increase in the total number of leukocytes in the spleen and MLN in mice that 
received 2.5x104 and an increase in total leukocyte numbers in the MLN of the mice 
that received 1x104 or 2.5x104 TEa T cells (Figure 3.5A and B). Similarly, TEa T cells 
were detectable in the spleen of both experimental groups compared to control mice 
(Figure 3.5C). There was no difference in myeloid cells (MC) (Gr1+CD11b+) or 
Ly6C+cells (monocytes (Mo)) and Ly6G+ cells (polymorphonuclear (PMN) leukocytes) 
in both the MLN (Figure 3.5D) and spleen (Figure 3.5E). The number of DCs was 
increased in both experimental groups in the MLN (Figure 3.5F) and spleen (Figure 
3.5G), which is in line with observations that DCs are important for GVHD initiation 
(434). Interestingly, B cells were increased in the MLN (with 1x104 TEa T cells) but 
not the spleen (Figure 3.5H and I). Additionally, there was no increase in the number 
of NK or iNKT cells (Figure 3.5C).  
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The changes in immune cell populations during GVHD were further investigated in 
terms of relative cell frequencies in a given lymphoid compartment. An examination 
of cells by flow cytometry showed a significant increase in the frequency of TEa T 
cells and myeloid cells (Mo and PMN). This is expected as alloreactive T cells in the 
spleen are known to be associated with the onset of GVHD and neutrophils have 
been shown to increase in frequency in the spleen in GVHD (435).There was a 
decrease in the frequency of NK cells, DCs, iNKT cells and B cells in the spleen in 
mice i.v. injected with 1x104 TEa T cells, compared to controls (Figure 3.6A). As DCs 
were decreased in absolute number, the decrease in the frequency of DCs must be 
due to the expansion of other populations. Furthermore, the majority of myeloid cells 
were Mo in the group that received 1x104 TEa T cells compared to in the control 
group, in which there was no difference between the frequency of Mo and PMN 
(Figure 3.6A). In contrast in the MLN, there were decreased frequencies of B cells, 
myeloid cells both Mo and PMN (Figure 3.6B) in group that received 1x104 TEa T 
cells compared to in the control group. Furthermore, in contrast to what was 
observed in the spleen, the majority myeloid cells were Mo in the control group 
(Figure 3.6B).  
Taken together, these findings show that in addition to TEa T cells being detectable 
in the spleen and MLN (as shown in the previous experiment), the onset of 
symptoms of GVHD is also associated with an expansion of DCs which are 
responsible for presenting alloantigen to TEa T cells. Perturbations in other immune 
cell populations such as an increase in the frequency of MC in the spleen also occur 
which is in line with what is expected in inflammation. However, MC were decreased 
in frequency in the MLN in mice that received TEa T cells, suggesting that as GVHD 
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is a complex multi-organ disease the immune response is not always uniform at all 
anatomical locations at disease onset.    
To assess whether the TEa T cells and myeloid cells observed in the spleen by flow 
cytometry were also detectable by confocal microscopy spleens from mice that 
received 1x104 TEa T cells or no TEa T cells were examined. Sections were stained 
for CD45.1, which is expressed by TEa T cells only, and Gr1, which is expressed by 
myeloid cells. TEa T cells could be detected in the spleens of mice that received 
1x104 TEa T cells (Figure 3.7B) cells but not controls (Figure 3.7A). The TEa T cells 
in the mice that received 1x104 TEa T cells appeared to be clustered in what may be 
a germinal centre with Gr1+ cells located in the surrounding tissue (Figure 3.7D). This 
confirmed that TEa T cells are detectable in the spleen as was observed from the 
flow cytometry analysis. 
 
3.3.3. Examination of different immune cells present 2 weeks post BM 
transplant  
In order to investigate the balance of donor and recipient cells are present two weeks 
post-transplant, and hence what cells might be available to interact with AT iNKT 
cells, CD45.1+ TCD BM was transferred into lethally irradiation CB6F1 recipients. 
Immune cells were isolated from the spleen on day 14 and analysed by flow 
cytometry.  
An examination of immune cell frequency in the spleen revealed a decrease in iNKT 
cells in chimeras compared to CB6F1 WT controls (Figure 3.8A). In addition, there 
were more recipient iNKT cells than donor iNKT cells in terms of frequency, 
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suggesting a radioresistant population of iNKT cells (Figure 3.8A). The overall 
frequency of recipient NK cells was also reduced in the chimeras compared to WT 
controls (Figure 3.8B), as was CD4+ and CD8+ T cell frequencies (Figure 3.8D). In 
contrast, there was an increase in overall frequency and donor frequency of Gr1+ 
cells (Figure 3.8C).   
 
3.3.4. GVHD caused by TEa T cells involves recognition of alloantigen and is 
not a product of homeostatic expansion 
To ensure that GVHD in this model was caused by recognition of alloantigen and not 
due to the homeostatic activation and expansion of the TEa T cells, 1x104 TEa T 
cells were injected into either CB6F1 (H2b/d) or B6 (H2b; syngeneic) recipients, both 
of whom had received TBI and TCD BM. Mice were culled on day 8 and the 
activation and expansion of TEa T cells in different tissues analysed. TEa T cells 
were found to have increased in frequency and number in the spleen and MLN of 
CB6F1 recipients compared to being barely detectable in syngeneic B6 mice (Figure 
3.9A-D). In addition, the TEa T cell frequency and number also dramatically 
increased in 2 GVHD target tissues namely, the SI and Liver (frequency only) 
compared to syngeneic controls (Figure 3.9E-G). A cohort of B6 (syngeneic) mice 
that received TCD BM and TEa T cells were followed for 50 days post BM 
transplantation (data not shown). No symptoms of GVHD were recorded, 
demonstrating that in the absence of alloantigen TEa T cells do not induce GVHD. 
Together these data demonstrate that TEa only expand and infiltrate GVHD target 
tissues when the recipient expresses the cognate alloantigen. 
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3.3.5. Expansion of alloreactive TEa T cells in CB6F1 recipients occurs 
concomitantly with the expansion of other inflammatory cells such as MC 
and DCs, as well as perturbations in other populations, in a location 
dependent manner 
Mice that had received TCD BM and TEa T cells were culled on day 8, prior to the 
expected earliest onset of disease, to enable all mice to be compared at the same 
time point, and in order that we could investigate which cells were contributing to 
GVHD. An examination of immune cell frequency and absolute numbers showed an 
increase in total CD4+ T cells and donor BM derived CD4+ T cells in the spleen and 
MLN of mice with GVHD (Figure 3.10A-D). In addition there was an increase in total 
CD4+ T cell frequency and donor CD4+ T cell frequency in the SI and Liver (Figure 
3.10E, G). Furthermore, the predominant population (in terms of frequency) of CD4+ 
T cells was host derived in all experiment groups in the MLN, SI and liver as well as 
the group that received BM only in the spleen (Figure 3.10 A, C, E, G). These 
observations are consistent with previous studies that have shown that host residual 
radio resistant T cells can be identified post BMT (436-439).  
In contrast, the only difference in B cells observed between mice that received TEa T 
cells or BMT only was that the frequency of donor cells in the MLN was decreased in 
the GVHD group compared to BMT controls (Figure 3.11C) and a decrease in the 
number of B cells in the SI in both the donor and host compartments in GVHD mice 
(Figure 3.11F). The observed decreases in B cells are in keeping with previous 
studies in humans and mice which suggest that B cell generation from B cell 
progenitors in the BM is delayed in GVHD (440-442). In the spleen, the dominant 
population in both experimental groups was recipient derived (Figure 3.11A, B), while 
in the MLN there was only an increase in recipient cells in the group that received BM 
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only (Figure 3.11C, D). Similarly, in the SI the dominant population was recipient 
derived in the disease group in terms of frequency (Figure 3.11E), whereas in terms 
of numbers the recipient population only dominated in the group that received BM 
only (Figure 3.11F). Collectively, these data suggest that day 8 is too early a time 
point for B cells to have reconstituted from the BM.  
There was no difference in NK cells between the GVHD and control group in the 
spleen in terms of cell number and in the Liver in terms of cell frequency (Figure 3.12 
A, B, G). NK cells were predominantly of donor origin in the spleen and liver in the 
mice which were in the disease group and additionally NK cells were mainly donor 
cells in the control mice in the liver (Figure 3.12 A, B, G) cells could not be 
convincingly detected in the MLN and SI. The tendency towards NK cells being 
predominantly of donor origin in mice that have GVHD may be due to the 
inflammatory conditions of the disease contributing to NK cell expansion.    
Donor iNKT cells were increased in the mice that received TEa T cells in the spleen 
compared to BMT controls in terms of frequency and absolute number (Figure 3.12C, 
D) and there was an decrease in the overall iNKT cell frequency in the liver of GVHD 
mice compared to BM controls, as well as a decrease in recipient derived cells in 
disease (Figure 3.12G). However, iNKT cells numbers and frequencies were similar 
in all groups in the SI (Figure 3.12E, F) and were not detectable in the MLN. The 
increase of iNKT cells in the spleen in mice with GVHD may be due to the 
inflammatory conditions leading to production of inflammatory cytokines leading the 
maintenance and proliferation of the donor iNKT cells. It is possible that at a later 
time point iNKT cells would also be observed to expand in other anatomical 
locations.  
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In terms of the provenance of the iNKT cells, recipient cells were the dominant 
population in both experimental groups in the spleen (Figure 3.12C, D), which was 
also true regarding the frequencies in the liver (Figure 3.12G). In contrast in the SI, 
the only difference observed was an increase in recipient iNKT cells in the GVHD 
group. The dominance of recipient iNKT cells observed is in keeping with the 
observation that radioresistant iNKT cells remain post-BMT, due to higher levels of 
anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) (443).   
Upon examination of MC in the MLN we observed a decrease in the frequency of MC 
in disease (Figure 3.13C), while in the SI there was an increase in total MC 
frequency and in total and recipient PMN frequency in disease (Figure 3.13E). (444, 
445). Regarding the provenance of the inflammatory myeloid cells in the spleen, 
MLN, SI and Liver recipient cells dominated in the Mo and PMN compartments in all 
locations (Figure 3.13A, C, E, G).This indicates that this time point is too early to 
observe full reconstitution by donor cells. Furthermore in terms of numbers, there 
was an increase in the number of recipient PMN and Mo compared to donor cells in 
the spleens of both experimental groups (Figure 3.13B) and an increase in the 
number of recipient PMN in both groups in the SI (Figure 3.13F), and neither subset 
dominated in the MLN (Figure 3.13D). In addition, in the group that received TEa T 
cells there is a higher frequency of PMN than Mo in the MLN (Figure 3.13C) and a 
higher frequency and number of PMN than Mo in the SI (Figure 3.13E).  
Mice with GVHD were found to have an increased frequency of donor DCs in the 
spleen compared to BMT controls (Figure 3.14A), however this was not observed in 
the MLN, where there was an increase in the number of recipient DCs in disease 
mice compared to controls (Figure 3.14C). In contrast, a significant increase in the 
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frequency and number of such cells was seen in non-disease CB6F1 mice, as well 
as recipient derived DCs in the SI (Figure 3.14E, F). The lack of expansion of donor 
DCs may suggest that the time point was too early to see an increase in donor DCs. 
Further examination revealed that in terms of frequency, in both experimental groups 
recipient DCs were the dominant population compared to donor cells in all locations 
(Figure 3.14A, C, E, G). This is in line with what was observed with other innate cells 
such as Mo, again suggesting that the innate compartment is not fully reconstituted 
by day 8.     
Collectively, these data demonstrate that although there was significant increase in 
TEa T cells, the donor cells had not fully engrafted by day 8. Furthermore, these data 
make evident the immunological context into which we planned to transfer iNKT cells 
in later experiments, which may have an influence on their response.  
 
3.3.6. Signs of damage can be observed in the liver and SI of mice with GVHD 
In order to investigate if the increased weight loss and clinical scores and expansion 
of TEa T cells and other inflammatory cells correlated with tissue damage in target 
organs of GVHD we harvested livers and SI samples to investigate if histological 
signs of GVHD were present. Liver lobes and small segments of the SI were 
harvested on day 8 just before the onset of disease and investigated using 
histopathlogy. In the SI, apoptotic crypt cells were identified in the SI of CB6F1 mice 
that received B6 TCD BM and TEa T cells, but not in BM controls (Figure 3.15A, B). 
Apoptotic crypt cells are a known sign of intestinal GVHD (446). As this was an early 
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time point, we did not expect to see extensive crypt damage, to investigate the 
occurrence of crypt damage it would be necessary to look after disease onset.  
In the liver bile duct damage and fibrotic tracts were seen in CB6F1 mice that 
received B6 TCD BM and TEa T cells, but not in BM controls. These features are 
signs of liver GVHD (3.15C) (446). Furthermore, perivascular infiltrates, a known sign 
of liver GVHD, were also observed in mice that had ongoing GVHD (Figure 
3.15D)(446). These histopathological signs of GVHD corroborate our previous 
findings regarding clinical scores, weight loss and infiltration of the SI and liver with 
TEa T cells.   
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3.4. Discussion  
We have established a robust model of GVHD involving weight loss, clinical 
symptoms and damage to the liver and GI tract. Zhang et al. previously showed that 
5x104 TEa T cells can induce lethal GVHD (433). Therefore, in the initial pilot study 
5x104 TEa T cells were administered (Figure 3.2). The mice required sacrifice due to 
weight loss and or clinical symptoms consistent with GVHD on day 10. The 
expansion of TEa T cells in the spleen and MLN of mice with GVHD was easily 
detectible using flow cytometry (Figure 3.2F, H). TEa T cells were also identified in 
the spleen from mice that received 1 x104 TEa T cells as well as by confocal 
microscopy in the spleen (Figures 3.5, 3.6 and 3.7). In terms of timing, the results 
were broadly consistent with what has previously been reported in the literature; 
disease onset was on day 20 for Zhang et al. and Day 14 for Koyama et al. (424, 
433).  
However we felt that the rapid disease progression may hamper the ability of iNKT 
cells to suppress GVHD, but we found that lower doses also induced GVHD with a 
similar kinetic (Figures 3.3 and 3.4). One factor that might be responsible for such 
aggressive GVHD was that purified TEa T cells were injected without any accessory 
cells such as Treg that may harbour immunomodulatory potential and slow the 
course of the disease. Treg would be present as contaminants in most T cell 
mediated models of GVHD. This was also the case in other labs that use this model, 
and therefore this model may be reflective of an extremely rapid form of acute GVHD 
(424, 433). Furthermore, it is the very fact that TEa T cells do not have the caveat of 
contaminating regulatory cells or indeed non-alloreactive cells that we chose this 
model. Indeed, this model provides us with the ability to stringently test the capacity 
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of iNKT cells to suppress GVHD, and assign those properties to iNKT cells 
specifically. 
Another possible factor which may have led to rapid death by GVHD in this model is 
that we are utilising TCR-transgenic T cells which recognise a specific alloantigen, 
rather than polyclonal T cells which are used in most models. However, even when 
we titrated the TEa T cells down to numbers as low as 1x103 (Figure 3.4) there was a 
limited impact on disease suggesting that lowering the numbers of such cells does 
not significantly impact the kinetics of the disease.  
Another possible explanationis is that excessive inflammation caused by the 
irradiation may cause GVHD to progress rapidly. All experiments conducted 
consisted of 2 doses of 550 cGy as this is what has been reported in the literature to 
result in lethal irradiation in CB6F1 mice (424). However, it is important to note that 
since variation in environmental pathogens due to different animal providers and 
facilities can affect GVHD it might be possible to slow progression by decreasing the 
irradiation dose (167). However, since UK regulations prohibit us testing to see if 
lower doses can still lethally irradiate a mouse, we decided to progress with the 
known and generally used lethal dose for CB6F1 mice.   
Disease onset occurs concomitantly with the detection of TEa T cells in the spleen 
and MLN (Figure 3.2) and we have also analysed GVHD mice just prior to disease 
onset and detected the expansion of TEa T cells in the spleen and MLN as well as in 
two target organs, namely the SI and the liver (Figure 3.9). This data argue that 
GVHD results from a genuine alloresponse in this model and is not merely a product 
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of homeostatic expansion of the TEa T cells as TEa T cells did not expand or cause 
disease in syngeneic controls (Figure 3.9, and data not shown).  
The decrease in the frequency of MC observed in the MLN may be due to them 
being located elsewhere at this time point, indeed neutrophils have been shown to 
infiltrate the intestine as a result of damage from irradiation and migrate to the MLN 
at a later point where they act as APCs (444). Indeed, there was an increase in total 
MC frequency and in total and recipient PMN frequency in the SI of mice that 
received TEa T cells on day 8 (Figure 3.13E). This observation is in line with what is 
expected as one would expect to see infiltration of immune cells during an 
inflammatory response more specifically during GVHD. Furthermore, in the group 
that received TEa T cells there is a higher frequency of PMN than Mo in the MLN 
(Figure 3.13C) and there was a higher frequency and number of PMN than Mo in the 
SI (Figure 3.13E). PMN are predominantly made up of neutrophils which are 
recruited to the intestinal during GVHD initiation when intestinal bacteria release due 
to loss of barrier integrity leads to their recruitment (445). Such cells then go on to 
contribute to tissue damage using ROS. In addition these cells are predominantly of 
donor origin which is in line with what is seen in the literature (445). Perhaps if we 
had looked in the SI after disease onset this increase would also have occurred in 
terms of absolute numbers. After disease onset, there was an increase in the 
frequency of MC (both MC and Mo) (Figure 3.6) in the spleen of diseased mice 
compared to controls which is not observed at Day 8. This is expected as the 
response is thought to affect the intestine first and then then become more wide-
spread (151, 153, 172, 421). 
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Another interesting observation is that CD4+ T cells are predominantly of recipient 
origin on day 8 (Figure 3.10). This is as expected as it is well known that there is a 
residual population of T cells following lethal irradiation (436-439). Furthermore, there 
is an increase in the frequency of donor BM derived CD4+ T cells in the spleens and 
MLN of mice with GVHD compared to syngeneic controls, perhaps indicative of TEa 
T cell derived IL-2 causing such cells to expand. 
It is also interesting to note that there was no change in the frequency of DCs in the 
spleen or MLN at day 8 (Figure 3.14A, C), whereas there was a decrease in the 
frequency of DCs in the spleen of GVHD mice at disease onset (Figure 3.7A). This is 
likely due to timing as one would expect an increase in inflammatory mediators after 
GVHD onset. Further examining the DCs at the day 8 time point, in the spleen we 
observed an increased frequency of donor DCs in the spleen compared to BMT 
controls (Figure 3.14A). In contrast the MLN, where there was no change in 
frequency between GVHD and controls, however an increase in the number of 
recipient DCs was observed in diseased mice (Figure 3.14B). Interestingly, a 
significant increase in the frequency of such cells was seen in non-disease CB6F1 
mice, as well as recipient derived DCs in the SI (Figure 3.14E). This decrease in DCs 
in the SI in disease may be due to the killing of donor DCs by TEa T cells in the SI, 
however, this is unlikely due to the fact that CD4+ T cells have poor cytotoxic 
function. A more likely hypothesis is that this observation is due to a perturbation of 
immune trafficking causing DCs to be directed to the MLN which is the priming LN for 
the SI and indeed there is an increase in the number of DCs in the MLN (Figure 
3.14B).  
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It is interesting to note that there is a radioresistant population of iNKT cells present 
in BM chimeras (Figures 3.8 and 3.12) and that population is increased in the spleen 
in GVHD compared to control mice as well as being the dominant population of iNKT 
cells in terms of numbers in the spleen and SI of GVHD mice (Figure 3.12C, D, F). 
This is in line with what has been shown in humans (447).This means that activating 
AT iNKT cells in future experiments, will also activate these residual cells and unlike 
the donor cells this cannot be circumvented by using KO BM.  
We also observed histological sings of damage in the SI, namely apoptotic crypt 
cells, which are a classic sign of gut GVHD (Figure 3.15) (448). In addition we 
observed liver cirrhosis, bile duct disruption and inflammatory infiltrates which are all 
signs of liver GVHD (Figure 3.15) (448). The degree of damage was not severe, 
however as the samples were taken just prior to disease onset in order to compare 
organs harvested contemporaneous and not according to survival. It is probably that 
if we examined mice at the height of disease the damage would be more marked. In 
addition, it would be interesting to observe the presence of GVHD associated 
cytokine such as IL-1β and TNF-α using RTqPCR in the future.  
In conclusion we have established a model of GVHD in which we can track 
allogeneic transgenic TEa T cells in vivo. These cells induce weight loss and clinical 
symptoms of disease, which appear concomitantly with the expansion of TEa T cells 
and GVHD associated perturbations in other immune populations. In addition, TEa T 
cells are easily identifiable in both lymphoid and non-lymphoid tissue where they 
expand following alloantigen recognition and facilitate damage in at least two target 
organs, namely the gut and liver. Therefore, this model provides us with a critical tool 
to investigate the ability of iNKT cells to influence GVHD in vivo.  
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3.5. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 The onset of GVHD like symptoms occurs concomitantly with TEa T cell expansion 
in the spleen and MLN CB6F1 mice were lethally irradiated and given 5x106 TCD B6 BM cells i.v. on 
day 0. On day 2, 5x10
4 
TEa T cells were administered via i.v. injection. Control mice received 
irradiation and BM transplant only. Mice were assessed for signs consistent with GVHD by monitoring 
(A) weight and (B) clinical symptoms. Mice were sacrificed prior to 20% weight loss and spleen and 
MLN derived leukocytes analysed by flow cytometry. Results are expressed as absolute numbers of 
leukocytes gated on (C, D, E, G) live cells and (C, D , F, H) absolute number of TEa T cells (gated on 
lymphocytes, live cells, TCR-β and CD4 and CD45.1 and Vα2 in the spleen and the MLN). Results are 
analysed using repeated measure two-way ANOVA with post hoc Tukey’s comparison for weight loss 
and clinical scores, and unpaired t-tests were used for cell numbers. Data shown are mean ± SD (n=3 
mice). *p<0.05, **p<0.01, versus control. See Appendix V for gating strategy.  
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Figure 3.3 TEa T cells induce weight loss, increased clinical signs of GVHD and death CB6F1 
mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice received 
2.5x10
4
 or 1x10
4
 or no TEa T cells via i.v. injection, on day 2. Mice were assessed for GVHD by 
monitoring (A) weight and (B) clinical scores consistent with GVHD. (C) Survival curve, mice were 
sacrificed before they exceeded 20% weight loss. Data shown are expressed as mean ± SD (n=5 
mice per group). Results are analysed using repeated measure two-way ANOVA with post hoc 
Tukey’s comparison for weight loss and clinical scores and Log-rank tests were used to analyse 
survival. *p<005, **p<0.01, ***p<0.001.  
*=1x10
4
TEa T cells vs. BM only  
†=2.5x10
4
 TEa T cells vs. BM only.  
‡ 1x10
4
TEa T cells vs 2.5x104 TEa T cells.     
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Figure 3.4 There is no significant change in weight loss, clinical score or survival with doses as 
low as 1x10
3
 TEa T cells CB6F1 mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. 
on day 0. Such mice received 1x10
4
, 5x10
3
, 2.5x10
3
, 1x10
3
 or no TEa T cells via i.v. injection, on day 
2. (A) Weight curves of mice show no significant difference as in the case with (B) clinical scores and 
(C) survival. Results are presented as the mean frequency of cells ± SD (n=2-3 mice). Results are 
analysed using repeated measure two-way ANOVA with post hoc Tukey’s comparison for weight loss 
and clinical scores and Log-rank tests were used to analyse survival.*p<0.05, **p<0.01 ***p<0.001, 
versus control.  
*= 5x10
3 
vs. no TEa T cells  
†= 1x10
4
 vs. no TEa T cells , 
‡= 2.5x10
3
 vs. no TEa T cells, 
§= 1x10
3
 vs. no TEa T cells.   
 
120 
 
 
 
 
 
 
 
121 
 
Figure 3.5 GVHD correlates with the presence of TEa T cells and expanded numbers of DCs 
and B cells in GVHD CB6F1 mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on 
day 0. Such mice received 2.5x10
4
 or 1x10
4 
or no TEa T cells via i.v. injection, on day 2. (A, B) Live 
leukocytes, were subdivided into (C) TEa T cells (TCR-β
+
, CD4
+
, CD45.1
+
Vα2
+
), NK cells 
(NK1.1
+
TCR-β
-
) and iNKT (TCR-β
+
PBS57 CD1d-tetramer
+
) cells in the spleen and myeloid cells (MC) 
(Gr1
+
CD11b
+
 cells), monocytes (Mo) (Gr1
+
 CD11b
+
Ly6C
+
) and polymorphonuclear (PMN) leukocytes 
(Gr1
+
 CD11b
+
Ly6G
+
) in (D) the MLN and (E) the spleen, DCs (MHC class II
+
CD11C
 +
) in (F) the MLN 
and (G) the spleen and finally B cells (CD19
+
) in (H) the MLN and (I) the spleen. Results are analysed 
using one-way ANOVAs. Results are presented as the mean number of cells ± SD (n=3-4 mice). 
*p<0.05, **p<0.01 ***p<0.001. See Appendix V for gating strategy. 
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Figure 3.6 The presence of TEa T cells correlates with an increase in the frequency of 
inflammatory monocytes
 
cells in the spleen in GVHD and there is a decreased frequency of B 
cells and inflammatory monocytes in the MLN in GVHD CB6F1 mice were lethally irradiated and 
given 5x10
6 
TCD B6 BM cells i.v. on day 0. Such mice received 1x10
4 
or no TEa T cells via i.v. 
injection, on day 2. (A, B) Cell frequencies mice i.v. injected with 1x10
4
 compared to controls or no 
TEa T cells. Live leukocytes were subdivided into TEa T cells (TCR-β,CD4, CD45.1
+ 
and Vα2
+
), NK 
cells (NK1.1
+
TCR-β
-
) and iNKT (TCR-β
+
PBS57
 
CD1d-tetramer
+
) cells in (A) the spleen. B cells 
(CD19
+
), myeloid cells (MC) (Gr1
+
 CD11b
+
), monocytes (Gr1
+
 CD11b
+
Ly6C
+
), polymorphonuclear 
(PMN) leukocytes (Gr1
+
 CD11b
+
Ly6G
+
) and DCs in (A) the spleen, and (B) the MLN. Results are 
analysed using unpaired t-tests. Results are presented as the mean frequency of cells ± SD (n=3-4 
mice).*p<0.05, **p<0.01 ***p<0.001. See Appendix V for gating strategy. 
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Figure 3.7 TEa T cells and Gr1
+
 cells can be detected in the spleens of mice with GVHD CB6F1 
mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice did or did not 
receive 1x10
4
 TEa T cells via i.v. injection, on day 2. Spleens were sectioned and stained for CD45.1 
(Green), Gr1 (Blue) and DAPI (not shown). Images showing CD45.1 in (A) Control mouse spleen (B) 
Mouse with 1x10
4
 TEa T cells mice. Images showing CD45.1 and Gr1 in (C) Control mouse spleen 
and (D) Mouse with 1x10
4
 TEa T cells mice, with suspected germinal centre. Images are 
representative images showing spleens n=3 mice per group.  
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Figure 3.8 iNKT frequencies decrease post BM transplant, however a population of host 
residual radioresistant iNKT cells can be identified along with an increase in Gr1
+ 
cells and a 
decrease in NK cells and T cells 2-weeks post BMT CB6F1 mice were lethally irradiated and given 
5x10
6
 TCD CD45.1 B6 BM cells i.v. on day 0. Mice were harvested on Day 14 to assess the extent of 
reconstitution. Live cells were pre-gated on lymphocytes, live/dead and CD45 expression and further 
divided into (A) iNKT cells (TCR-β
+
PBS57
 
CD1d-tetramer
+
), (B) NK cells (NK1.1
+
TCR-β
-
) (C) Gr1
+
 
(Gr1
+
), (D) CD4
+
 T cells (TCR-β
+
, CD4
+
) and CD8
+
T cells (TCR-β
+
, CD8
+
). Donor cells were identified 
by CD45.1 expression as determined by a CD45.1 B6 control. *p<0.05, **p<0.01 ***p<0.001. Results 
are analysed using unpaired t-tests. Results are presented as mean ± SD, n=5 transplanted mice 
versus 3 WT controls. See Appendix V for gating strategy. 
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Figure 3.9 GVHD is caused by recognition of alloantigen by TEa T cells, not as a result of 
homeostatic expansion of such cells  CB6F1 mice were lethally irradiated and given 5x106 T cell 
deplete TCD CD45.1 B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 or no (control) TEa T 
cells via i.v. injection, on day 2. These were also compared to syngeneic controls (B6 mice which 
received CD45.1 B6 BM on Day 0 and TEa T cells on day 2). Mice were harvested on Day 8, just 
before the onset of disease. Live lymphocytes were gated on CD45 expression and further divided into 
TEa T cells (TCR-β+CD4
+
CD45.1
+
 Vα2
+
), in the (A, B) spleen, (C, D), MLN (E, F), SI and (G) Liver. 
Results are analysed using one-way ANOVAs with multiple comparisons. *p<0.05, **p<0.01 
***p<0.001. Results are presented as mean ± SD, and include 3-4 independent experiments, spleen 
n=8-9 mice per group, MLN and SI n=5-6 mice per group, Liver n=3 mice per group. See Appendix V 
for gating strategy. 
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Figure 3.10 There is an increase in the frequency of CD4
+
 T cells and in some locations the 
numbers of CD4
+
 T cells in CB6F1 mice that receive TEa T cells compared to syngeneic and BM 
controls, and this increase is dominated by recipient cells at day 8 CB6F1 mice were lethally 
irradiated and given 5x10
6
 TCD CD45.1 B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 or 
no (control) TEa T cells via i.v. injection, on day 2. These were also compared to syngeneic controls 
(B6 mice which received CD45.1 B6 BM on Day 0 and TEa T cells on day 2). Mice were harvested on 
Day 8, just before the onset of disease. and further divided into CD4
+
 T cells (TCR-β
+
, CD4
+
), those 
which were either CD45.1
+
(donor), CD45.2
+
 (recipient) derived or TEa T cells (CD45.1
+
CD45.2
+
)
 
 in 
the (A, B) spleen (C, D), MLN (E, F), SI and (G) Liver. Results are analysed using one-way ANOVA 
with multiple comparisons. *p<0.05, **p<0.01 ***p<0.001. Results are presented as mean ± SD, and 
include 3-4 independent experiments, spleen n=8-9 mice per group, MLN and SI n=5-6 mice per 
group, Liver n=3 mice per group. See Appendix V for gating strategy. 
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Figure 3.11 B cells were predominantly of recipient origin and the frequency of donor cells in 
the MLN was decreased in the GVHD group compared to BMT controls and there was a 
decrease in the number of cells in the SI in both the donor and host compartments of such 
mice consistent with B cells showing delayed reconstitution in GVHD  CB6F1 mice were lethally 
irradiated and given 5x10
6
 TCD CD45.1 B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 or 
no (control) TEa T cells via i.v. injection, on day 2. Mice were harvested on Day 8, just before the 
onset of disease. Live lymphocytes were further divided into B cells (B220
+
) 
 
those which were either 
CD45.1
+
(donor), CD45.2
+
 (recipient) derived in the (A, B) spleen, (C, D) MLN and (E, F) SI. Results 
are analysed using unpaired t-tests. *p<0.05, **p<0.01 ***p<0.001. Results are presented as mean ± 
SD, and include 3-4 independent experiments, spleen n=8-9 mice per group, MLN and SI n=5-6 mice 
per group. See Appendix V for gating strategy. 
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Figure 3.12 NK cells are primarily of donor origin in mice that receive TEa T cells compared to 
BM controls while donor iNKT cells are increased in the spleen of mice that receive TEa T cells 
compared to BMT controls in terms of frequency and absolute number and are primarily 
recipient derived  CB6F1 mice were lethally irradiated and given 5x106 TCD CD45.1 B6 BM cells i.v. 
on day 0. Such mice received either 1x10
4
 or no (control) TEa T cells via i.v. injection, on day 2. Mice 
were harvested on Day 8, just before the onset of disease. Live cells were pre-gated on lymphocytes, 
live/dead and CD45 expression and further divided into iNKT cells (TCR-β
+
PBS57
 
CD1d-tetramer
+
) 
those which were either CD45.1
+
(donor), CD45.2
+
 (recipient) derived in the (A, B) spleen, (C, D) SI 
and (G) Liver. Results are analysed using unpaired t-tests. *p<0.05, **p<0.01 ***p<0.001. Results are 
presented as mean ± SD, and include 3-4 independent experiments, spleen n=8-9 mice per group, SI 
n=5-6 mice per group, Liver n=3 mice per group. See Appendix V for gating strategy. 
133 
 
 
 
 
 
134 
 
Figure 3.13 There was a decrease in the frequency of MC in the MLN in GVHD mice, while in the 
SI of GVHD mice MC were increased CB6F1 mice were lethally irradiated and given 5x10
6
 TCD 
CD45.1 B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 or no (control) TEa T cells via i.v. 
injection, on day 2. Mice were harvested on Day 8, just before the onset of disease. Live cells were 
pre-gated on cells, live/dead and CD45 expression and further divided into Gr1
+
CD11b
+
(myeloid cells) 
which were either Ly6C
+
 (monocytes) and Ly6G
+ 
(polymorphonuclear (PMN) leukocytes) and divided 
further into those which were either CD45.1
+
(donor), CD45.2
+
 (recipient) derived in the (A,B) spleen 
(C,D) MLN (E, F) SI and (G) Liver. Results are analysed using unpaired t-tests. *p<0.05, **p<0.01 
***p<0.001. Results are presented as mean ± SD, and include 3-4 independent experiments, spleen 
n=8-9 mice per group, MLN and SI n=5-6 mice per group, Liver n=3 mice per group. See Appendix V 
for gating strategy. 
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Figure 3.14 There was a perturbation in the frequency and numbers of DCs which varied by 
anatomical site  CB6F1 mice were lethally irradiated and given 5x10
6
 TCD CD45.1 B6 BM cells i.v. 
on day 0. Such mice received either 1x10
4
 or no (control) TEa T cells via i.v. injection, on day 2. Mice 
were harvested on Day 8, just before the onset of disease. Live cells were pre-gated on cells, 
live/dead and CD45 expression and further divided into DCs (CD11c
+ 
MHC class II
+
) , those which 
were either CD45.1
+
 (donor) and CD45.2
+
 (recipient) derived in the (A,B) spleen (C,D), MLN (E, F) SI 
and (G) Liver. Results are analysed using unpaired t-tests. *p<0.05, **p<0.01 ***p<0.001. Results are 
presented as mean ± SD, and include 3-4 independent experiments, spleen n=8-9 mice per group, 
MLN and SI n=5-6 mice per group, Liver n=3 mice per group. See Appendix V for gating strategy. 
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Figure 3.15 GVHD associated damage is observed in the Liver and SI which correlates with the 
presence of effector cells CB6F1 mice were lethally irradiated and given 5x10
6
 TCD CD45.1 B6 BM 
cells i.v. on day 0. Additionally, one group received the addition of 1x10
4
 TEa T cells. Mice were 
harvested on Day 8, just before the onset of disease, and lobes of liver and sections of SI were fixed 
and paraffin embedded and cut into 3 µm sections. Representative images show H&E stained SI at 
40X magnification showing (A) apoptotic crypts in CB6F1 mice that received TEa T cells compared to 
(B) BM only control with no apoptotic crypts. Liver sections at 20X showing (C) bile duct damage (*) 
and () fibrotic tract and (B) perivascular infiltrates in mice that received TEa T cells, compared to (D) 
an hepatic portal triad from CB6F1 mice which received TCD B6 BM only. Representative images for 
n=6 mice for mice that received BM and TEa T cells, n=5 mice for mice that received BM only.    
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CHAPTER 4 EXPANDING iNKT CELLS IN VITRO  
 
 
 
 
 
 
 
4.1. Introduction 
iNKT cells have been shown to be able to suppress GVHD, while maintaining the 
anti-tumour effect and therefore present an attractive potential therapeutic strategy to 
treat GVHD (234, 238). The frequency of murine iNKT cells varies depending on 
location. They are rare population of cells in the mouse thymus, LNs and the blood 
where they make up 0.2-0.7% of lymphocytes (250-252). In contrast iNKT cells are 
enriched in the adipose tissue they make up 10-25% of T cells in the adipose tissue 
(or 2-8% of lymphocytes); while in the liver iNKT cells constitute 20-50% of T cells 
(246-254). We chose the spleen as the source of iNKT cells due to the prevalence of 
such cells (~1-2%) (250-253) and due to the fact we can easily isolate relatively high 
numbers of cells. Furthermore, spleen is part of the blood circulatory route and blood 
is the most easily acquired source of iNKT cells in humans. 
The majority of iNKT cells in the spleen are described as Th1-like (or NKT1) cells, 
like Th1 cells they express T-bet and produce IFN-γ (320, 330, 331). NKT1 cells can 
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be either CD4+ or CD4- and can be NK1.1+, or NK1.1- (320). Although primarily 
thought of as proinflammatory, especially in the context of anti-tumour immunity 
(449), iNKT cell derived IFN-γ has also been shown to be involved in tolerance 
induction. In a fully mismatched model of heart transplant in which cardiac allograft 
rejection was blocked by means of co-stimulatory or integrin blockade, long term 
acceptance was observed in WT but not iNKT cell deficient mice (399). Furthermore, 
this study went on to show using IFN-γ-/- mice, that IFN-γ is critical for the iNKT cell 
mediated graft acceptance. This does not however, directly confirm that iNKT cells 
are the source of IFN-γ.  
NKT2 cells express high levels of GATA3 and interferon regulatory factor 4 (IRF-4) 
and produce IL-4, IL-9 and IL-13 (310, 332, 333). NKT2 cells are the predominant 
subset in the spleens of BALB/c mice, however they are also found in B6 spleens 
(310, 330, 331). NKT2 cells have been described to exacerbate allergic inflammation 
in the lungs (310, 320, 333). However, they can also play a regulatory role. IL-13 has 
been shown to suppress anti-tumour immunity in a model of tumour growth-
regression/recurrence and to be suppressive in a model of contact dermatitis, 
although it was not confirmed that the iNKT cells were the source of IL-13 in either 
case (450, 451). Similarly, IL-4 has been shown to be suppressive upon UV-light 
irradiation induced immune suppression, although again this IL-4 was not directly 
confirmed to be coming from the iNKT cells (452).  
The spleen also plays host to a small population of IL-17 producing iNKT cells 
(NKT17) (320). IL-17 producing iNKT cells have been shown to be involved in airway 
inflammation (453, 454). Therefore, one might predict that they would not be 
beneficial in a disease such as GVHD. Finally, splenic iNKT cells produce very low 
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levels of IL-10 (331). NKT10 cells have been shown to be a distinct regulatory 
subset, with the capacity to impair anti-tumour immunity (320, 336). However, they 
can be induced in response to repeated activation with αGal and are enriched in 
adipose tissue (249, 336).   
In humans, the expression of CD4 can be used to delineate functionally distinct iNKT 
cell subsets. CD4+ iNKT cells make both NKT1 and NKT2 cytokines, while CD4- iNKT 
cells primarily make T-bet associated cytokines (330, 340, 341, 455). Although they 
are assumed to be proinflammatory this may not always be the case as increased 
numbers of CD4- iNKT cells in HSC transplants has been shown to reduce the risk of 
acute GVHD in humans (408). In mice CD4-NK1.1- iNKT cells have been shown to be 
the main source of IL-17 in FI splenic iNKT cells (335). A study performed before the 
generation of CD1d-PBS57 tetramers showed that NK1.1- and NK1.1+ iNKT cells 
reciprocally regulate GVHD in mice (456). In this study, NK1.1+ T cells were found to 
suppress GVHD by an IL-4 dependent mechanism. Furthermore, CD4+ iNKT cells 
have more recently been shown to protect from GVHD lethality in one model (126, 
234).  
iNKT cells make up between 0.001% and 1% of peripheral blood lymphocytes in 
humans (457, 458). Given the relative paucity of iNKT cells it is envisaged that they 
would need to be expanded in order to make any potential therapy translatable. 
Therefore, we set about expanding iNKT cells based on existing protocols. One 
protocol for expanding iNKT cells involves using BMDCs pulsed with αGal and a 
cocktail of cytokines (413), while another relied on αCD3 and αCD28 ligation with 
mAbs and various cytokines (273). The BMDC expansion protocol used bone-
marrow leukocytes expanded/differentiated with GM-CSF and IL-4 to increase MHC 
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II and co-stimulatory molecules together with pulsing with αGal (459). In addition IL-2 
and IL-7 were added to the culture as IL-7 is required for iNKT survival and 
homeostasis (460) and IL-2 is a general growth promoting cytokine for iNKT cells and 
can activate such cells independent of TCR-mediated recognition of glycolipids (231).  
The second protocol relied on plate bound αCD3 and soluble αCD28 mAbs to trigger 
a TCR and co-stimulatory signal along with IL-2 and IL-7 (414). Unlike the first 
protocol where IL-12 would be produced by DCs (461), IL-12 was also added to the 
culture. IL-12 production has been shown to be TLR driven, especially in the context 
of microbial infection (461). Importantly, human iNKT cells can also be expanded, 
making them a viable cellular therapy. Indeed, Exp iNKT cells have been used in a 
phase 1 clinical trial for advanced melanoma and advanced and recurrent Non-Small 
Cell Lung carcinoma (396, 462). The Exp iNKT cells were characterised and were 
found to be functional and produce IFN-γ and IL-4. These trials showed that 
expanding and infusing in vitro generated Exp iNKT cells was both feasible as safe.  
Although the phenotype of FI iNKT cells is well studied, the phenotype of Exp cells 
has not been extensively investigated. The secretion of cytokines by the Exp cells 
has been measured using enzyme-linked immunosorbent assays (ELISAs), but what 
cytokines the cells have the potential to make post expansion upon stimulation has 
not been rigorously examined at the single cell level (413, 414). Notably, the studies 
looking at secreted cytokines did not measure IL-10 production, a cytokine of interest 
to us due to its immunosuppressive properties. If a particular subset of iNKT cells 
was found to be suppressive, it would be preferable to isolate and expand such cells, 
or sort the cells post expansion.   
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4.2. Aims and hypothesis 
As our ultimate aim was to investigate the ability of different subsets of Exp iNKT 
cells to influence GVHD following adoptive transfer we first phenotyped FI splenic 
iNKT cells. Due to the fact that the iNKT cells would require expansion in order to 
make any potential cellular therapy translational, we also aimed to optimise a 
protocol to expand these cells in vitro and fully characterise the Exp cells, so that 
ultimately we could investigate their suppressive effects. While the function of Exp 
iNKT cells may be different in humans, if suppressive activity was attributed to a 
specific subset of iNKT cells in mice, this information could be used to select human 
iNKT cells with analogous functions for expansion. We hypothesised that splenic 
iNKT cells could be expanded in vitro, that the cells would retain their original pattern 
of cytokine secretion and that such cells would be predominantly NKT1 cells.   
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4.3. Results 
4.3.1. iNKT cells are a rare pleiotropic population of cells in the thymus, blood 
and peripheral LNs 
Ultimately, we are interested in identifying the iNKT cells subset that may suppress 
GVHD. Therefore we initially set out to confirm that we could identify iNKT cells in B6 
mice. Cells were isolated from the spleen, thymus, blood and several LNs and 
analysed by flow cytometry. We identified iNKT cells in the spleen where they made 
up ~1%, peripheral LNs and blood where they made up ~0.1% and the thymus where 
they made up ~0.2% of lymphocytes (Figure 4.1B). Given the relative frequency and 
the ease of isolating large number of cells from the spleen, we decided to proceed 
with characterising splenic iNKT cells with the ultimate aim of transferring them to 
bone-marrow transplant recipients to investigate their suppressive potential in GVHD.     
We then set out to characterise subsets of iNKT cells is the spleen. FI splenocytes 
were stimulated with PMA and ionomycin in the presence of BFA and monensin and 
analysed by flow cytometry. The production of cytokines associated with the known 
subsets of iNKT cells namely IFN-γ, IL-4, IL-10, IL-13 and IL-17 were measured. 
Upon activation, the majority of iNKT cells produced IFN-γ (57%), while only a 
relatively minor population of iNKT cells were capable of producing IL-17 (~7%) 
(Figure 4.2A, B). In addition, iNKT cells produced IL-4 (~34%) and IL-13 (~25%) and 
only ~2% of cells were able to produce IL-10 (Figures 4.2A, B). Furthermore some 
iNKT cells were capable of producing more than one cytokine simultaneously for 
example approximately a third of iNKT cells could co-produce IL-4 and IL-13 (Figure 
4.2C). However, IL-17 and IFN-γ tended to delineate separate subsets, as did IL-4 
and IL-17A (Figure 4.2C).  
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Further to our investigation of cytokine production by splenic iNKT cells, the 
transcription factor expression in such cells was examined. Cells were stained for 
RORγT, T-bet and E4BP4 (NFIL3) and analysed by flow cytometry. Unsurprisingly, 
given the dominance of IFN-γ, T-bet was the dominant transcription factor, 
accounting for ~70% of iNKT cells (Figure 4.3A, B). In addition, RORγT was 
expressed in approximately 10% of iNKT cells while <3% of iNKT cells expressed 
E4BP4. Initial studies also involved staining for GATA3, however the antibody was 
deemed suboptimal. In addition GATA3 is not NKT2 specific (310). Therefore we 
decided to preferentially use IL-4 and IL-13 to delineate NKT2 cells.  
In summary, we have shown that the majority of iNKT cells in the spleen are NKT1 
iNKT cells, which express T-bet and IFN-γ. There is also a population of NKT2 cells 
and a minor population of NKT17 cells.  
 
4.3.2. iNKT cells can be expanded in vitro using αGal pulsed BMDCs but fail to 
retain their original phenotype 
Next, we set out to expand iNKT cells based on a previously published method (413). 
BM cells from B6 mice were cultured for 7 days in the presence of IL-4 and GM-CSF. 
On day 6, αGal was added to the culture (Figure 4.4A). The following day purified 
splenic iNKT cells (Figure 4.4B) were plated with irradiated BMDCs in the presence 
of IL-2 and IL-7 and expanded for 14 days (Figure 4.4C, D). Cells were monitored 
and split as required. Average fold expansion was 2.7.  
On day 14 the Exp iNKT cells were briefly stimulated with PMA and ionomycin and 
analysed for expression of IFN-γ, IL-4, IL-10, IL-13 and IL-17. Surprisingly, few Exp 
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iNKT cells expressed IFN-γ (~9%). However, many more iNKT cells expressed IL-4 
(~64%) and/or IL-17 (~28%) when compared to FI iNKT cells (Figure 4.5A, C). 
Furthermore, we saw the emergence of iNKT cells that were able to produce IL-10 
(~31%), a property that was not present in FI cells (Figures 4.5A, C). We further 
investigated Exp iNKT cells in terms of transcription factor expression. Consistent 
with the presence of IL-10 producers we saw the emergence of E4BP4 expressing 
iNKT cells (~35%) (Figure 4.5B, D). RORγT+ iNKT cells were also found as were T-
bet+ iNKT cells; however they were no longer the dominant population (Figures 4.5B, 
D).  
In summary, the Exp cells showed a different phenotype to the FI cells and were no 
longer predominantly NKT1 cells. Of particular interest was the emergence of the IL-
10 producing iNKT cells, given the propensity of IL-10 to act in an 
immunosuppressive manner.  
 
4.3.3. iNKT cells expanded in vitro using anti-CD3 and anti-CD28 show an 
altered phenotype compared to FI iNKT cells 
Given the time-consuming nature and inconsistency of producing BMDCs we sought 
to determine whether anti-CD3 and anti-CD28 mAbs could also expand iNKT cells in 
vitro. We set out to expand purified iNKT cells based on previously published 
methods (414). Purified iNKT cells were plated at a concentration of 5x105/mL with 
anti-CD3 and anti-CD28 in the presence of IL-2, 12 and later IL-7 (Figure 4.6). Cells 
were monitored daily, split as required and restimulated with anti-CD3 on day 8. We 
noted that there was a massive drop in cell numbers between days 0 and 2 (Average 
fold expansion was ~1.6 when calculated from day 0, but ~7 when calculated from 
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day 2). It is common when transferring cells in vitro that there is initially a large 
decrease in numbers to the stress of the artificial conditions. Therefore, we decided 
that going forward fold expansion would be calculated from day 2.  
On day 14 the Exp iNKT cells were stimulated with PMA and ionomycin and 
analysed for cytokine production by flow cytometry. We observed no change in the 
ability of iNKT cells to produce IFN-γ or IL-4 however, it should be noted that IFN-γ 
expression was highly variable in the Exp cells (Figure 4.6B, C). Interestingly, we saw 
an increase in IL-10 production (from ~2% to 24%), in IL-13 (from ~25% to 84%) and 
in IL-17 (from ~8% to 33%) in the Exp cells compared to the FI cells (Figure 4.6B, C).  
To confirm the observed increases in the production of certain cytokines, we further 
examined Exp iNKT cells for transcription factor expression. Consistent with the 
increase in IL-10 a marked increase in E4BP4 expression was observed (from ~3% 
amongst FI iNKT cells to 75% Exp iNKT cells). In addition, the increase in IL-17 
production by Exp iNKT cells correlated with a significant increase in the proportion 
of cells expressing RORγT (from ~10% to 49% in FI compared to Exp iNKT cells, 
respectively; Figure 4.7A, B). Furthermore, there was no change in the expression of 
T-bet in the Exp cells but the expression was highly variable in the Exp iNKT cells 
(Figures 4.7A, B). Taken together these finding imply an altered phenotype in the 
Exp cells, wherein the Exp iNKT cells acquire the ability to produce IL-10 along with 
an increase in IL-17 and copious amounts of IL-13.   
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4.3.4. The cytokines produced by iNKT cells using PMA and Ionomycin are 
indicative of more physiological stimulation 
PMA and ionomycin are chemicals used to bypass the need for surface receptor 
cross-linkage that is required under physiological conditions in order to initiate the 
signalling cascade that leads to T cell activation. This is an artificial means of 
activating cells and we wanted to investigate if the phenotype of the Exp cells was 
maintained under more physiological conditions. To this end, FI and Exp iNKT cells 
were stimulated with PMA/Ionomycin, anti-CD3/CD28 mAbs or αGal-pulsed BMDC. 
Cells were stained for IFN-γ, IL-4, IL-10, IL-13 and IL-17. There was no significant 
difference in cytokine staining between PMA and ionomycin (Figures 4.8B, E), anti-
CD3 and anti-CD28 (Figure 4.8C, E) and αGal pulsed BMDCs (Figure 4.8D, E) in 
terms of production of any of the aforementioned cytokines. iNKT cells can rapidly 
release cytokines in response to activation as they have pre-formed mRNA which 
allows the cells to respond quickly without the need for transcription (463, 464). We 
wondered whether different methods of stimulation might lead to an increase in 
transcription factor expression due to a rapid de novo transcription factor expression. 
We found that there was no difference in the expression of E4BP4, RORγT or T-bet 
between stimulation with PMA and ionomycin (Figure 3.10B, E), Anti-CD3 and anti-
CD28 (Figure 3.10C, E) and αGal pulsed BMDCs (Figure 3.10D, E). Together, these 
data suggest that using PMA and ionomycin is representative of a genuine 
physiological response and not merely an artefact of chemical stimulation.  
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4.3.5. Exp iNKT cells take on complex effector phenotypes 
As a result of the observation of altered phenotype in the Exp cells compared to the 
FI iNKT cells the differences in phenotype between such populations was further 
investigated. iNKT cells were expanded as described in section 4.3.3 and harvested 
on day 14. In this series of experiments we observed a decrease in IFN-γ production 
in the Exp cells (from ~80% in FI to 11% in Exp iNKT cells) and an increase in IL-13 
expression (from 40% in FI to 83% in Exp iNKT cells; (Figure 4.10C). However, while 
IL-10 expression was higher in the Exp cells it was highly variable over these three 
experiments and therefore unlike in previous experiments no significant increase in 
the Exp cells was seen.  
Interestingly, we saw the emergence of iNKT cells capable of producing between 2 
and at least 4 of the cytokines examined (Figures 4.10 A, B, C). Whilst the only FI 
iNKT cells that could produce multiple cytokines were those that produced IL-4 and 
IL-13, within Exp iNKT cells there was the emergence of cells capable of producing 
IFN-γ and IL-10, IL-17 and IL-4, IL-17 and IL-10, IL-13 and IL-10 and IL-4 and IL-10 
(Figures 4.10 A, B, C). However, IFN-γ and IL-17 remained largely mutually exclusive 
(Figures 4.10 A, B, C). Furthermore, within the Exp iNKT cells there were cells able 
to produce 3 cytokines (IL-13, IL-17 and IL-4 or IL-13 IL-10 and IL-4 or IL-4, IL-17 
and IL-10; Figures 4.10 A, B, C) and even 4 cytokines (IL-4, IL-17, IL-10 and IL-13; 
Figure 4.10A, B, C). Clearly, these data suggested that expanding iNKT cells in vitro 
leads to emergence of a complex effector phenotype with Exp iNKT cells capable of 
producing multiple cytokines on reactivation.   
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4.3.6. The increased proportions of IL-17 producing iNKT cells following 
expansion is due to outgrowth of NKT17 cells rather than conversion of 
NKT1 to NKT17 cells 
One robust observation when analysing the potential of iNKT cells to produce certain 
cytokines before and after expansion was that there was always a marked increase 
in cells able to produce IL-17 after expansion. The increase in NKT17s could be 
either due to the outgrowth of IL-17 producing iNKT cells, or due to conversion of 
IFN-γ producing iNKT cells into those that could produce IL-17. Given our 
observation that there was no significant increase in cells capable of producing both 
IL-17 and IFN-γ, (i.e. an intermediate population that one might expect if conversion 
was occurring; Figure 4.10C), we hypothesised that NKT17 cells were able to 
outgrow NKT1 under these conditions. 
We planned to remove IL-17 producing cells, and expand the remaining iNKT cells to 
examine the possibility that NKT1 to NKT17 conversion. Originally we sought to 
delineate iNKT cell subsets based on surface markers expression which would 
enable us to sort specific subsets of iNKT cells prior to expansion. Indeed, CD4-
NK1.1- cells have been reported to produce high levels of IL-17 (335). We observed 
that IFN-γ+ iNKT cells were either CD4+NK1.1+, CD4+NK1.1- or CD4-NK1.1+ but not 
CD4-NK1.1- (Figure 4.11A). This suggests that removing the CD4-NK1.1- population 
would be a useful means for removing IFN-γ- cells. Furthermore, we found that IL-17+ 
iNKT cells were mainly confined to CD4-NK1.1- population (Figure 4.11B). This is in 
keeping with the observations by Coquet et al. who found that CD4-NK1.1- cells 
produce IL-17 (335). However, given that divisions based on surface markers were 
not absolute and subject to variation, we decided that removing IL-17 producing cells 
would be better achieved using reporter mice.  
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In order to separate NKT17 from the pool of iNKT cells to be expanded, we sorted 
RORγT- iNKT cells from RORγT-GFP mice. Such cells devoid of NKT17 were then 
expanded in vitro using the anti-CD3 and anti-CD28 mAbs and cytokines as before. 
Expanding such cells, proved extremely difficult, which in itself is an argument that 
the cells capable of producing IL-17 proliferate more aggressively in these cultures. 
Indeed, the RORγT- iNKT cells expanded more poorly than poorly expanding FI iNKT 
cells (Figure 4.12A). Importantly, the Exp iNKT cells failed to make IL-17 upon 
stimulation with PMA and ionomycin (Figure 4.12B, C) but retained their ability to 
produce IFN-γ (Figure 4.12C). These data suggest that the increase in IL-17 
producing cells is due to the outgrowth of NKT17 cells that out-compete poorly 
proliferative NKT1 cells. 
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4.4. Discussion 
iNKT cells present an attractive potential cellular therapy due to the availability of 
ligands that specifically activate these cells. Although iNKT cells have been shown to 
exhibit potent immunomodulatory properties, they are not a homogenous population. 
Thus it is important to understand the complexity of their phenotype and functional 
heterogeneity in order take advantage of their potential as a cellular therapy. The 
phenotype of iNKT cells that we observed was consistent with what is reported in the 
literature. IFN-γ producing cells were the dominant subset observed in the spleen, 
with IL-4 and IL-13, IL-17 and very little IL-10 producing cells present (310, 320, 330, 
331) (Figure 4.2).  
One thought provoking observation was the emergence of IL-10 and E4BP4 
expressing in splenic iNKT cells upon expansion (Figures 4.6-4.10).This was a 
surprising observation given that NKT10 cells are most commonly found in the 
adipose tissue in mice (249). In terms of IL-10 secretion by Th cells, Wraith et al. 
have shown that antigen strength controls the generation of IL-10 secreting cells 
(465). After repeated activation, these cells maintain the ability to produce IFN-γ but 
take on the ability to produce IL-10 and in this way act in a self-limiting manner (466). 
It is possible that a similar negative feedback mechanism is occurring when the cells 
are continually activated with a strong antigenic signal provided by either αGal or 
anti-CD3, throughout the expansion. Indeed, it has been demonstrated in vivo that 
repeated stimulation with αGal leads to induction of IL-10 production by iNKT cells 
(336). We observed a significant increase in iNKT cells that can produce IL-10 and 
IFN-γ in the Exp cells compared to the FI cells (Figure 4.6C).  
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NKT10 cells have been shown to be a distinct regulatory subset, with the ability to 
suppress anti-tumour immunity (336). Furthermore, iNKT cell derived IL-10 has been 
shown to be required for corneal graft survival (233). Therefore, we hypothesised that 
NKT10 cells may be suppressive in the context of GVHD.  
IL-10 was not the only cytokine that was altered in the Exp cells, such cells also 
showed an increase in their ability to produce IL-13 and IL-17 (Figures 4.6). IL-13 is a 
NKT2 cytokine and has been shown to have an immunosuppressive role in a model 
of tumour growth-regression-recurrence (451); therefore NKT2 cells producing IL-13 
might have a protective role against GVHD. However, it would be important to bear in 
mind that it might affect the GVT response.  
IL-17 is generally regarded to be a proinflammatory cytokine; indeed IL-17 producing 
iNKT cells have been shown to be involved in inducing airway inflammation (453, 
454). However, NKT17 cells have been shown to also produce IL-22 (467), and IL-22 
produced by innate lymphoid cells (ILCs) has been shown to reduce susceptibility to 
GVHD (468, 469). The Exp iNKT cells were negative for IL-22 expression (data not 
shown). Therefore, NKT17 cells are unlikely to be protective. Furthermore, previous 
studies which have demonstrated the suppressive effects of FI iNKT cells have used 
CD4+ iNKT cells to suppress GVHD (126, 234, 456) and IL-17+ iNKT cells are mainly 
found in the CD4-NK1.1- fraction (335). While we have seen that this segregation is 
not true of Exp splenic iNKT cells (data not shown), it does suggest that removing IL-
17 producers might be useful.  
In addition there were perturbations in IFN-γ expression. In one series of experiments 
there was a significant decrease in IFN-γ production in the Exp iNKT cells compared 
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to the FI cells (Figures 4.8, 9). However, this was not as robust at the alterations in 
other cytokines as this decrease was not shown to be consistent upon further 
repeating this experiment (Figure 4.6). 
It was interesting to observe that there was no difference in the expression of 
cytokines between the different methods of stimulation namely PMA and ionomycin, 
anti-CD3 and anti-CD28 and αGal pulsed BMDCs (Figures 4.8, 9). PMA activates 
protein kinase C which leads to NFκB signalling. Ionomycin is a Ca2+ ionophore, 
which triggers Ca2+ release which is required for NFAT signalling. NFκB and NFAT 
are important transcription factors for T cell activation. As such, using PMA and 
Ionomycin is an artificial mode of stimulation and thus it was noteworthy that there 
was no significant difference between the alternative methods of staining. In the 
future, it would also be useful to include an unstimulated control to see the 
background level of cytokines production. It would also help to determine if residual 
signal remains from stimulation by anti-CD3 and anti-CD28 during the expansion. 
A previous study by Coquet et al. saw a difference between anti-CD3 and anti-CD28 
stimulation, which the authors suggested was a result of the requirement of spleen 
iNKT cells for DC derived factors such as IL-12 and IL-18 (335). However, in this 
experiment the authors were looking at secreted cytokines using ELISAs. This 
means that some of the cytokines could be coming from the BMDCs as they have the 
capacity to make many of the same cytokines. In addition in this study FI cells were 
used, while we were comparing Exp cells. As the phenotype of the Exp iNKT cells is 
different to that of FI they may not necessarily respond in the same way to 
stimulation. It is also important to note that this is a different time point as we looked 
at 4 h while the earliest time point investigated in this study was 24 h. It is possible 
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that at a later time point we would have observed a difference in cytokine production 
between anti-CD3 and anti-CD28 and BMDC stimulation.  
One striking observation was that not only did the Exp cells have altered cytokine 
expression they also took on complex effector phenotypes not observed in the FI 
cells. The Exp cells were capable of making at least four and possibly more cytokines 
(Figure 4.12). Given the propensity of iNKT cells to be involved in a myriad of 
immune responses generally attributed to a specific subtype of iNKT cells, this raises 
the question as to what the functionality of such a complex phenotype would be in 
the context of GVHD. 
Further to the functional properties of these polyfunctional cells, this also raises the 
question as to whether some of these phenotypes are intermediate between the 
iNKT cell subtypes, and whether peripheral iNKT cells are committed to a specific 
lineage or can behave in a more promiscuous manner. The functional plasticity of 
iNKT cells is not well understood. iNKT cells can express a range of cytokines, 
transcription factors and chemokines and can respond to their local 
microenvironment (309, 470-472). Furthermore, the phenotype of iNKT cells is tissue 
dependent, and stimulating iNKT cells with APCs from different tissues can lead to 
different cytokine response (289, 309, 334). This suggests that peripheral iNKT cells 
may possess at least some degree of functional plasticity. In addition, as previously 
mentioned IL-17 production can be induced in peripheral iNKT cells under the right 
conditions and this is also the case with FOXP3 expression in both mice and humans 
(454, 473-475). However, there is no direct evidence as to which if any peripheral 
iNKT cells possess functional plasticity and to definitively prove the existence of such 
a phenomenon cell tracing and single cell studies would be required.  
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It is also possible that some of the changes in frequency observed are due to 
outgrowth of subsets of iNKT cells due to their superior capacity to expand. However, 
this does not explain the ability of the Exp cells to produce multiple cytokines. It is 
possible that certain subsets of iNKT cell are taking on the ability to make multiple 
cytokines or, that there is peripheral conversion of iNKT cells occurring, or indeed a 
combination of both.  
To address the possibility that outgrowth or peripheral conversion of particular 
subsets was occurring we made use of RORγT reporter mice, as a means to sort out 
the predominant population in the FI cells (namely IFN-γ+). We found that RORγT- 
iNKT cells were extremely difficult to expand, supporting our hypothesis that IL-17 
producing iNKT cells are more proliferative. Furthermore, the Exp cells were 
predominantly IFN-γ+. It is likely that outgrowth of IL-17 producing cells is at least a 
contributing factor to their overrepresentation in the Exp cells compared to the FI 
cells.  
We attempted to verify our hypothesis using IL-17+ splenic iNKT cells. However the 
number of iNKT cells isolated was not sufficient to achieve a level of confluence 
compatible with expansion. It should also be noted that the reason for the increase in 
IL-10 and IL-13 production by the Exp cells was not examined directly, however as 
this population is not present in the FI cells it is likely to be occurring as a result of 
differentiation of the iNKT cells. However, the exact ontogeny of the various 
phenotypes has not been thoroughly investigated and it would be interesting to look 
at this in the future using cells from fate mapping mice. Furthermore, the stability of 
the Exp iNKT cells has not been investigated and it would be interesting to 
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investigate the stability of such cells perhaps to carry out epigenetic analysis of the 
relevant regions.  
In conclusion, we have optimised a protocol for expanding iNKT cells in vitro, which 
leads to the alteration in the phenotypes of the Exp iNKT cells compared to those 
seen in their FI counterparts. Of note is the increase in IL-10 and IL-13 production, 
both of which have been shown to have suppressive effects in certain contexts. We 
also saw the emergence of iNKT cells capable of producing multiple cytokines which 
may have functional implications upon investigation of the propertied of such cells. 
This alteration in phenotypes is robust and occurs regardless of the method of 
stimulation employed. The expansion of these cells will enable us to thoroughly 
investigate their ability to influence alloreactive responses.   
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4.5. Figures 
 
 
Figure 4.1 iNKT cells are a rare population of cells in the thymus, blood and peripheral LNs 
Cells were isolated from B6 mice, and were analysed by flow cytometry. (A) Leukocytes were gated on 
lymphocytes (FSC-A, SSC-A), live cells and TCR-β versus PBS-57 tetramer, tetramer positive cells 
were identified using an unloaded control. (B) iNKT cells were gated as the splenocytes in the thymus, 
blood, brachial LN, inguinal LN, MLN and axillary LN. n=3 mice.  
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Figure 4.2 A high frequency of FI splenic iNKT cells secrete IFN-γ, but only a small frequency of 
such cells produce IL-17A Splenocytes were isolated from B6 mice and cells were stimulated with 
PMA and ionomycin and cultured in the presence of BFA and monensin. iNKT cells were gated as in 
Figure 4.1A. Cells were analysed by flow cytometry for intracellular production of IFN-γ, IL-4, IL-10, IL-
13 and IL-17A (A) Representative dot plots showing cytokine production (B) Graph showing cytokine 
expression. (C). Representative dot plots of cytokine production. Data shown are mean ± SD (n=11-18 
mice). Results are analysed using one-way ANOVA with multiple comparisons *p<0.05, **p<0.01, 
***p<0.001.  
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Figure 4.3 FI splenic iNKT cells express high levels of T-bet and low levels of E4BP4 and 
RORγT  Splenocytes were isolated from B6 mice and cells were stimulated with PMA and ionomycin 
in the presence of BFA and monensin. iNKT cells were gated as in Figure 4.1A. Cells were analysed 
by flow cytometry for expression of E4BP4, RORγT and T-bet. (A) Representative dot plots showing 
transcription factor expression (B) Average transcription factor expression. Data shown are mean ± 
SD (n=8-9 mice). Results are analysed using one-way ANOVA with multiple comparisons ***p<0.001.  
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Figure 4.4 iNKT cells can be expanded using BMDCs pulsed with αGal  (A) B6 BM cells were 
cultured for 7 days in the presence of GM-CSF and IL-4, αGal was added to the culture on day -1. 
Cells were irradiated on Day 0 and cultured with (B) purified iNKT cells from B6 spleens in the 
presence of IL-2 and IL-7. (C, D) The cells were monitored and split as required and harvested at Day 
14. (D) Representative graph showing iNKT cell expansion, graph is representative of 4 independent 
experiments.   
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Figure 4.5 Exp iNKT cells predominantly produce IL-4, while a smaller frequency of such cells 
produce IFN-γ, IL-10 and IL-17 and additionally such cells differentially express transcription 
factors  B6 BM cells were cultured for 7 days in the presence of GM-CSF and IL-4, αGal was added 
to the culture on day -1. Cells were irradiated on Day 0. Purified iNKT cells from B6 spleens were 
plated with BMDCs (at a ratio of 10:1) in the presence of IL-2 and IL-7, monitored and split as required 
and harvested at Day 14. On Day 14 Exp iNKT cells were stimulated with PMA and ionomycin and 
cultured in the presence of BFA and monensin and analysed by flow cytometry. Cells were gated on 
live expanded lymphocytes, followed by TCR-β versus PBS-57 tetramer, followed by the various 
cytokines (IFN-γ, IL-4, IL-10, and IL-17) or transcription factors (E4BP4, RORγT and T-bet). (A) 
Representative dot plots showing cytokine production. (B) Representative plots showing transcription 
factor expression. (C) Average cytokine production. (D) Average transcription factor expression. Data 
shown are mean ± SD from 4 independent experiments. Results are analysed using one-way ANOVA 
with multiple comparisons *p<0.05,***p<0.001. 
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Figure 4.6 iNKT cells can be expanded using anti-CD3 and anti-CD28 and an increased 
frequency of Exp iNKT cells can produce IL-10, IL-13 and IL-17 compared to FI cells  (A) Cells 
were expanded using anti-CD3 and anti-CD28, in the presence of IL-2, IL-12 and IL-7 for 14 days. On 
Day 14 Exp iNKT cells were stimulated alongside FI iNKT cells with PMA and Ionomycin and cultured 
in the presence of BFA and monensin and analysed by flow cytometry. The production of IFN-γ, IL-4, 
IL-10, IL-13 and IL-17A was measured. Cells were gated on live lymphocytes or live expanded 
lymphocytes, followed by TCR-β versus PBS-57 tetramer, followed by the various cytokines. (B) 
Representative dot plots showing cytokines production, results are representative of 11-17 
independent experiments (C) Graph showing cytokine production, data shown are mean ± SD. Results 
are analysed using t-tests. ***p<0.001.  
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Figure 4.7 Exp iNKT cells exhibit increased expression of E4BP4 and RORγT compared to FI 
iNKT cells  Cells were expanded using anti-CD3 and anti-CD28, in the presence of IL-2, IL-12 and IL-
7 for 14 days. On Day 14 the Exp iNKT cells were analysed by flow cytometry alongside FI iNKT cells 
for expression of E4BP4, RORγT and T-bet. Cells were gated on live lymphocytes or live expanded 
lymphocytes, followed by TCR-β versus PBS-57 tetramer, followed by the various transcription factors. 
(B) Representative dot plots showing transcription factor expression. Results are representative of 8-
12 independent experiments (B) Graph showing transcription factor expression, data shown are mean 
± SD. Results are analysed using t-tests***p<0.001.  
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Figure 4.8 Chemical induced cytokine secretion by iNKT cells is representative of a 
physiological response  Cells were expanded using anti-CD3 and anti-CD28, in the presence of IL-
2, IL-12 and IL-7 for 14 days. On Day 14 (A) FI iNKT cells were stimulated with PMA and Ionomycin in 
the presence of BFA and monensin and analysed by flow cytometry alongside Exp iNKT cells 
stimulated with (B) PMA and Ionomycin, (C) Anti-CD3 and Anti-CD28 or (D) BMDCs pulsed with αGal 
and the production of IFN-γ, IL-4, IL-10, IL-13 and IL-17A was measured. Cells were gated on live 
lymphocytes or expanded lymphocytes, followed by TCR-β versus PBS-57 tetramer, followed by the 
various cytokines. Representative dot plots showing cytokines. (E) Graph showing cytokine production 
by expanded iNKT cells in 3 independent experiments, data shown are mean ± SD. Results are 
analysed using one-way ANOVAs with multiple comparisons. All n.s. non-significant.   
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Figure 4.9 Confirmation that iNKT cells express the corresponding transcription factors 
associated with the cytokines secreted by such cells  Cells were expanded using anti-CD3 and 
anti-CD28, in the presence of IL-2, IL-12 and IL-7 for 14 days. On Day 14 (A) FI iNKT cells were 
stimulated with PMA and Ionomycin and in the presence of BFA and monensin and analysed by flow 
cytometry alongside Exp iNKT cells stimulated with (B) PMA and Ionomycin, (C) anti-CD3 and anti-
CD28 or (D) BMDCs pulsed with αGal (all in the presence of BFA and monensin) and the expression 
of E4BP4, RORγT and T-bet was measured. Cells were gated on live lymphocytes or live expanded 
lymphocytes, followed by TCR-β versus PBS-57 tetramer, followed by the various transcription factors. 
Representative dot plots showing transcription factor (E) Graph showing transcription factor 
expression in 3 independent experiments. All n.s. non-significant.   
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Figure 4.10 iNKT cells expanded using anti-CD3 and anti-CD28 exhibit complex effector 
phenotypes  Cells were expanded using anti-CD3 and anti-CD28, in the presence of IL-2, IL-12 and 
IL-7 for 14 days. On Day 14 the FI iNKT cells were stimulated alongside Exp iNKT cells and both FI 
and Exp iNKT cells were stimulated with PMA and Ionomycin, in the presence of BFA and monensin 
and analysed by flow cytometry, and the production of IFN-γ, IL-4, IL-10, IL-13 and IL-17A. Cells were 
gated on live lymphocytes or live expanded lymphocytes, followed by TCR-β versus PBS-57 tetramer, 
followed by the various cytokines (A) Representative dot plots showing cytokines production in FI iNKT 
cells (B) Representative dot plots showing cytokines production in Exp iNKT cells (C) Graph showing 
cytokine production in 3 independent experiments, data shown are mean ± SD. Results are analysed 
using t-tests *p<0.05, **p<0.01, ***p<0.001.  
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Figure 4.11 The distribution of IFN-γ and IL-17 producing iNKT cells cannot be confined to a 
particular subset based on CD4 and NK1.1 expression  Cells were expanded using anti-CD3 and 
anti-CD28, in the presence of IL-2, IL-12 and IL-7 for 14 days. On Day 14 FI iNKT cells were 
stimulated with PMA and Ionomycin, in the presence of BFA and monensin and analysed by flow 
cytometry. Cells were gated on live lymphocytes or live expanded lymphocytes cells, followed by TCR-
β versus PBS-57 tetramer and then divided into CD4
+
NK1.1
+
 CD4
+
NK1.1
-
 CD4
-
NK1.1
+
 and CD4
-
NK1.1
-
 and IFN-γ and IL-17 was investigated within the various subsets. (A). Comparison of IFN-γ 
production within the CD4 and NK1.1 based subsets (B) Comparison of IL-17 production within the 
CD4 and NK1.1 based subsets. Graphs showing cytokine expression in 4 independent experiments. 
Results were analysed using one-way ANOVAs *p<0.05, ***p<0.001.  
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Figure 4.12 IFN-γ
+
 and IL-17
+
 iNKT cells primarily expand as separate lineages   On day 0, GFP- 
iNKT cells from RORγT reporter mice and WT NKT cells from B6 mice were isolated and (A) all cells 
were expanded using anti-CD3 and anti-CD28. for 14 days in the presence of IL-2, IL-12 and IL-7. On 
Day 14 the expanded iNKT cells were stimulated with PMA and Ionomycin, in the presence of BFA 
and monensin and analysed by flow cytometry. Cells were gated on live lymphocytes or live expanded 
lymphocytes, followed by TCR-β versus PBS-57 tetramer, followed by the various IFN-γ and IL-17 (B) 
Representative examples of IL-17 versus IFN-γ production in RORγT– and WT Exp iNKT cells. (C) 
Cumulative data from 2-3 independent expression showing IFN-γ versus IL-17 production in RORγT– 
and WT Exp iNKT cells. 
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CHAPTER 5 INVESTIGATING THE SUPPRESSIVE 
CAPACITY OF INKT CELLS IN VITRO  
 
 
 
 
 
 
 
5.1. Introduction 
In Chapter 4 we found that Exp iNKT cells show an increased capacity to produce IL-
10 and IL-13 upon activation. In vivo studies have reported that multiple injections 
with αGal leads to iNKT cells producing IL-10, which have been shown to have a 
protective effect when transferred into Jα18-/- mice with EAE (336). They were also 
shown to suppress anti-tumour immunity (336). iNKT derived IL-10 has also been 
demonstrated to be essential for corneal graft survival (233). Given the suppressive 
role of IL-10 secreted by iNKT cells after repeat αGal injections, we reasoned that 
Exp iNKT cells, which also have the capacity to produce IL-10, may also display an 
enhanced ability to suppress T cell responses.  
In vitro suppression assays are a useful and efficient way to investigate the 
suppressive activity of a population of cells. They are commonly used in the Treg 
field to investigate the ability of Treg populations to suppress T cells and to identify 
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the molecules involved in Treg mediated suppression. The first Treg suppression 
assays were described 20 years ago (476, 477) and contributed to the paradigm that 
CD25+ T cells are able to suppress Tcon. In addition, such assays require few 
reagents and facilitate the investigation of several factors in one experiment. T cells 
are typically activated with either APCs or anti-CD3 and anti-CD28 and proliferation 
measured by labelling the Tcon with fluorescent dyes or assessing uptake of tritiated 
thymidine. It is also possible to investigate antigen specific responses using 
transgenic mice (478).  
Several studies have demonstrated that Exp human iNKT cells can suppress T cells 
in vitro, however to our knowledge, to date no such suppression assays have been 
published investigating the suppressive effects of FI or Exp murine iNKT cells. This 
may be due to the rarity of these cells making it difficult to carry out these 
experiments. There is also one example of a suppression assay preformed with 
CD8+NKT-like cells, which were shown to be able to suppress alloreactive T cells by 
killing antigen bearing DCs (479). Given that we have expanded iNKT cells in vitro 
we felt there was a distinct possibility that testing the suppressive capacity of such 
cells in vitro would be a convenient and fruitful method to test the suppressive 
properties of Exp iNKT cells in vitro. Using such a system would allow the 
investigation of not only whether Exp iNKT cells are suppressive but also whether the 
suppression is mediated by immunosuppressive cytokines (given that they readily 
produce IL-10) or cell surface interactions. 
IL-10 was originally discovered by Mosmann in 1989, as a cytokine that inhibits the 
effects IL-2 and IFN-γ (480). It was originally called ‘‘cytokine synthesis inhibitory 
factor’’ (CSIF)(480). IL-10 was originally thought to be solely produced by T cells, but 
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it is now known that NK cells, B cells, DCs, cytotoxic T cells, γδ T cells, mast cells 
and other granulocytes also produce IL-10 (481-489). IL-10 works through binding to 
the IL-10r (IL-10r), which is composed of two chains IL-10r1 and IL-10r2 and 
intracellular signalling mainly occurs via Janus kinase (JAK)/signal transducer of 
activation (STAT) pathway (490). 
IL-10 has an inhibitory effect on immunity and can suppress proinflammatory cellular 
activity, and can simultaneously promote anti-inflammatory functions of such cells. 
For example, it can suppress the secretion of TNF-α, IL-1β, IL-6 IL-8, G-CSF and 
GM-CSF by macrophages, while enhancing anti-inflammatory molecules such as IL-
1r and soluble TNFr (491-495). As well as acting on APCs, IL-10 can also directly 
suppress T cell activity by suppressing T cell mediated production of IL-2, IFN-γ and 
IL-4 production (496, 497). IL-10 has also been shown to be critical for Treg to 
mediate tolerance to alloantigen in the context of skin transplantation in mice (498). 
In addition to immunosuppressive cytokines, co-inhibitory receptors are also 
employed by the immune system to maintain self-tolerance and as such prevent 
autoimmunity (499). Co-inhibitory molecule ligands can be expressed by tumours, 
immunoprivileged tissues or by APCs whereby they are able to directly interact with 
and suppress Tcon. Alternatively, co-inhibitory molecules can be expressed by 
immunomodulatory cells such as Treg and play a role in cell-mediated suppression.  
An example of a co-inhibitory molecule is cytotoxic T-lymphocyte-associated protein 
4 (CTLA-4) which is constitutively expressed on Treg and can inhibit T cell responses 
by attenuating the ability of APCs to present antigen and hence reducing T cell 
priming, or by inducing the indoleamine 2,3-dioxygenase (IDO) production thereby 
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suppressing T cell proliferation (500, 501). IDO acts by inhibiting tryptophan 
catabolism which is required for T cell proliferation. (502). Other co-inhibitory 
molecules that are expressed on Treg and have been shown to mediate 
immunosuppression by either directly suppressing T cells or inhibiting antigen 
presentation include immunoreceptor tyrosine-based inhibition motif domain (TIGIT), 
Lymphocyte activation gene 3 (LAG-3), PD1 and T cell immunoglobulin and mucin 
domain 3 (TIM-3) (503-507). In conclusion, as we have seen Exp iNKT cells are 
functionally distinct from their freshly-isolated counterparts. However, whether Exp 
iNKT cells are immunosuppressive has yet to be determined. In this chapter we will 
test the suppressive ability of both Exp iNKT and FI iNKT cells in vitro. 
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5.2. Aims and hypothesis  
Given our observation in chapter 4 that Exp iNKT cells have an altered cytokine 
secretion pattern compared to the FI iNKT cells we hypothesized that such cells may 
have additional suppressive properties.  
Therefore, we aimed to test whether Exp and/or FI iNKT cells could suppress 
alloreactive T cell responses in vitro. Furthermore, we determined the cell-surface 
expression/function of co-inhibitory molecules by iNKT cells and tested whether 
selected molecules played a role in iNKT cell-mediated suppression. 
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5.3. Results 
5.3.1.  Alloreactive T cell proliferation is suppressed in the presence of αGal 
activated Exp iNKT cells  
In chapter 4 we showed that Exp iNKT gained the ability to produce IL-10 following in 
vitro culture. Given the propensity of IL-10 to act in an immunosuppressive manner 
(508), we reasoned that the Exp cells might show enhanced immunosuppressive 
properties compared to FI cells. In order to investigate the immunomodulatory 
potential of Exp iNKT cells, we designed an in vitro suppression assay that was 
reflective of the GVHD model described in Chapter 3. To this end, purified CFSE 
labelled TEa T cells were cultured with irradiated BMDC from CB6F1 (H2b/d) mice 
that had or had not been pulsed for 24 h with αGal. Such cells were cultured in the 
presence or absence of Exp iNKT cells. Cultures were left for 4 days before being 
analysed by flow cytometry. 
Strikingly, there was a significant decrease in the frequency of divided TEa T cells in 
the presence activated iNKT cells (from 79±5% proliferation to 13 ±2% proliferation), 
which was evident at ratios as low as 1:0.1 (47±7% proliferation) (Figure 5.1A and B). 
Furthermore, there was a decrease in the number of proliferating cells; once again 
this was true of ratios as low as 1:0.1 (Figure 5.1C). Importantly, suppression was 
occasionally but inconsistently observed when cells were not activated with αGal. 
However the level of suppression was minor compared to that of Exp iNKT cells 
activated with αGal (Figure 5.1A-C).  
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Interestingly when we looked at the CFSE Median Fluorescence intensity (MFI) of the 
divided cells there was no difference in the level of CFSE of divided TEa T cells in 
the presence or absence of activated Exp iNKT cells suggesting that although there 
were less dividing TEa T cells in the presence of activated iNKT cells the cells that 
were dividing did so at the same rate as in control cultures (Figure 5.1D). 
 
5.3.2. Exp iNKT cells are more potent at suppressing alloreactive T cell 
proliferation than their FI counterparts.  
The difference in cytokine secretion (particularly with respect to IL-10) between FI 
and Exp iNKT cells led us to speculate that immunosuppression may be a feature 
acquired by Exp iNKT cells that was not shared by FI iNKT cells. In order to test this 
hypothesis we set-up in vitro assays (as described in section 5.2.1.) with either Exp 
iNKT cells or FI iNKT cells.  
Activated Exp iNKT suppressed TEa T cell proliferation as previously shown (from 
78±1% proliferation to 27±1% proliferation) (Figure 5.2A-C). However, the addition of 
FI iNKT cells to cultures resulted in no decrease in the percentage of dividing cells 
67±10% proliferation) and only a small albeit significant decrease in TEa T cell 
number (Figure 5.2A-C). In terms of MFI, we observed that the addition of FI cells in 
the absence of αGal to the suppression assay lead to a decreased MFI, however this 
was not observed in repeat experiments. This suggests that, as was the case with 
the Exp iNKT cells, in the presence of FI iNKT cells there were less dividing TEa T 
cells however the cells that were dividing did so at the same rate as in control 
cultures (Figure 5.2D). In conclusion, we found that Exp iNKT cells potently 
suppressed the T cell response to alloantigen in vitro. This was dependent on the re-
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activation of Exp iNKT cells at the point of T cell recognition of alloantigen and was 
confined to Exp iNKT cells. This further suggests that following in vitro expansion, 
iNKT cells acquire potent immunomodulatory properties that are not seen in FI cells. 
5.3.3. IL-10 and IFN-γ are not required for the immunosuppressive properties 
of activated Exp iNKT cells 
IL-10 and IFN-γ can both act in an immunosuppressive manner in the context of 
transplantation (233, 399, 498, 509-511). We therefore investigated whether either 
IL-10 or IFN-γ were required for Exp iNKT cell-mediated suppression. CFSE labelled 
TEa T cells were activated with irradiated CB6F1 BMDCs pulsed with αGal and were 
cultured with or without Exp iNKT cells (at a ratio of 1:0.25). In selected wells, anti-IL-
10r or anti-IFN-γ mAbs were added to such cultures. As before, cells were cultured 
for 4 days and analysed by flow cytometry.  
Exp iNKT cells suppressed TEa T cells in terms of the frequency and number of 
dividing cells (Figure 5.3A-C). The addition of either anti-IL-10r or anti-IFN-γ failed to 
significantly affect the suppression of alloreactive T cells in terms of frequency 
(Figure 5.3A, B). The number of proliferating cells was also reduced in the presence 
of anti-IL-10r or anti-IFN-γ mAbs (Figure 5.3C). Taken together these findings imply 
that the mechanism of suppression utilized by Exp iNKT cells is independent of IL-10 
or IFN-γ.   
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5.3.4. Exp iNKT cell suppression of alloreactive T cells is not mediated by iNKT 
cell consumption of IL-2 
Activated T cells and iNKT cells both express the high affinity IL-2r α chain, CD25, 
we wanted to test whether iNKT cells might be starving activated TEa T cells of IL-2 
thus preventing their proliferation. First, given that Exp iNKT cells were better at 
suppressing than the FI cells, we investigated to see if the level of CD25 between 
such populations varied. We found that there was an increase in the frequency of 
Exp iNKT cells expressing CD25 compared to the FI cells, indeed almost all the Exp 
cells expressed CD25 (Figure 5.4A and B). It was therefore feasible that the Exp 
iNKT cells were limiting IL-2 availability for activated TEa T cells. To investigate this 
possibility in vitro suppression cultures were carried out in an excess of exogenous 
IL-2.  
Interestingly, we found that Exp iNKT cells were still able to suppress TEa T cells in 
the presence of IL-2 (Figure 5.4-C-E). Together, these findings suggest that Exp 
iNKT cells do not suppress T cell responses by starving responding Tcon of IL-2.  
 
5.3.5. Anti-CD3 and anti-CD28 stimulated iNKT cells do not suppress TEa T 
cells in vitro 
Thus far we had used BMDC to drive both alloreactive T cells and iNKT cells raising 
the possibility that suppression was via signalling to the APC. Therefore, we asked 
whether Exp iNKT cells could suppress TEa T cells in an APC free system using anti-
CD3 and anti-CD28 mAbs to stimulate both iNKT cells and conventional T cells. 
Surprisingly, we found that not only did the Exp iNKT cells not suppress TEa T cells 
when stimulated with anti-CD3 and anti-CD28 but the addition of Exp iNKT cells 
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resulted in an increase in the percentage of TEa T cells that had divided as well as in 
absolute TEa T cell number (Figure 5.5A-C). These data therefore suggest that either 
there is a requirement for BMDCs to mediate the suppressive effect or that activation 
by anti-CD3 and anti-CD28 renders T cells resistant to suppression.  
 
5.3.6. The expression of co-inhibitory receptors is increased in activated iNKT 
cells 
Due to our observation that Exp iNKT cells could suppress TEa T cells stimulated 
with BMDCs but not anti-CD3 and anti-CD28, we next sought to investigate if BMDCs 
affected the phenotype of Exp iNKT cells in terms of co-inhibitory molecules 
expression. A previous study in our lab looked at the alteration in gene expression in 
iNKT cells, 48 hrs after in vivo activation with αGal. Since we were also looking at 
cells which have been activated (albeit during the course of the expansion), we 
decided to look to this microarray for cell surface molecules that are upregulated 
during activation which have known suppressive effects. The microarray showed the 
upregulation of several candidate molecules namely PD1, Lag-3, TIM-3 and TIGIT 
(Figure 5.6A-C).  
As a result of these observations we decided to investigate if there were differences 
in the expression of some of these markers in Exp iNKT cells following culture with 
unpulsed BMDCs, anti-CD3 and anti-CD28 or αGal pulsed BMDCs. The expression 
of markers proved to be highly variable depending on the experiment, possibly due to 
the fact that the Exp iNKT cells have a more varied phenotype than the FI iNKT cells. 
However, in all three independent experiments, stimulation with αGal pulsed BMDCs 
resulted in the highest frequency of Exp iNKT cells expressing LAG-3 (Figure 7A, D, 
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E), PD1 (Figure 7B, D, E) and TIGIT (Figure 7C, D, E). Our observation that Exp 
iNKT cells express LAG-3, PD1 and TIGIT after activation combined with the 
microarray the data suggest that one or more co-inhibitory molecules such as PD1, 
TIGIT and LAG-3 could be responsible for mediating the suppressive effect of Exp 
iNKT cells in vitro.  
Given the fact that only activated Exp iNKT cells potently suppressed T cell 
responses in vitro we next examined the expression of LAG-3, PD1 and TIGIT on 
activated FI iNKT cells. To this end, FI iNKT cells were stimulated with either anti-
CD3/CD28 or αGal pulsed BMDCs and analysed after 6 h. The frequency of FI iNKT 
cells expressing either LAG-3, PD1 or TIGIT was low in the FI iNKT cells regardless 
of activation (Figure 5.8). Given the fact that these molecules are co-inhibitory 
receptors we sought to determine if one or more of them were responsible for the 
suppressive effect of the Exp iNKT cells.  
Durgan et al showed that there was increased anti-tumour immunity in the absence 
of PDL1:PD1 interactions (512). Therefore we decided to test whether PDL:PD1 
interactions were important for Exp iNKT cell suppression. To this end, a suppression 
assay was performed using a ratio of 1:1 TEa T cells to Exp iNKT cells which we 
have previously shown results in robust suppression of T cell responses in vitro 
(Figure 5.1). Blocking antibodies for PD1 (which is expressed on Exp iNKT cells) and 
PDL1 and PDL2, which are expressed on BMDCs (unpublished data by Jones et al.), 
were added to test their involvement in the suppressive mechanism. Blocking PD1 or 
PDL1/2 did not impact the ability of Exp iNKT cells to suppress TEa T cells in terms 
of either frequency or number of proliferating TEa T cells (Figure 5.9A-C). The level 
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of CFSE was not changed in the presence of anti-PDL1 and anti-PDL2 blockade, 
(Figure 5.9D).  
Taken together these findings show that Exp iNKT cells differentially express a 
panoply of co-inhibitory surface markers. Although we have shown a lack of 
involvement of the PD1/PDL1/2 pathway there are other candidate 
immunomodulatory molecules which may play a role in iNKT cells mediated 
suppression.   
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5.4. Discussion  
The most significant finding of this chapter was that Exp iNKT cells but not FI iNKT 
cells potently suppress an alloreactive T cell response in vitro (Figure 5.1). This 
finding is validated by three human studies that Exp human iNKT cells were shown to 
suppress alloreactive T cells in vitro (408, 513, 514). However, as these studies used 
unseparated T cells as responder cells it is possible that Treg were also involved in 
the suppressive mechanism. Furthermore, these studies did not investigate if FI 
human iNKT cells can suppress alloreactive T cells in vitro. One of these studies 
details the mechanism of suppression, which in this case occurs via iNKT cell 
mediated lysis of the DCs (408). This would be an interesting experiment to carry out 
in the future using murine iNKT cells.  
Phenotypic analysis of Exp iNKT cells revealed that they functionally distinct 
compared to FI iNKT (Figures 4.6 and 4.8). In particular, Exp iNKT cells produced 
high levels of IL-10, IL-13 and IL-17 whilst maintaining IFN-γ secretion (Figure 4.6). 
IL-10 and IFN-γ have both been found to be immunosuppressive in the context of 
transplantation (although IFN-γ is classically a proinflammatory cytokine) (233, 399, 
498, 509-511, 515). However, blocking the IL-10r or neutralising IFN-γ failed to affect 
suppression (Figure 5.3). It is possible however that the suppressive effect could be 
mediated by other cytokines that are secreted by Exp iNKT cells such as IL-13. IL-13 
has been shown to suppress anti-tumour immunity in a model of tumour growth-
regression/recurrence and to be suppressive in a model of contact dermatitis, 
although it was not confirmed that the iNKT cells were the source of IL-13 in either 
case (450, 516).  
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One way to test if soluble factors, such as cytokines, are involved in suppression 
would be to activate T cells in the presence of supernatant harvested from re-
activated Exp iNKT cells. Although soluble molecules were not exhaustively tested 
we might argue that as suppression is consistent but the cytokines that Exp iNKT 
cells produced at the end of an expansion varied, the modulation of cytokine 
production in Exp iNKT cells may not relate to the suppressive effect of these cells. 
However, although the signature cytokines may not be involved in suppression 
another cytokine could be involved. Such a cytokine could be common to all subsets 
of iNKT cell or unique to one or more subset. In addition we have not investigated the 
stability of Exp iNKT cells and thus we don’t know if they still make these cytokines 
during the response. Indeed preliminary analyses of supernatants harvested from 
such suppression assays showed variable cytokine detection between experiments 
(data not shown).  
Another possibility was that given that CD25 is highly expressed in Exp iNKT cells 
they could be out-competing the TEa T cells for IL-2 and therefore starving the TEa T 
cells of IL-2 which is required for survival and proliferation. There is precedence for 
this as this mechanism of suppression has been reported to be used by Treg (477, 
517, 518). However, performing assays in the presence of excess IL-2 did not affect 
the suppression by Exp iNKT cells therefore; the mechanism of suppression is 
unlikely to involve IL-2 sequestration by iNKT cells.  
In addition to secreted molecules such as cytokines, Exp iNKT cells may suppress 
via the expression of certain cell surface molecules with immunomodulatory potential. 
Ideally, we would have performed a microarray of the Exp cells compared to the FI 
cells, to see if there were significant changes in the expression of genes related to T 
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cell suppression. However, due to time and money constraints we looked to a 
microarray that was performed on in vivo activated iNKT cells. The array showed that 
there was upregulation of many co-inhibitory molecules on activated iNKT cells after 
48h (Figure 5.6). We looked at the expression of such molecules on FI and Exp iNKT 
cells and found that consistent with the array data they were upregulated on the Exp 
cells and were further increased following re-activation with BMDCs presenting αGal 
the most efficient mode of activation (Figure 5.7). However, the upregulation of 
molecules such as LAG-3, PD1 and TIGIT was confined to Exp iNKT cells as most FI 
iNKT cells did not express these molecules even after stimulation (Figure 5.8).  
There are many suppressive co-inhibitory molecules that could be responsible for 
suppression either directly or indirectly, and this would be an interesting line of 
investigation. Indeed similar mechanisms of suppression have been observed to be 
mediated by Treg for example TIGIT is expressed on a distinct subset of Treg and 
can suppress Th1 and Th17 cells by inducing the expression of fibrinogen-like 
protein 2 (Fgl2) a soluble suppressive molecule that promotes Treg mediated 
suppression of Tcon (503). In addition, TIGIT-Fc has been shown to alleviate acute 
GVHD by binding to CD155 on DCs (504). This promotes DCs to develop a 
regulatory phenotype with attenuated antigen presentation capacity and the ability to 
suppress CD8+ T cells via IL-10 production (504). It is possible that TIGIT could be a 
suppressive mechanism employed by Exp iNKT cells to suppress alloreactive T cells. 
This could occur via either Fgl2, or through interactions with CD155 on DCs 
promoting to the generation of immunoregulatory DCs in a similar manner to Treg 
mediated suppression.   
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LAG-3 is another co-inhibitory molecule which confers a suppressive ability upon 
Treg, enabling them to suppress Tcon, while Treg from LAG3-/- mice exhibit 
diminished suppressive capacity (505). Upon engagement of MHC class II on 
CX3CR1+ macrophages LAG-3+ Treg cells have been shown to inhibit IL-1β and IL-
23 production by such cells, thereby promoting immune tolerance (519).  
PD1 is another co-inhibitory molecule that has also been shown to play a role in Treg 
mediated suppression of Tcon, PD1-/- mice retain normal levels of FOXP3, but lack 
functionally suppressive Treg (506). TIM-3 may also play a suppressive role, it has 
been shown to be expressed on 40% of FOXP3+ T cells which infiltrate in a model of 
skin-graft rejection and were shown to robustly suppress Tcon in vitro (507). 
Furthermore, FOXP3+ TIM-3+ Treg have been shown to inhibit Tcon in RA and Head 
and Neck cancer although the exact mechanism by which this occurs is not 
understood (520, 521).   
In many cases it is unclear how these molecules function to suppress Tcon 
responses. They may rely on cell-cell contact to transmit inhibitory signals to mediate 
their suppressive effects, or ligation to their ligands may help them to maintain a 
suppressive phenotype, or to induce other cell surface or secretory molecules or 
even to act through another cell. Whatever the case may be work by the Brenner Lab 
as part of the Immunological Genome Project revealed that co-inhibitory receptors 
are expressed on iNKT cells and thus may play a role in any potential iNKT mediated 
suppression (522). Furthermore, we examined the role of PD1/PDL1 in 
immunomodulation by Exp iNKT cells but found that disruption of this pathway failed 
to impact suppression. However, as we found that LAG-3 and TIGIT were expressed 
upon stimulation with αGal BMDCs (Figure 5.7), it would be interesting to investigate 
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the involvement of co-inhibitory molecules such as these in the mechanism of 
suppression. This could occur either through direct T cell suppression or indirectly 
though BMDCs. Indeed, the ligand for LAG-3 is MHC class II is expressed on 
BMDCs (Appendix V) and one of the ligands for TIGIT is CD155 is also expressed on 
BMDCs (505).  
Another interesting possible mechanism of suppression could be that the Exp iNKT 
cells are killing the TEa T cells, either directly, or through killing the BMDCs and 
thereby preventing antigen presentation. Indeed, human CD8+NKT-like cells have 
been reported to suppress T cells in vitro by killing antigen bearing DCs. (479). 
Similarly, human CD4- iNKT cells have been shown to suppress Tcon in a human in 
vitro suppression assay, by mediating the lysis of DCs and thereby inhibiting T cell 
proliferation (408). In addition, iNKT cells from the spleen, liver and thymus were 
shown to be able to kill A2 lymphoma cells with or without CD1d transfection (523). 
Furthermore, this study also showed that killing is CD1d and antigen dependent in 
vivo and that killing is more potent in the presence of a strong iNKT cells antigen like 
αGal than a weak stimulator like OCH. Interestingly, iNKT cell mediated killing was 
shown to be mediated through the CD95/CD178 (Fas-Fas-L) in vivo (523). It remains 
a possibility that Exp iNKT cells prevent T cell activation using a similar mechanism 
therefore it would be worthwhile blocking Fas-Fas-L interactions to see if this had any 
effect on the suppression. It would also be useful to look at apoptosis of both BMDCs 
and TEa T cells. Furthermore, it would be interesting to investigate if Exp iNKT cell 
mediated suppression is maintained when BMDCs are pulsed with C20.2 instead of 
αGal.  
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Finally, we noted that Exp iNKT cells were unable to suppress alloreactive T cells 
that were stimulated with anti-CD3 and anti-CD28. There could be several reasons 
for this. One possibility is that the activation of T cells with anti-CD3/CD28 results in a 
response that is resistant to suppression. Alternatively, it may be the anti-CD3/CD28 
stimulation of Exp iNKT cells fails to elicit the mechanism of suppression. It is also 
possible that the mechanism of suppression involves the modification of allogeneic, 
glycolipid presenting APC.  
It would be interesting to investigate if the αGal has to be presented by the BMDCs 
presenting alloantigen to the T cells or whether suppression occurs as long as both T 
cell and Exp iNKT cells are activated by BMDC. This could be tested by mixing αGal 
pulsed B6 BMDCs to provide iNKT activation and CB6F1 BMDCs to activate the TEa 
T cells. If suppression is not seen in this system then this would imply that Exp iNKT 
cells suppress TEa T cells by modification of the alloantigen-presenting APC. This 
could work by Exp iNKT cells inducing a phenotypic change in the BMDCs reducing 
their ability to stimulate TEa T cells (such as loss of co-stimulatory molecules) or 
killing of BMDC or inducing the BMDC to express molecules that suppress T cell 
responses themselves, one such molecule being IDO. Treg have been reported to 
use both mechanisms via the expression of co-inhibitory molecule CTLA-4 to 
suppress T cells (500, 501).  
At this point we have shown that there are cells with different functional activities 
present within the Exp iNKT cells (Figure 4.12). It is possible that all of the cells share 
a common suppressive mechanism or that the ability to suppress T cell responses is 
restricted to Exp iNKT cells with a certain phenotype. It would be interesting to test 
the various subsets of iNKT cells to see if their ability to suppress differs. This could 
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be achieved by sorting functional subsets using cytokine or transcription factor 
reporter mice, although as we have seen some subsets do not expand well so this 
could be difficult in the mouse. If a specific subset of iNKT cells harbours the 
suppressive activity then performing RNA-Seq studies may reveal a cell surface 
molecular signature for the cells that could be used to sort the immunosuppressive 
Exp iNKT cells to maximise functional activity before transfer into HSC/solid organ 
transplant recipients.  
In conclusion, we found that re-activated Exp iNKT cells but not FI iNKT cells potently 
suppress the response of alloreactive T cells in vitro. Although the mechanisms of 
suppression used by Exp iNKT cells remain to be elucidated this provides us with the 
exciting prospect that Exp iNKT cells have developed suppressive properties which 
may impact alloreactive T cell-driven pathology in vivo in conditions such as GVHD.   
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5.5. Figures  
Figure 5.1 Activated Exp iNKT cells suppress alloreactive T cell responses in vitro TEa T cells 
were purified and labelled with CFSE and stimulated with BMDCs ± αGal ± Exp iNKT cells (at 
decreasing ratios from 1:1 to 0.1). Cells were analysed by Flow Cytometry on Day 4 and proliferating 
TEa T cells were gated on live cells, TCR-β and CD4, Vα2 and proliferating cells based on CFSE 
staining. (A) Representative plots showing CFSE profile of TEa T cells. (B) Proliferating TEa T cells 
percentage. (C) Proliferating TEa T cell number. (D) Proliferating TEa T cells MFI. Data is 
representative of 2 independent experiments, each experiment done in triplicate for the titration and 4 
independent experiments, each in triplicate for all other conditions. Results are analysed using one-
way ANOVA with multiple comparisons. *p<0.05 ,***p<0.001.See Appendix V for gating strategy.  
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Figure 5.2 Activated Exp iNKT cells but not FI iNKT cells can suppress alloreactive T cells in 
vitro  TEa T cells were purified and labelled with CFSE and stimulated with BMDCs ± αGal ± Exp or FI 
iNKT cells (at a 1:1 ratio). Cells were analysed by Flow Cytometry on Day 4 and proliferating TEa T 
cells were gated on live cells, TCR-β and CD4, Vα2 and proliferating cells based on CFSE staining. 
(A) Representative plots showing CFSE profile of TEa T cells (B) Proliferating TEa T cells percentage. 
(C) Proliferating TEa T cell number. (D) Proliferating TEa T cells MFI. Data is representative of 3 
independent experiments, each done in triplicate. Results are analysed using one-way ANOVA with 
multiple comparisons. *p<0.05, ***p<0.001. See Appendix V for gating strategy. 
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Figure 5.3 IL-10 and IFN-γ are not required for the suppression of alloreactive T cells by 
activated Exp iNKT cells  TEa T cells were labelled with CFSE and stimulated with BMDCs ± αGal ± 
Exp iNKT cells (at a ratio of 1:0.25) ± αIL-10r or ±IFN-γ. Cells were analysed by Flow Cytometry on 
Day 4 and proliferating TEa T cells were gated on live cells, TCR-β and CD4, Vα2 and proliferating 
cells based on CFSE staining. (A) Representative plots showing CFSE profile of TEa T cells. (B) 
Proliferating TEa T cells percentage. (C) Proliferating TEa T cell number. Data is representative of 3 
independent experiments, each done in triplicate. Results are analysed using one-way ANOVA with 
multiple comparisons. ***p<0.001. See Appendix V for gating strategy. 
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Figure 5.4 Activated Exp iNKT cells suppress alloreactive T cells in vitro through an IL-2 
independent mechanism  (A, B) Exp iNKT cells were stained for CD25, and gated on live 
lymphocytes, TCR-β and PBS-57 tetramer and CD25. TEa T cells were purified and labelled with 
CFSE and stimulated with BMDCs ± αGal ± Exp iNKT cells in the presence of excess IL-2. Cells were 
analysed by Flow Cytometry on Day 4 and proliferating TEa T cells were gated live cells, TCR-β and 
CD4, Vα2 and proliferating cells based on CFSE staining. (C) Representative plots showing CFSE 
profile of TEa T cells (D) Proliferating TEa T cell percentage. (E) Proliferating TEa T cell number. Data 
is representative of 2 independent experiments, each done in triplicate. Results are analysed using t-
tests.*p<0.05 **p<0.01 ***p<0.001. See Appendix V for gating strategy. 
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Figure 5.5 Activated Exp iNKT cells cannot suppress anti-CD3, anti-CD28 stimulated 
alloreactive T cells in vitro  TEa T cells were purified and labelled with CFSE and stimulated with 
αCD3 and αCD28 ± Exp iNKT cells. Cells were analysed by Flow Cytometry on Day 4 and proliferating 
TEa T cells were gated on live cells, TCR-β and CD4, Vα2 and proliferating cells based on CFSE 
staining. (A) Representative plots showing CFSE profile of TEa T cells. Data is representative of 2 
independent experiments. (B) Proliferating TEa T cell percentage. (C) Proliferating TEa T cell number. 
Data is representative of 2 independent experiments, each done in triplicate. Results are analysed 
using t-tests. **p<0.01. See Appendix V for gating strategy. 
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Figure 5.6 Activated iNKT cells show an increased expression of immune checkpoint 
molecules LAG-3, PD1 and TIGIT IFN-γ reporter mice were given i.p. 2µg of αGal or PBS. After 48h 
iNKT cells were isolated from αGal or PBS injected mice using beads following by FACS sorting and 
RNA was extracted and a microarray was performed. Relative expression of (A) Lag-3 (LAG-3 gene) 
(B) Havcr2 (TIM-3 gene) (C) Tigit (TIGIT gene) (D) Pdcd1 (PD-1 gene) (E) Hierarchical Clustering of 
Lag-3, Havcr2, Tigit and Pdcd1. Figures are from 2 pooled experiments. Results are analysed using 
ANOVAs with eBayes empirical parameter improvement. 
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Figure 5.7 Activated Exp iNKT cells show an increased expression of immune checkpoint 
molecules LAG-3, PD1 and TIGIT Exp iNKT cells were either left in unstimulated or stimulated with 
unpulsed BMDCs, anti-CD3 and anti-CD28 or αGal pulsed BMDCs and incubated for 6 h. Cells were 
analysed by Flow Cytometry and gated on expanded lymphocytes, live cells and TCR-β versus PBS-
57 tetramer followed by LAG-3, PD1 or TIGIT. Representative plots of Exp iNKT cells stained for (A) 
LAG-3, (B) PD1 and (C) TIGIT. (D) Percentage expression of LAG-3, PD1 and TIGIT in Exp iNKT 
cells. (E) Normalised expression of LAG-3, PD1 and TIGIT, such expression is measured relative to 
unstimulated expression which is set at 100%. Plots are representative of 3 independent experiments, 
and graphs are from 3 compiled experiments. Results are analysed using one-way ANOVA with 
multiple comparisons. All results were non-significant.  
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Figure 5.8 Activated FI iNKT cells show no difference in expression of LAG-3, PD1 and TIGIT 
regardless of the mode of activation  FI iNKT cells were either left in unstimulated or stimulated with 
unpulsed BMDCs, anti-CD3 and anti-CD28 or αGal pulsed BMDCs and incubated for 6 h. Cells were 
analysed by Flow Cytometry and gated on lymphocytes, live and TCR-β versus PBS-57 tetramer 
followed by (A) LAG-3, (B) PD1 and (C) TIGIT. Graphs are from 3 compiled experiments. Results are 
analysed using one-way ANOVA with multiple comparisons. All results were non-significant.  
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Figure 5.9 Activated Exp iNKT cells suppress alloreactive T cells in vitro through a PDL1/2 
independent mechanism in vitro TEa T cells were purified and labelled with CFSE and stimulated 
with BMDCs ± αGal ± Exp iNKT cells at a 1:1 ratio) ±PD1 or PDL1 or PDL2. Cells were analysed by 
Flow Cytometry on Day 4 and proliferating TEa T cells were gated live cells, TCR-β and CD4, Vα2 and 
proliferating cells based on CFSE staining. (A) Representative plots showing CFSE profile of TEa T 
cells. (B) Proliferating TEa T cell percentage. (C) Proliferating TEa T cell number. (D) Proliferating TEa 
T cell MFI. Data is representative of 1 experiment, done in triplicate. Results are analysed using one-
way ANOVA with multiple comparisons. **p<0.01 ***p<0.001. See Appendix V for gating strategy. 
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CHAPTER 6 INVESTIGATING THE ABILITY OF 
iNKT CELLS TO INFLUENCE GVHD 
 
 
 
 
 
 
 
6.1. Introduction 
iNKT cells were originally thought to contribute to GVHD, and it wasn’t until 1999 that 
it was observed that depletion of NK1.1+ cells from bone-marrow grafts led to an 
increased occurrence of GVHD in mice (456). In addition, observations in humans 
have found an association between the increased number of iNKT cells in HSC 
transplants and the incidence and severity of GVHD. One study found that there was 
a decreased incidence of grade II-IV acute GVHD in patients that received in excess 
of the median number of contaminating iNKT cells (408). Furthermore, greater 
numbers of iNKT cells in the HSC transplant was found to correlate with both 
improved GVHD and progression free survival (409). Another study showed that the 
recovery of iNKT cells post-transplant was associated with reduced non-relapse 
mortality without a risk of relapse and increased the overall survival rate (410). 
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As a result of these observations, attempts have been made to artificially manipulate 
the frequency of the remaining iNKT cells by using fractionated non-myeloablative 
irradiation of lymphoid tissues and anti-T cell antibodies. This was shown to lead to 
over representation of NK1.1+ and DX5+ T cells in B6 and BALB/c mice respectively 
and to prevent GVHD in BALB/c mice that had received fully mismatched B6 
transplants (524). Using IL-4-/- mice this was shown to be mediated by either donor or 
host derived IL-4. The same group later showed that host iNKT cells could induce the 
expansion of Treg which was IL-4 dependent and was lost in Jα18-/- recipients (525).  
There have also been several clinical trials which validate the use of reduced 
intensity conditioning regimes. Patients that received total lymphoid irradiation (where 
only lymphoid organs are exposed to irradiation) and T cell depletion and HCT 
transplants to treat haematopoietic malignancies had a very low risk of acute GVHD 
and other transplant related mortalities (447). Two more recent trials confirmed this 
and in addition patients showed that the anti-tumour effect was maintained, however 
none of these trials have examined the role that iNKT cells may play in this protection 
(447, 526).  
As well as boosting the number of iNKT cells through conditioning regimes, the ability 
of adoptively transferred (AT) iNKT cells to suppress GVHD has also been explored. 
The first study transferred small numbers of DX5+ cells (40% of which are iNKT cells) 
into a model of semi-allogeneic BMT and found that this led to decreased clinical 
symptoms of GVHD and increased survival (235). The Negrin lab later specifically 
isolated CD4+ NKT cells and showed that they could suppress GVHD at a low dose, 
through an IL-4 dependent mechanism (234). They later went on to show that this 
effect was mediated by CD4+ iNKT cell mediated expansion of CD11b+Gr-1int MDSCs 
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which lead to the expansion of CD4+CD25+FoxP3+Treg which are required for the 
protective effect to be mediated (126, 238). Furthermore, this effect could still be 
obtained using third party iNKT cells (126).  
The ability of glycolipids to activate iNKT cells and hence manipulate GVHD has also 
been investigated. Hashimoto et al. have reported that a single injection with αGal 
significantly decreases morbidity and mortality in a B6 to BALB/c model of GVHD, 
and this protective effect did not occur in CD1d-/- or IL-4-/- recipient mice (527). The 
opposite was seen by Kuns et al. who showed that αGal injection induced hyperacute 
GVHD and early mortality in B6 to B6D2F1 and BALB/c to B6 models (528). The 
difference between the responses to αGal is likely due to the recipient mice used. 
This suggests a role for remaining recipient iNKT cells. BALB/c mice are known to be 
Th2 biased (529-531), and therefore it is likely that the IL-4 rich environment 
contributed to the protective effect. In support of this hypothesis, C20.2 an αGal 
analogue that is biased towards Th2 cytokines (278), failed to exacerbate GVHD in 
B6 to B6D2F1 and BALB/c to B6 GVHD models and in most settings inhibited it (528).  
iNKT cells have been reported be able to prevent GVHD while maintaining the anti-
tumour effect. Existing therapies that involve depleting T cells in the graft can reduce 
GVHD, however this comes at a cost as it results in impaired engraftment and 
reduces the anti-tumour effect (148, 532). The Holy Grail in the treatment of GVHD is 
the dampening down of the GVHD response while still maintaining the anti-tumour 
effect. Higher numbers and ratios of iNKT to Tcon have been shown to be associated 
with decreased GVHD occurrence and increased tumour progression free survival in 
humans (409, 410). In addition, in a mouse model of total lymphoid irradiation, host 
iNKT cells were shown to be protective, by preventing the tissue damage induced by 
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donor T cells. However despite this the donor T cells maintained their cytotoxic 
function and could still kill the B cell lymphoma cells (533). CD1d-/- or Jα18-/- recipient 
mice were able to clear the tumour cells but died from GVHD (533). Furthermore, 
adoptively transferring iNKT cells did not affect the eradication of a B cell lymphoma 
(202, 234). In terms of the clinical relevance of these findings, reduced conditioning 
regimes in humans have also been shown to preserve the GVL effect and patients 
showed a significant increase in the percentage of iNKT cells in the blood (534).   
In order to be clinically translatable it is likely that iNKT cells would need to be 
expanded in vitro. Indeed two studies have shown that Exp iNKT cells can provide 
some protection from GVHD (237, 513). Yang et al. observed an increased survival 
with Exp iNKT cells compared to Tcon only along with higher IL-4 in the serum of Exp 
iNKT cell treated mice. The mice treated with Exp iNKT cells exhibited 80% survival 
at day 60, but all mice died within 38 days of the control group (237). This is in 
contrast to studies where for example 80% of mice adoptively transferred with 
2.5x104 FI iNKT cells survived past day 100 (234). It is worth noting that this study 
used very high numbers of Exp iNKT cells (1x107). A recent study transferred Exp 
human iNKT cells into a xenograft model of GVHD and found that mice treated with 
Exp human iNKT cells showed approximately 63% survival on day 56, which was a 
significant increase compared to control xenograft GVHD mice which all died by 
approximately day 50 (513).   
Interestingly, another study injected BMT recipient mice with 1x106 Exp iNKT and 
showed that survival was prolonged to between 60 days with syngeneic Exp iNKT 
cells and 50 days with allogeneic Exp iNKT cells. However, importantly Jα18-/- 
BALB/c recipient mice did not survive beyond ~25 days, implying that the Exp cells 
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may have had an effect early but it was the residual host iNKT cells which lead to 
prolonged survival at least in this model (535). This study calls into question the 
contribution of the AT iNKT cells in prolonging the survival and suggests that AT cells 
play a role earlier in the course of disease that is then taken over by residual 
recipient cells. 
Much study is required to understand the relative contribution of residual versus 
donor iNKT cells. In addition, while it is likely that IL-4 is involved in the protection 
mediated at least in part by donor Exp iNKT cells, the exact mechanism has not been 
fully elucidated and it has not been determined if Treg are involved. Furthermore, to 
date donor FI cells have been more potent and effective than Exp cells in prolonging 
survival and the phenotype of the Exp iNKT cells might be one explanation for this. In 
addition the role of specific subsets of iNKT cells in protection from GVHD has not 
been investigated. While clearly, there is a lot that remains unknown about the 
protective effects of Exp iNKT cells in GVHD, they are a potentially viable and safe 
therapy for GVHD, as they have been shown to be feasible and safe in a stage 1 
clinical trial for advanced melanoma and advanced and non-small cell lung 
carcinoma (396, 462).  
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6.2. Aims and hypothesis 
 As iNKT have been observed to suppress GVHD in a B6 to BALB/c model of GVHD 
(126, 234), we aimed to investigate the ability of such cells to suppress alloreactive 
transgenic T cells in the model we established in chapter 3. We aimed to investigate 
the ability of both FI and Exp iNKT cells to suppress GVHD. Furthermore, we planned 
to look at the suppressive ability of different subsets of iNKT cells as well as the 
propensity of different glycolipids to influence the alloreactive response.  
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6.3. Results 
6.3.1.  αGal activated FI iNKT cells exacerbate initial weight loss after GVHD 
FI iNKT cells have been shown to be suppressive in mouse models of GVHD in 
which B6 cells were transferred to BALB/c recipients (126, 234, 238). Furthermore, 
activating iNKT cells with αGal in a B6 to BALB/c model of GVHD was shown to be 
protective as they were required to polarize donor T cells towards a Th2 response 
(527). Therefore, we set out to investigate if the adoptive transfer of FI iNKT cells 
could ameliorate TCR-transgenic T cell induced GVHD (set up in chapter 3). 
To this end, mice received TBI and TCD BM on day 0, and on day 2 1x105 FI B6 
iNKT cells (the highest dose used in previous studies) were i.v. injected 
concomitantly with disease causing TEa T cells i.v., with or without αGal i.p. (Figure 
6.1). Such mice were compared to mice that received TBI and TCD BM on day 0 and 
TEa only, FI iNKT only or FI iNKT and αGal on day 2. Mice that received FI iNKT 
cells and αGal lost significantly more weight compared to mice that received FI iNKT 
only, however all mice gradually increased weight with time and survived past day 50 
without registering clinical scores (Figure 6.1A, D, E). These data imply that 
activating iNKT cells can lead to increased weight loss even in the absence of 
alloreactive T cells via the activation of residual recipient iNKT cells or BM derived 
iNKT cells as well as the AT FI iNKT cells.  
Following from this, mice that received TEa T cells + FI iNKT cells + αGal lost more 
weight between days 4-6, than mice that received TEa T cells alone (Figure 6.1B). 
There was no difference in the survival of such mice, however they did exhibit 
significantly higher clinical scores on day 9 (Figure 6.1B, D, E). This suggests that the 
adoptive transfer and activation of FI iNKT cells in the context of disease-causing 
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TEa T cells exacerbates GVHD. Mice that received TEa T cells + FI iNKT + αGal 
showed increased weight loss and clinical scores and decreased survival compared 
to mice that received FI iNKT cells and αGal alone (Figure 6.1C) confirming that the 
TEa T cells caused GVHD. Mice that received TEa T cells + FI iNKT with or without 
αGal cells exhibited increased clinical scores on day 9 compared to mice that 
received TEa T cells only (Figure 6.1E). Together these data suggest that activating 
iNKT cells with αGal exacerbates GVHD. However, it does not tell us the relative 
contribution of recipient or donor BM derived cells compared to AT FI iNKT cells.  
6.3.2. Activated iNKT cells increase the frequencies of TEa T cells in the spleen 
Next, we sought to investigate if activating iNKT cells during the GVHD-causing TEa 
T cell response impacted the frequency or number of other immune cells. To this end 
mice that received TEa T cells + iNKT +αGal were compared to mice that received 
TEa T cells + iNKT cells alone. Mice were sacrificed when they reached 20% weight 
loss or the maximum clinical severity allowed and the spleen and MLN analysed. 
Mice were sacrificed between days 10 and 14.  
Notably there was an increase in the frequency of TEa T cells in the spleens of mice 
that received TEa T cells + iNKT +αGal compared to TEa T cells + iNKT alone 
(Figure 6.2A). However, this was not reflected in absolute numbers (Figure 6.2B). In 
addition, no alteration in the frequency or number of donor or recipient-derived T cells 
were seen in the MLN (Figure 6.2C, D). In terms of other lymphocytes populations 
there was no change in the frequency or number of B cells (Figure 6.3A-D) or NK 
cells (Figure 6.3E-H) in either the spleen or MLN. 
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Interestingly, there was a significant increase in the overall frequency of iNKT cells 
and the frequency of AT iNKT cells in the spleens of mice that received TEa T cells + 
iNKT cells +αGal compared to TEa T cells + iNKT cells alone, as well as an increase 
in the number of AT iNKT cells (Figure 6.3E, F). In the MLN the only difference in 
iNKT cells was that there was an increase in the frequency of AT iNKT cells in the 
mice that received iNKT cells +αGal compared to TEa T cells + iNKT cells alone 
(Figure 6.3G). In terms of innate populations there was no difference in the frequency 
or number of myeloid cells or DCs in the spleen or MLN (Figure 6.4A-H). 
Collectively, these data suggest that activating iNKT cells leads to an increase in the 
frequency of AT iNKT cells in the spleen and MLN, and that this increase results in 
an increase in the frequency of TEa T cells. There were no other perturbations 
observed in other immune populations that were investigated, when iNKT cells were 
activated with αGal. This suggests that decreased survival was due to the activation 
of the AT iNKT cells. 
 
6.3.3. Transferred iNKT cells that have been activated by αGal in vivo persist 
and retain their ability to secrete IFN-γ 
In order to investigate if the AT iNKT cells survive long term as well as the nature of 
the phenotype of such cells in terms of cytokines production, mice that received 
either iNKT cells alone or iNKT cells +αGal were analysed on day 50. We observed 
an increase in iNKT cell frequency in the spleen of mice that received iNKT cells + 
αGal compared to iNKT cells alone (Figure 6.5A), however similar numbers of iNKT 
cells were present in both sets of mice (Figure 6.5B). There was also no difference in 
the frequency or absolute numbers of iNKT cells in the MLN. (Figure 6.5 C, D).  
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Interestingly, spleen iNKT cells that had been previously activated demonstrated an 
enhanced frequency of IFN-γ producing iNKT cells (Figure 6.5E). However, we did 
not identify the provenance of these iNKT cells so they could be AT iNKT cells or of 
donor or host origin, or likely a combination of all three. Together these data suggest 
that there is an increase in the frequency of iNKT cells in mice that received iNKT + 
αGal compared to iNKT cells alone, even 50 days post-transplant. However as the 
numbers of iNKT cells are very low, it seems unlikely that such cells could have a 
biological effect at this late time point.  
 
6.3.4. Activating iNKT cells with C20.2 in GVHD exacerbates initial weight loss 
and does not lead to a significant increase in survival  
Due to our observation that αGal administration leads to exacerbation of GVHD 
(Figure 6.1), we decided to explore the possibility of using an alternative glycolipid. 
C20.2 is an αGal analogue, which has been shown in most settings to inhibit GVHD 
in B6 to B6D2F1 and BALB/c to B6 GVHD models (528). Therefore, we set out to 
investigate the effects of C20.2 in our model. 
Mice were given TBI and TCD BM on day 0, followed by TEa T cells + iNKT cells + 
i.p. C20.2 or TEa T cells only or C20.2 only on day 2. Mice that received C20.2 lost 
significantly less weight compared to mice that received TEa T cells + iNKT +C20.2 
or TEa T cells alone, and ultimately went on to gain weight (Figure 6.6A). Such mice 
showed 100% survival (Figure 6.6B) and did not register clinical scores (Figure 
6.6C).  
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On day 5 and 6, mice that received TEa T cells + iNKT cells + i.p. C20.2 lost 
significantly more weight and had enhanced clinical scores compared to mice that 
received TEa T cells only (Figure 6.6A and C). This led to the death of 80% of mice 
by day 5 (Figure 6.6B), suggesting that activating the AT iNKT cells with C20.2 
exacerbates the initial decrease in weight loss that occurs after irradiation (Figure 
6.6A). Interestingly, the remaining surviving mice went on to show a 2 day delay in 
death (Figure 6.6B), onset of weight loss (Figure 6.6A) and clinical scores (Figure 
6.6C) compared to those that received TEa T cells only.  
Together these data suggest that although there is no significant increase in survival 
in mice that received TEa T cells + iNKT +C20.2, compared to those that receive TEa 
T cells alone, if the exacerbation of the initial weight loss after irradiation was 
prevented then iNKT cells may diminish GVHD.  
6.3.5. iNKT cell numbers increase in the spleens of mice that received C20.2 
without affecting the number or frequency of TEa T cells  
In order to investigate if C20.2 has an effect on iNKT cells frequency and number, 
cells were isolated from the spleens of mice that received TEa T cells only or TEa T 
cells + iNKT cells +C20.2 at the time of disease onset which was between days 10 
and 12. There was no change in the frequency or number of TEa T cells between the 
2 groups (Figure 6.7A, B) despite an increase in the number of AT FI iNKT cells in 
mice that received TEa T cells + iNKT +C20.2 (Figure 6.7D). However, there was no 
increase observed in the overall number of iNKT cells or in the number of recipient or 
donor derived iNKT cells (Figure 6.7D). In addition the frequency of iNKT cells was 
also unaffected (Figure 6.7C). Together these data suggest that while C20.2 can 
impact the number of AT iNKT cells, unlike αGal, C20.2 does not affect the frequency 
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or number of TEa T cells. This is in keeping with the mice all exhibiting weight loss 
and clinical signs of GVHD as all mice had succumbed to GVHD by day 13 (Figure 
6.6).  
 
6.3.6. Residual or BM derived iNKT cells and not the transferred iNKT cells are 
responsible for modest increase in survival  
As a result of the observation that mice that received TEa T cells + iNKT + C20.2 
seemed to have a modest increase in survival, we sought to determine whether the 
remaining recipient or donor derived iNKT cells or the AT FI iNKT cells were 
mediating this effect. Equally important, we also investigated whether the 
exacerbated weight loss observed after irradiation was attributable to the activation of 
recipient or donor derived iNKT cells or the AT FI iNKT cells. To this end, mice 
received TBI and TCD BM and either TEa T cells alone or together with C20.2. 
Importantly, no additional iNKT cells were transferred to these mice.  
In keeping with previous experiment mice that received TEa T cells only exhibited 
weight loss from day 8 onwards (Figure 6.8A). However there was no significant 
difference between mice that received a single or multiple injections of C20.2 (Figure 
6.8B). Mice that received a single shot of C20.2, showed 100% survival (Figure 6.8E) 
and did not register clinical scores (Figure 6.8F). Receiving multiple shots of C20.2 
did not significantly affect weight loss, however one mouse had to be sacrificed on 
day 5 (Figure 6.8B, E).  
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Interestingly, on day 8 and 9 mice that received TEa T cells only, lost significantly 
more weight than those that received TEa T cells and C20.2 (Figure 6.8C). This 
occurred concomitantly with an increase in survival in mice that received TEa T cells 
and C20.2 compared to TEa T cells alone (Figure 6.8E) and a decrease in clinical 
scores in the presence of C20.2 (Figure 6.8F). Furthermore, the exacerbated weight 
loss seen following adoptive transfer of iNKT cells and C20.2 (Figure 6.6A) was not 
observed on administration of C20.2 in the absence of adoptive transfer of iNKT cells 
(Figure 6.8C). 
Together, these data suggest that the modest increase in survival observed when 
C20.2 is administered is a result of activating either residual iNKT cells or 
contaminating iNKT cells in the BMT. It also suggests while multiple shots of C20.2 
are tolerable it does cause initial weight loss, so such use in future experiments 
would need to be approached with caution.  
 
6.3.7. T-bet-/- iNKT cells activated with C20.2 exacerbate GVHD  
In Figure 6.6 we observed that weight loss was exacerbated when FI iNKT cells were 
injected concomitantly with C20.2 but that mice that survived beyond this point went 
on to do marginally better. Subsequently, we showed that the exacerbated initial 
weight loss was caused by the AT iNKT cells. However, as iNKT cells exist as 
multiple subsets with distinct effector functions it was possible that this unwanted 
side-effect was attributable to a particular subset. Given that ~57% of FI iNKT cells 
produce IFN-γ (Figure 4.2), and that αGal a glycolipid that is known to leads to 
production of Th1 cytokines exacerbates GVHD (Figure 6.1), we reasoned that 
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removing Th1 type cytokines might eradicate the pronounced weight loss following 
irradiation. Therefore, iNKT cells were purified from T-bet-/- mice and were transferred 
to mice that also received irradiation, TCD BM and TEa T cells (Figure 6.9).  
Surprisingly, we observed that mice that received TEa T cells + T-bet-/- iNKT cells + 
C20.2 lost significantly more weight between days 4-6 than mice that received TEa T 
cells alone which resulted in one mouse having to be sacrificed (Figure 6.9A, B, C). 
In addition, such mice also lost significantly more weight, presented with decreased 
survival and increased clinical scores compared to mice that received TEa T cells 
+C20.2 on days 8 and 9 (Figure 6.9A, C, D).  
Despite the fact that TEa T cells + WT iNKT cells + C20.2 did not show exacerbated 
weight loss after irradiation as in Figure 6.6, they still showed a modest decrease in 
survival compared to mice that received TEa T cells + C20.2 (Figure 6.9A, C).  
Together these data suggest that the NKT1 subset of iNKT cells is not responsible 
for increased weight loss after irradiation and indeed these cells may temper the 
impact of other subsets on weight.  
 
6.3.8. RORγt- iNKT cells activated with C20.2 exacerbate GVHD  
Given that exacerbated weight loss after irradiation was not attributable to NKT1 cells 
we decided to determine whether it was IL-17 producing NKT17 cells that were 
mediating this effect. Although the spleen only hosts a small proportion of IL-17 
producing iNKT cells (8) IL-17 producing iNKT cells have been shown to be involved 
in proinflammatory responses in airway inflammation and as such one might predict 
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that they would not be beneficial in the setting of bone-marrow transplantation (453, 
454).  
To this end, RORγT- iNKT cells were purified from RORγT reporter mice and were 
transferred to mice that also receive TBI, TCD BM and TEa T cells (Figure 6.10). We 
observed that in this experiment, there was no increased weight loss after irradiation 
observed from day 4-6, however as this occurred in the presence of both WT and 
RORγT- iNKT cells, we cannot conclude that there was any benefit to transferring 
RORγT- iNKT cells (Figure 6.10A). 
 We observed that mice that received TEa T cells + WT or RORγT- iNKT +C20.2 
mice lost significantly more weight than mice that received BMT only (Figure 6.10A). 
This corresponded with decreased survival and an increase in clinical scores (Figure 
6.10B, C). Mice that received TEa T cells + RORγT- iNKT cells +C20.2 also did 
worse in terms of survival than mice that received TEa T cells + WT iNKT cells 
+C20.2 or TEa T cells alone, which was also reflected in increased clinical scores 
(Figure 6.10B, C). 
Even in the absence of the decreased weight loss after irradiation, mice did not show 
increased survival (Figure 6.10B). Importantly, while none of the differences in 
survival were substantial, the fact that RORγT- iNKT cells +C20.2 lead to a decrease 
in survival implies that removing such cells from FI iNKT cells was futile. 
6.3.9. Exp iNKT cells can survive and can be identified in vivo following BMT   
Given the lack of success at alleviating GVHD with FI iNKT cells we sought to test 
whether iNKT cells that had been expanded in vitro would have a different impact in 
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this setting. Indeed, we found that Exp iNKT cells were better at suppressing 
alloreactive T cell responses in vitro in Chapter 5.  
First we conducted a pilot experiment to test whether Exp iNKT cells could survive 
following transfer in vivo (Figure 6.11). B6 iNKT cells were expanded for 14 days with 
anti-CD3 and anti-CD28 with IL-2, IL-12 and IL-7 before being transferred to mice 
that had received TBI and TCD BM on day 0. One mouse also received C20.2 to 
activate the transferred cells. The transferred Exp iNKT cells were 75% pure and 
produced IFN-γ (39%), IL-4 (50%), IL-10 (35%), IL-13 (88%) and IL-17 (38%) on re-
stimulation (Figure 6.11A, B). The transferred Exp iNKT cells proved to be easily 
detectable in the spleen (Figure 6.11C), MLN (Figure 6.11D) and SI (Figure 6.11E). 
 
6.3.10. GVHD mice that receive Exp iNKT cells activated with C20.2, show 
increased survival compared to mice that receive Exp iNKT cells alone  
As we could successfully detect the Exp iNKT cells in vivo, we proceeded to 
investigate their ability to suppress GVHD. Mice were given TBI and TCD BM on day 
0, followed on day 2 by TEa T cells + Exp iNKT cells with and without C20.2 or TEa T 
cell + C20.2 alone. The injected cells were 72% pure and produced IFN-γ (88%), IL-4 
(16%), IL-10 (20%), IL-13 (98%) and IL-17 (28%) upon in vitro re-stimulation (Figure 
6.12A, B).  
Mice that received TEa T cells +Exp iNKT with C20.2 showed no difference in weight 
loss however they did show significantly increased survival and lower clinical scores 
from day 9-11 compared to mice that received TEa T cells +Exp iNKT without C20.2 
(Figure 6.12C, D, E). However, neither group showed increased survival even 
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compared to the group that received TEa T cells +C20.2 alone (Figure 6.12D). 
Collectively these data show that while activating iNKT cells with C20.2 incurs a 
marginal survival benefit, and delayed onset of clinical scores compared to mice that 
do not receive C20.2, these benefits are not significantly increased with AT Exp iNKT 
cells, and therefore the modest protective effect is likely predominantly mediated by 
host residual iNKT cells.   
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6.4. Discussion  
This chapter set out to investigate the ability of both FI and Exp iNKT cells to 
influence GVHD in a model where GVHD is caused by TCR-transgenic T cells (TEa 
T cells) that recognise a BALB/c-derived H2I-Eα peptide presented by H2I-Ab in 
CB6F1 recipients. In addition we sought to investigate the impact of specific subsets 
of iNKT cells on GVHD. We observed that residual iNKT cells can incur a slight 
survival benefit when activated with C20.2, however transferring FI or Exp iNKT cells 
did not lead to attenuation of GVHD or an increase in survival. Both recipient-derived 
and AT iNKT cells have previously been shown to attenuate GVHD in other models 
(126, 234, 236-238, 524).   
The use of reduced intensity irradiation has been shown to lead to over 
representation of DX5+ T cells in BALB/c mice and to prevent GVHD in BALB/c mice 
that had received fully mismatched B6 transplants. This was shown to be dependent 
on recipient derived IL-4 (524, 525). Furthermore, the majority of studies that have 
shown the beneficial effect of AT FI iNKT cells in models of GVHD have also been 
carried out using BALB/c recipient mice (126, 234, 238). BALB/c mice are known to 
be Th2 biased (529), and IL-4 production has been shown to be important in the 
mechanism observed in these models (234). A single injection with αGal significantly 
decreases morbidity and mortality in a B6 to BALB/c model of GVHD but neither B6 
to B6D2F1 nor BALB/c to B6 GVHD models (527, 528).The protective effect observed 
in BALB/c recipients does not occur in CD1d-/- or IL-4-/- recipient mice (527). In 
contrast, C20.2 an αGal analogue that is biased towards Th2 cytokines (278), failed 
to exacerbate GVHD in B6 to B6D2F1 and BALB/c to B6 GVHD models and in most 
settings inhibited it (528).  
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This requirement for IL-4 at least for this mechanism, may be the reason that much of 
the success suppressing GVHD with iNKT cells has been achieved in BALB/c 
recipients or using glycolipids to promote Th2 type responses. We observed only a 
modest increase in survival as a result of activating recipient iNKT cells (Figure 6.8). 
The CB6F1 recipient mice are a cross between B6 and BALB/c mice. A study of 
leismania major showed that while B6 and BALB/c mice show Th1 and Th2 
responses respectively in the first 5 months of infection, CB6F1 show a response in 
which both type 1 and type 2 cytokines are elevated (536). Therefore it is possible 
that they do not confer protection to the same extent as BALB/c recipients due to 
their intermediate phenotype between BALB/c and B6. Furthermore, although we 
adoptively transferred B6 iNKT cells as was used in previous studies, as the 
recipients are CB6F1 mice they may differentially impact the phenotype of the 
transferred cells compared to BALB/c recipients.  
Treg have also been repeatedly shown to be required by iNKT cells to suppress 
GVHD in BALB/c mice. The same group that used reduced intensity conditioning 
regime to prevent GVHD via iNKT cells, later went on to show that host iNKT cells 
induced the expansion of Treg which was IL-4 dependent and was lost in Jα18-/- 
recipients (525). Furthermore, the Negrin group showed that the protective effect 
observed when iNKT cells are transferred into a B6 to BALB/c model of GVHD also 
requires Treg (238). In our studies we did not transfer Treg as TEa T cells have a re-
arranged TCR genes which precludes selection of Treg raising the possibility that 
suppression would have been observed with the co-transfer of Treg.  
 
216 
 
However, we do not know if mechanisms exist in which FI iNKT cells or subsets of 
such cells can suppress independently of Treg. In Chapter 5, we observed that both 
FI and Exp iNKT cells could suppress TEa T cells in vitro without the requirement for 
Treg. Similar results have been reported with Exp human iNKT cells where the iNKT 
cells suppressed T cell activation by the cytolysis of DCs (408). These results 
suggest a mechanism of suppression by which Exp iNKT cells can suppress 
alloreactive T cells in a cytokine and Treg independent pathway. Whether 
suppression can occur independently of Treg and IL-4 in vivo is currently unknown. 
However, it is unlikely that cytolysis of DCs occurs in vivo, due to the sheer number 
of iNKT cells that would be required to kill all alloantigen bearing APCs, and to 
simultaneously maintain APCs to present glycolipids to the iNKT cells.  
While we did not observe suppression of GVHD with Exp iNKT cells, there could be 
several reasons for this. It is possible that Exp iNKT cells also require Treg in order to 
suppress GVHD (although they could suppress alloimmune responses in vitro in their 
absence; Chapter 5, (Figure 5.1). It should be noted that many of the reports of iNKT 
cells suppressing GVHD involve the transfer of splenocytes which would include 
Treg, so we cannot rule out the requirement for Treg in Exp iNKT cell mediated 
suppression (237, 513). Another possibility is that the Exp cells have a complex 
phenotype as seen in Chapter 4, and that any suppressive effect of a particular 
subset is masked by other proinflammatory subsets. To test this hypothesis it would 
be necessary to sort the cells, preferable post expansion, as preferentially expanding 
some subsets is difficult as seen in the data presented in chapter 4.  
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A further possibility is that suppression might have been seen on transfer of 
increased numbers of Exp iNKT cells. We transferred 1x105 Exp iNKT cells, which is 
in line with the numbers used in other studies that used FI cells and 10 fold more 
cells than the disease-causing TEa T cells (234). One previous study used 1x107 Exp 
iNKT cells to suppress GVHD whilst in a xenograft model of GVHD 5x105 iNKT cells 
were transferred to prevent GVHD (237, 513). However, as we had observed in 
Chapter 5 (Figure 5.2), Exp iNKT cells are more potent at suppressing alloreactive T 
cells in vitro we decided to start with 1x105 iNKT cells. Furthermore, in the study that 
utilized 1x107Exp iNKT cells mice had lost up to 35% of their initial weight before 
recovering, and we were mindful of breaching our project license which only allowed 
up to 20% weight loss.  
Another study used BM and 1x107 splenocytes to induce GVHD along with 1x106 Exp 
iNKT cells (535). This study showed that it was host-residual iNKT cells that prolong 
survival in this context. Jα18-/- BALB/c recipient mice did not survive beyond ~25 
days. This suggests that Exp iNKT cells may have an effect early on but it is the 
residual host iNKT cells which lead to prolonged survival in this model. The 
previously described studies did not address the relative contribution of the AT Exp 
iNKT cells versus recipient iNKT cells, and therefore it is possible that the 
suppression in these models is at least partly mediated by host cells. Therefore, it is 
unclear if increasing the number of Exp iNKT cells would lead to suppression of 
GVHD in our model.  
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The relative contribution of donor versus recipient iNKT cells in the suppression of 
GVHD is not well understood. iNKT cells are radioresistant and express high-levels of 
anti-apoptotic protein Bcl-2 (443). In the studies carried out by the Negrin Lab, they 
do not definitively show whether recipient iNKT cells are involved at least in initiating 
the suppressive effects of FI iNKT cells. Mice that receive conventional T cells 
without iNKT cells are compared to those in which FI iNKT cells are also added. 
However, CD1d-/- or Jα18-/- recipients were not tested for their ability to prevent 
GVHD (126, 234). We observed that the marginal protective effect observed with 
C20.2 was seen regardless of the presence of AT iNKT cells, which supports the 
idea that host iNKT cells are important in early protection from GVHD.  
To definitively confirm this we would have to use CD1d-/- or Jα18-/- donor B6 BM, 
however as we depleted to T cells including the iNKT cells from the graft donor BM 
derived iNKT cells are unlikely to contribute. We also looked at iNKT cells 2 days 
post BM transplant in the spleen and MLN to determine the extent of iNKT cell 
survival post TBI. However, although detectable, numbers of both recipient and 
donor iNKT cells were vanishingly small (data not shown). Therefore, it is possible 
that donor or recipient iNKT cells may mediate the minimal attenuation of GVHD that 
was seen it is unlikely. However, we cannot rule out potential local effects so it may 
have been more revealing to assess iNKT cell number in GVHD target organs. 
In addition to recipient iNKT cells modestly extending survival in the GVHD model, 
somewhat surprisingly, we found that transfer of either FI or Exp iNKT cells followed 
by activation with either αGal or C20.2 led to increased weight loss after irradiation. 
This may be due to the cytokines being produced by the AT iNKT cells leading to 
increased inflammation. Indeed in the case of αGal there was an increase in the 
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frequency of disease causing TEa T cells upon administration to mice that received 
TEa T cells + iNKT cells (Figure 6.2).  
Due to this exacerbated weight loss we hypothesized that removing potentially 
pathogenic subsets of iNKT cells such as NKT1 cells or NKT17 cells might alleviate 
this exacerbated weight loss after irradiation and perhaps lead to an increase in 
overall survival. The dominant subset of iNKT cells found in the spleen is IFN-γ 
secreting NKT1s however transferring T-bet-/- iNKT cells did not prevent the 
increased weight loss and exacerbated death through GVHD (Figure 6.9). This was 
surprising as T-bet-/- mice have been shown to produce increased levels of IL-4, 
which has been shown to be protective in models of GVHD in which BALB/c 
recipients are used (234, 238, 310, 525). These data would suggest that IFN-γ or 
perhaps something else under the transcriptional control of T-bet in fact has 
beneficial effect in GVHD in this model, which would point to another population 
being the pathogenic subset. However, transferring iNKT cells that were devoid of 
NKT17 cells also promoted weight loss and GVHD (Figure 6.10).  
These seemingly multifarious observations, could be explained by the fact that we 
are transferring the FI iNKT cells into an inflammatory environment in which 
irradiation has led to tissue damage and there has been an expansion of 
inflammatory cells and alloreactive T cells. Indeed bystander activation of iNKT cells 
can occur by means of IL-2 produced by alloreactive T cells (231). Furthermore, the 
phenotype of the iNKT cells may be influenced by the microenvironment into which 
they are transferred or the activation with glycolipids. This may lead to the AT iNKT 
cells exhibiting an inflammatory phenotype regardless of the cells transferred and 
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perhaps in the absence of one proinflammatory cytokine the cells compensate by 
making increased quantities of other pathogenic subsets.  
Although we did not thoroughly investigate the stability of the phenotype of either the 
AT FI or Exp iNKT, there is evidence that the outcome of iNKT cell activation is 
strongly influenced by the context in which the iNKT cells are activated. For example, 
the co-culture of thymic iNKT cells with APCs from the spleen in the presence of 
αGal, leads to a significant increase in IFN-γ expression, which was reduced when 
thymic iNKT cells were co-cultured with thymic APCs (334). This is thought to be as a 
result of the fact that co-stimulatory molecules are expressed at different levels 
depending on their tissue of origin. 
As was the case with the remaining recipient iNKT cells, the genetic background of 
the recipient mouse may also play a role. In previous studies that AT FI iNKT cells B6 
BM and cells were transferred into BALB/c recipients (126, 234, 238). As previously 
mentioned the CB6F1 mice show a response in which both type 1 and type 2 
cytokines are elevated (536). Therefore it is possible that their ability to skew the 
immune response towards a type 2 response may not be sufficient to incur iNKT cells 
with sufficient ability to produce IL-4. Studies have shown that B6 lineage diversity is 
intrinsically determined and the phenotype of these cells was not perturbed by 
exposure to BALB/c cells during development or in BM chimeras (310, 537).  
However, as we have discussed in the context of GVHD the iNKT cells are being 
transferred into an inflammatory environment. The influence of GVHD on the 
phenotype of AT B6 iNKT cells has not been studied, although serum from such mice 
was Th2 biased and suppression did not occur if IL-4-/- iNKT cells were transferred 
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(126, 238). Transferred iNKT cells being either NKT1 or NKT17 biased by the 
microenvironment could be an explanation for the detrimental effect of T-bet-/- or 
RORγT- iNKT cells in our model of GVHD. Although it is important to remember, that 
if Treg are required in our model, even sufficient IL-4 production by iNKT cells would 
not induce protection.  
In conclusion, although we did not observe any increase in survival during GVHD 
with either FI or Exp iNKT cells this could be as a result of disparities between GVHD 
models, or a requirement for Treg. Both of these possibilities can be addressed in 
future studies. In addition it will be important to understand the relative contribution of 
donor versus recipient iNKT cells and the stability of AT cells in order to understand 
how adoptively transferring iNKT cells in humans can be both safe and effective in 
the context of GVHD.  
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6.5. Figures 
Figure 6.1 Activated iNKT cells exacerbate initial weight loss and GVHD  CB6F1 mice were 
lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 
TEa T cells, TEa T cells + 1x10
5
 FI iNKT cells, TEa T cells  + iNKT cells + αGal, iNKT cells + αGal or 
iNKT cells only, on day 2. Mice were monitored and (A) iNKT vs iNKT + αGal weight loss to day 50 (B) 
Weight loss TEa only versus TEa T cells + iNKT versus TEa T cells + iNKT + αGal. (C) Weight loss 
TEa T cells + iNKT + αGal versus iNKT + αGal. (D) Survival of all groups (E) Clinical scores of all 
groups. Results were analysed using repeated measure 2-way ANOVA with post hoc Tukey’s 
comparison for weight loss and clinical scores and Log-rank tests were used to analyse survival. 
*p<0.05, **p<0.01 ***p<0.001. Results are presented as mean ± SD, and n=3 mice per group.  
*= iNKT vs iNKT +αGal†= TEa T cells vs. TEa T cells + iNKT + αGal 
‡= TEa T cells + iNKT + αGal vs. iNKT + αGal 
§= TEa T cells vs. TEa T cells +iNKT  
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Figure 6.2 There is an increase in the frequency of total CD4
+
 T cells and TEa T cells in the 
spleens of mice that received TEa T cells + iNKT + αGal compared to those that received TEa T 
cells + iNKT cells only  CB6F1 mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on 
day 0. Such mice received either 1x10
4
 TEa T cells, TEa T cells + 1x10
5
 iNKT cells or TEa T cells + 
iNKT cells + αGalon day 2. Mice were sacrificed when they reached 20% weight loss, or were deemed 
to be at the maximum clinical symptoms allowed by our license. Spleen and MLN derived leukocytes 
were analysed by flow cytometry. Results are expressed as CD4 T cells were gated live lymphocytes 
and TCR-β and CD4 and CD45.1 (donor iNKT cells) or CD45.2 (Donor or recipient) or CD45.1 and 
Vα2 (TEa T cells) in (A, B) the spleen and (C, D) the MLN. Results are analysed using t-tests to 
compare TEa T cells + iNKT versus TEa T cells + iNKT + αGal. Mouse that received TEa T cells only 
mouse is included as a reference point. **p<0.01. Results are presented as mean ± SD, and n=3 mice 
per group. See Appendix V for gating strategy. 
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Figure 6.3 There is an increase in the number and frequency of AT iNKT cells in the spleens of 
mice that received TEa T cells + iNKT + αGal compared to those that received TEa T cells + 
iNKT cells only CB6F1 mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. 
Such mice received either 1x10
4
 TEa T cells, TEa T cells + 1x10
5
 FI iNKT cells or TEa T cells + FI 
iNKT cells + αGalon day 2. Mice were sacrificed when they reached 20% weight loss, or were deemed 
to be at the maximum clinical symptoms allowed by our license. Spleen and MLN derived leukocytes 
were analysed by flow cytometry. Results are expressed as (A, C, E, G, I, K) percentage live 
leukocytes and (B, D, F, H, J, L) absolute numbers of live leukocytes. B cells were on live lymphocytes 
and B220 in the spleen (A, B) and MLN (C, D). NK cells were gated on live lymphocytes and NK1.1
+
 
TRC-β
- 
in the (E, F) spleen and (G, H) MLN. iNKT cells were gated on live lymphocytes and TCR-β 
and PBS-57 tetramer in the (I, J) spleen and (K, L) MLN. Results are analysed using t-tests to 
compare TEa T cells + iNKT versus TEa T cells + iNKT + αGal. Mouse that received TEa T cells only 
mouse is included as a reference point. **p<0.01. Results are presented as mean ± SD, and n=3 mice 
per group. See Appendix V for gating strategy. 
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Figure 6.4 There is no difference in the number or frequency of myeloid cells in the spleens or 
MLN of mice that received TEa T cells + iNKT + αGal compared to those that received TEa T 
cells + iNKT cells only  CB6F1 mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on 
day 0. Such mice received either 1x10
4
 TEa T cells, TEa T cells + 1x10
5
 FI iNKT cells, orTEa T cells + 
FI iNKT cells + αGalon day 2. Mice were sacrificed when they reached 20% weight loss, or were 
deemed to be at the maximum clinical symptoms allowed by our license. Spleen and MLN derived 
leukocytes were analysed by flow cytometry. Results are expressed as (A, C, E, G) percentage live 
leukocytes and (B, D, F, H) absolute numbers of live leukocytes. Cells were gated on live leukocytes 
and Gr1
+
CD11b
+
(myeloid cells (MC)) which were either Ly6C
+
 (monocytes (Mo)) and Ly6G
+ 
(polymorphonuclear (PMN) leukocytes) in (A, B) the spleen and (C, D) the MLN. DCs were gated on 
live leukocytes and CD11c and MHC class II in the (E, F) spleen and the (G, H) MLN. Results are 
analysed using t-tests to compare TEa T cells + iNKT versus TEa T cells + iNKT + αGal. Mouse that 
received TEa T cells only mouse is included as a reference point. Results are presented as mean ± 
SD, and n=3 mice per group. See Appendix V for gating strategy. 
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Figure 6.5 There is an increase in the absolute number of IFN-γ
+
 iNKT cells in the spleen and a 
decrease in IL-17
+ 
iNKT cells in the MLN of mice with activated iNKT cells CB6F1 mice were 
lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice received FI iNKT cells + 
αGal or FI iNKT cells only, on day 2. Such mice were let go and harvested on day 50. iNKT cells were 
gated on live lymphocytes and TCR-β and PBS-57 tetramer. Results are expressed as percentage of 
live leukocytes in the (A) the spleen and (C) the MLN and absolute numbers of live leukocytes in (C) 
the spleen and (D) the MLN and frequency and number of iNKT cells expressing IFN-γ, IL-10 and IL-
17 in the (E, F) spleen and (G, H) MLN. Results are analysed by unpaired t-tests. *p<0.05, **p< 0.01. 
Results are presented as mean ± SD, and n=3 mice per group.  
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Figure 6.6 Activating iNKT cells with C20.2 in GVHD exacerbates initial weight loss and does 
not lead to a significant increase in survival CB6F1 mice were lethally irradiated and given 5x10
6
 
TCD B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 TEa T cells, TEa T cells + 1x10
5
 FI 
iNKT cells + C20.2 or C20.2 only, on day 2. Mice were monitored and (A) Weight loss (B) Survival and 
(D) Clinical scores were recorded. Results are analysed using repeated measure 2-way ANOVA with 
post hoc Bonferroni comparison for weight loss and clinical scores and Log-rank tests were used to 
analyse survival. *p<0.05, **p<0.01 ***p<0.001. Results are presented as mean ± SD, and n=5 mice 
per group for TEa T cell only group and n=10 mice for TEa T cells + iNKT +C20.2, n=3 for C20.2 
alone. Data is pooled from 2 independent experiments.   
*= TEa T cells vs. TEa T cells + iNKT + C20.2  
†= TEa T cells vs. C20.2 
‡= TEa T cells + iNKT + C20.2 vs. C20.2 
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Figure 6.7 There is an increase in the number of iNKT cells in the spleens of mice that received 
TEa T cells + iNKT cells + C20.2 compared to TEa T cells alone  CB6F1 mice were lethally 
irradiated and given 5x10
6
 TCD depleted B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 
TEa T cells or TEa T cells + 1x10
5
 FI iNKT cells + C20.2on day 2. Mice were sacrificed when they 
reached 20% weight loss, or were deemed to be at the maximum clinical symptoms allowed by our 
license. Spleen derived leukocytes were analysed by flow cytometry. Results are expressed as (A, C) 
percentage live leukocytes and (B, D) absolute numbers of live leukocytes in the spleen. (A, B) TEa T 
cells were gated on live lymphocytes, TCR-β and CD4 and CD45.1 and Vα2
+
in the spleen. (C,D) iNKT 
cells were gated on live lymphocytes and TCR-β and PBS-57 tetramer of total, recipient (CD45.2
+
) 
and donor (CD45.2
+
CD45.2
+
) origin. Results are analysed by unpaired t-tests. *p<0.05. Results are 
presented as mean ± SD, and n=6 mice per group for TEa T cell only group and TEa T cells + iNKT 
+C20.2, n=3. 
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Figure 6.8 Modest increase in survival in mice that receive TEa T cells +C20.2 compared to 
those that received TEa T cells alone is caused by residual iNKT cells CB6F1 mice were lethally 
irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 TEa T 
cells, TEa T cells + C20.2 or C20.2 only, on day 2. An additional group of mice received further i.p.’s of 
C20.2 on days 5, 8, 11, 14 and 17. Mice were monitored and weight loss was monitored in mice that 
received (A) C20.2 single shot, versus C20.2 multiple shots versus TEa T cells only (B) FI iNKT only 
versus iNKT +C20.2 (C) TEa T cells versus TEa T cells + C20.2 and (D) survival and (E) clinical 
scores were recorded in all groups. Results are analysed using repeated measure 2-way ANOVA with 
post hoc Bonferroni comparison for weight loss and clinical scores and Log-rank tests were used to 
analyse survival. *p<0.05, **p<0.01 ***p<0.001. Results are presented as mean ± SD, and n=2 mice 
for TEa T cells, n=5 mice for C20.2 multiple i.p.’s C20.2 n=3 for C20.2 one i.p. and n=3 for TEa T cells 
+ one i.p. C20.2.  *= TEa T cells vs. C20.2 multiple i.p.’s        
                            †=. TEa T cells vs. C20.2 one shot 
                            ‡= TEa T cells vs. TEa T cells + C20.2 one i.p.   
                            §= C20.2 one i.p. vs. TEa T cells + C20.2 one i.p.  
                            ¶= C20.2 one i.p. vs. C20.2 multiple i.p.’s.   
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Figure 6.9 iNKT cells from T-bet
-/- 
mice exacerbate GVHD  CB6F1 mice were lethally irradiated and 
given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 TEa T cells, TEa T cells + 
C20.2 or TEa T cells + 1x10
5
 WT or T-bet
-/- 
FI iNKT cells + C20.2 on day 2. Mice were monitored and 
(A, B) Weight loss and (C) Survival and (D) Clinical scores were recorded. Results are analysed using 
repeated measure 2-way ANOVA with post hoc Bonferroni comparison for weight loss and clinical 
scores and Log-rank tests were used to analyse survival. *p<0.05, **p<0.01 ***p<0.001. Results are 
presented as mean ± SD, and n=5 mice for TEa T cells + T-bet
-/- 
iNKT cells + C20.2, n=3 mice for all 
other groups. See Appendix V for phenotype of T-bet
-/-
 mice.   
*= TEa T cells + T-bet
-/- 
iNKT +C20.2 vs. TEa T cells + vehicle  
†= TEa T cells + T-bet
-/- 
iNKT +C20.2 vs. TEa T cells + C20.2  
‡= TEa T cells + WT iNKT +C20.2 vs. TEa T cells + C20.2  
§= TEa T cells + T-bet
-/- 
iNKT +C20.2 vs. TEa T cells + WT iNKT cells + C20.2  
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Figure 6.10 RORγT negative iNKT cells do not increase survival in GVHD  CB6F1 mice were 
lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 
TEa T cells, TEa T cells + 1x10
5
 WT or RORγT negative FI iNKT cells + C20.2 or no injection on day 
2. Mice were monitored and (A) Weight loss and (B) Survival and (C) Clinical scores were recorded. 
Results are analysed using repeated measure 2-way ANOVA with post hoc Bonferroni comparison for 
weight loss and clinical scores and Log-rank tests were used to analyse survival. *p<0.05, **p<0.01 
***p<0.001. Results are presented as mean ± SD, and n= 4 mice for TEa T cells only, n= 5 mice for 
TEa T cells + WT iNKT + C20.2, n=3 mice for TEa T cells + RORγT negative iNKT cells + C20.2 and 
n=2 mice for BM only.   
*= BM versus vs. TEa T cells + WT iNKT +C20.2 
†= BM versus vs. TEa T cells + RORγT negative iNKT +C20.2 
‡= TEa T cells vs. TEa T cells + RORγT negative iNKT +C20.2 
§= TEa T cells + WT iNKT +C20.2 vs. TEa T cells + RORγT negative iNKT +C20.2 
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Figure 6.11 AT Exp iNKT cells can be identified in the spleen, MLN and SI of mice with BMT  
CB6F1 mice were lethally irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice 
received 1x10
5 
Exp iNKT cells ± C20.2 on day 2. (A) iNKT cells were gated on live and TCR-β and 
PBS-57 tetramer. Exp iNKT cells were phenotyped for (B) Cytokines before injection. Mice were 
sacrificed on day 10 and donor CD45.1
+
 iNKT cells were identified in the (C) spleen, (D) MLN and (E) 
SI. n=1 mouse per group (as this was a pilot experiment).  
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Figure 6.12 Mice that receive TEa T cells + Exp iNKT cells activated with C20.2, show increased 
survival compared to mice that receive TEa T cells + Exp iNKT cells  CB6F1 mice were lethally 
irradiated and given 5x10
6
 TCD B6 BM cells i.v. on day 0. Such mice received either 1x10
4
 TEa T 
cells, TEa T cells + 1x10
5 
Exp iNKT cells or TEa T cells + Exp iNKT cells + C20.2 on day 2. (A) Prior to 
injection, Exp iNKT cells were phenotyped for (B) Cytokines. Mice were monitored and (C) Weight loss 
and (D) Survival and (E) Clinical scores were recorded. Results are analysed using repeated measure 
2-way ANOVA with post hoc Bonferroni comparison for weight loss and clinical scores and Log-rank 
tests were used to analyse survival. *p<0.05, **p<0.01 ***p<0.001. Results are presented as mean ± 
SD, and n= 2 mice for TEa T cells + C20.2, n= 6 mice for TEa T cells + Exp iNKT cells + C20.2, n=3 
mice for TEa T cells + Exp iNKT cells.   
*= TEa T cells + expanded iNKT cells vs. TEa T cells + expanded iNKT cells +C20 
†= TEa T cells +C20.2 vs. TEa T cells + expanded iNKT cells +C20 
‡= TEa T cells + C20.2 vs. TEa T cells + expanded iNKT cells 
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CHAPTER 7 DISCUSSION 
 
 
 
 
 
 
 
 
7.1. Summary of data 
7.1.1. Summary of Chapter 3 data 
In chapter 3 we aimed to set up a model of GVHD in which we could track the 
response of disease-causing alloreactive T cells. To this end, we established a model 
based on a previously report in which CB6F1 mice endogenously produce and 
present an H2IEα peptide in the context of H2IAb enabling recognition by TEa T cells 
(424, 432, 433). Initial experiments showed that TEa T cells could induce weight loss, 
increased clinical scores and death upon transfer to irradiated CB6F1 mice (Figures 
3.2, 3.3). This occurred on a timescale similar to previous studies (424, 433). This 
was true of numbers of TEa T cells ranging from 5x104 down to 1x103 (Figures 3.2-
3.4). However, at lower numbers incomplete penetrance was observed and the 
optimal induction of GVHD that still resulted in complete penetrance was obtained 
using 1x104 TEa T cells (Figure 3.3). Therefore, we decided to proceed with using 
this dose for subsequent experiments.  
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Concomitant with the onset of GVHD we detected TEa T cells in the spleens and 
MLN of diseased mice (Figures 3.2, 3.5). Furthermore, there was an increase in the 
frequency of myeloid cells in the spleens of GVHD mice, which is consistent with the 
onset of GVHD (Figure 3.6). In addition, we could detect TEa T cells and Gr1+ cells in 
the spleens of mice with GVHD using confocal (Figure 3.7).  
Further to this we examined the spleens, MLN and two target organs namely the liver 
and SI just prior to disease onset (day 8). We observed an expansion of TEa T cells 
in all these anatomical locations in an allogeneic setting but not following transfer to 
syngeneic mice, confirming that the expansion of TEa T cells was allospecific and not 
due to homeostatic proliferation (Figure 3.9). Interestingly, we observed that recipient 
iNKT cells were increased in number and frequency compared to donor iNKT cells, 
suggesting that a radioresistant population of iNKT cells remained which could 
impact GVHD (Figure 3.12). Furthermore, we detected signs of damage on day 8 in 
the SI and the liver, two target organs of GVHD (Figure 3.15).  
Our reason for choosing this particular model was due to the high precursor 
frequency of alloantigen specific cells, which would not be present in models which 
use polyclonal T cells to induce GVHD. This would this enable us to stringently test 
the capacity of iNKT cells to suppress GVHD, and assign those properties to iNKT 
cells specifically, and not any contaminating Treg. However, one caveat of the model 
is that the high precursor frequency and lack of Treg resulted in the model being 
extremely acute which may be difficult to control with immunoregulatory cells.  
Another caveat is that this model is driven solely by CD4+ T cells, as are many 
mouse models of GVHD in which successful suppression of GVHD has been seen 
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(418, 538). This ignores the contribution of CD8+ T cells to GVHD, which is known to 
occur in humans in both MHC matched and MHC mismatched settings (539-542). 
Another issue that the disease is caused essentially by a monoclonal population of T 
cells recognising a single MHC-peptide which may not exactly mirror what occurs 
when polyclonal T cells recognise multiple alloantigens. Despite these caveats, this 
model was chosen due to its potential to enable detailed mechanistic dissection and 
elucidation of the role of specific cell populations such as iNKT cells in suppressing 
GVHD. Collectively, the observations in chapter 3 demonstrate that we have 
established a robust model of GVHD in which we can follow the response of 
alloreactive T cells in lymphoid and non-lymphoid tissues. 
 
7.1.2. Summary of Chapter 4 data 
Ultimately we sought to investigate the capacity of different subsets of iNKT cells to 
impact GVHD, therefore we first phenotyped iNKT cells. Furthermore, as iNKT cells 
would likely have to be expanded in vitro in order to make their use as a cellular 
therapy clinically viable, we set about expanding and characterising the resultant 
iNKT cells in vitro.  
In line with previous reports we found that iNKT cells made up approximately 1% of 
splenic iNKT cells (Figure 4.1) (250-253). Upon stimulation with PMA and Ionomycin, 
IFN-γ (57%) was dominant cytokine produced by FI iNKT cells while only ~7% of 
such cells produced IL-17 (Figures 4.2). In addition, FI iNKT cells produced IL-4 
(~34%) and IL-13 (~25%), while only ~2% of cells were able to produce IL-10 
(Figures 4.2). In line with these observations T-bet was the dominant transcription 
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factor with ~70% of the cells expressing T-bet, while ~10% expressed RORγT 
(Figure 4.3).  
iNKT cells could be expanded with BMDCs pulsed with αGal or ant-CD3 and anti-
CD28 (Figures 4.4, 4.6). This was a difficult process and expansion did not always 
generate sufficient cells to be used in functional assays, however as human cells are 
easier to expand this would not be an issue in terms of translation (543). Indeed 
human iNKT cells have been sufficiently expanded to use in two phase 1 clinical 
trials for advanced melanoma and advanced and recurrent Non-Small Cell Lung 
carcinoma (396, 462).  
When stimulated with PMA and Ionomycin, the iNKT cells expanded using αGal 
pulsed BMDCs produced less IFN-γ (~9%) than FI iNKT cells, IL-4 (~28%) was found 
to be similar but and interestingly we observed the emergence of iNKT cells able to 
express IL-10 (~31%) which were not present in their FI counterparts (Figure 4.5). 
Expansion with anti-CD3 and anti-CD28 also led to an increase in IL-10 (from ~2% to 
24%), in IL-13 (from ~25% to 84%) and in IL-17 (from ~8% to 33%) with no changes 
in IFN-γ and IL-4 production compared to FI iNKT cells (Figure 4.6).  
The changes in the cytokine producing ability of Exp iNKT cells was also reflected in 
changes in transcription factor expression. For example, an increase in E4BP4 
expression was observed (from ~3% amongst FI iNKT cells to 75% Exp iNKT cells) 
(Figure 4.7). Similarly, the proportion of cells expressing RORγT was markedly 
increased (from ~10% to 49% in FI compared to E iNKT cells, respectively; (Figure 
4.7). The Exp iNKT cells produced similar cytokines upon stimulation with anti-CD3 
and anti-CD28 or αGal pulsed BMDCs compared to PMA and Ionomycin (Figure 4.8).  
239 
 
The Exp iNKT cells also took on complex effector phenotypes with some Exp iNKT 
cells capable of making between two and at least four cytokines on reactivation, 
which was not observed in the FI iNKT cells, suggesting that some the Exp iNKT 
cells took on the ability to produce cytokines not seen in the FI cells (Figure 4.10). 
Although this is clearly interesting and potentially a confounding factor with using 
these cells to manipulate disease we did not investigate the stability of these 
phenotypes in vivo. Furthermore, Exp human iNKT cells have a different phenotype 
(396, 462, 513, 544). However our observations do emphasises the importance of 
investigating the phenotype of human Exp iNKT cells extensively when these cells 
are used in clinical trials as this may affect the function, effectiveness and safety of 
such cells.  
Further, to this we investigated the lineage diversification of Exp iNKT cells. Exp 
sorted RORγT- iNKT cells proved to be very difficult to expand perhaps suggesting 
that the increase in IL-17 producing iNKT cells following expansion was the result of 
outgrowth of the NKT17 population present at the beginning of cultures (Figure 4.12).  
Together, these observations suggest that Exp iNKT cells take on the ability to 
produce multiple additional cytokines upon in vitro expansion and constitute a 
potential population of immunomodulatory cells to be investigated in vitro and in vivo 
for their ability to influence alloresponses.  
 
7.1.3. Summary of Chapter 5 data  
As we observed in Chapter 4, Exp iNKT cells have complex effector phenotypes 
compared to FI iNKT cells, in terms of their pattern of cytokine secretion. In this 
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chapter we aimed to investigate the suppressive properties of such cells in vitro. In 
order to investigate their suppressive capacity in vitro we designed a suppression 
assay in which CFSE labelled TEa T cells were stimulated with α-Gal-pulsed 
allogeneic (CB6F1) BMDCs. The assay was then used to test the impact of FI and 
Exp iNKT cells on a T cell alloresponse.   
Interestingly, we found that activated Exp iNKT cells suppressed TEa T cell 
proliferation (from 79%±5% proliferating cells to 13±2% at a ratio of 1:1 TEa T cells to 
Exp iNKT cells; Figure 5.1). Furthermore, the Exp iNKT cells were found to suppress 
proliferation at ratios as low as 1:0.1 (Figure 5.1). This was also true in terms of 
numbers. Furthermore, we found that activated Exp iNKT cells were significantly 
more potent at suppressing TEa T cells than FI iNKT cells (Figure 5.2).  
We investigated the mechanism used by iNKT cells to suppress T cell responses in 
vitro and found that that neither IL-10 nor IFN-γ was required (Figure 5.3). In addition, 
iNKT cells did not simply out-compete the TEa T cells for IL-2 (Figure 5.4). 
Interestingly we found that Exp iNKT cells could not suppress TEa T cells when they 
were stimulated with anti-CD3 and anti-CD28 (Figure 5.5). This suggests a possible 
involvement of the allogeneic DCs in the suppressive mechanism, or that the anti-
CD3 anti-CD28 stimulated T cells were too potent to suppress. A caveat with this 
experiment was that anti-CD3 and anti-CD28 would also activate the iNKT cells and 
therefore could also affect their suppressive function. Moreover, iNKT cells have 
previously been reported to become anergic in the presence of a strong TCR signal 
with co-stimulation (545). While one recent in vitro human study showed that Exp 
human iNKT cells can suppress T cells stimulated with anti-CD3 and anti-CD28 the 
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source of conventional T cells also contained Treg which may have contributed to 
suppression (513). 
In order to explore candidate molecules that could be involved in immunosuppression 
we analysed microarray results for the modulation of cell surface molecules on iNKT 
cells which had been activated with αGal for 48h compared to PBS controls (Figure 
5.6). We found that LAG-3, PD-1 and TIGIT were all upregulated in the activated 
cells (Figure 5.6). To confirm these molecules were expressed on Exp iNKT cells we 
stimulated the Exp cells with either αGal pulsed BMDCs or anti-CD3 and anti-CD28 
(Figure 5.7). The expression of these molecules proved to be highly variable 
depending on the experiment, possibly due to the fact that the Exp iNKT cells have a 
more varied phenotype than the FI iNKT cells. However, in all three independent 
experiments, stimulation with αGal pulsed BMDCs resulted in the highest frequency 
of Exp iNKT cells expression LAG-3, PD1 and TIGIT (Figure 5.7). Combined with the 
microarray these data suggest that one or more co-inhibitory molecules such as PD1, 
TIGIT and LAG-3 could be responsible for mediating the suppressive effect mediated 
by Exp iNKT cells in vitro.  
We also analysed the expression of LAG-3, PD1 and TIGIT in FI iNKT cells and 
found that the expression of all three molecules was low regardless of whether they 
were activated with anti-CD3 and anti-CD28 or αGal pulsed BMDCs (Figure 5.8). 
However, we showed that the PD1 pathway was not involved in Exp iNKT cell 
mediated suppression (Figure 5.9). However, we did not examine if LAG-3 or TIGIT 
was utilized by Exp iNKT cells. Unfortunately, we were unable to perform RNA-Seq of 
FI and Exp iNKT cells which may have revealed additional molecules that may 
contribute to the suppression seen by Exp iNKT cells. 
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Together, these findings suggest that Exp iNKT cells alone can suppress TEa T cells, 
and their suppressive activity is more potent than FI iNKT cells. This suppression is 
not mediated by IFN-γ, IL-10, IL-2 sequestration by iNKT cells, or the PD1 pathway. It 
would be interesting to investigate in further experiments if suppression was 
mediated by a soluble factor. One way to do this would be to investigate the 
suppressive properties of supernatant derived from activated Exp iNKT cells or 
perhaps to conduct experiments where the iNKT cells and conventional T cells were 
separated by a transwell. It would also be worthwhile to repeat some of the 
experiments using C20.2 instead of αGal to activate the Exp iNKT cells as this is 
reported to promote a Th2-type response (278). Finally it would be interesting to see 
if the glycolipid and alloantigen needed to be on the same APC. To do this αGal 
pulsed B6 BMDCs (to provide iNKT cell activation) and unpulsed CB6F1 BMDCs (to 
provide TEa stimulation) could have been used. If suppression still occurred it would 
suggest that it is not important that iNKT cells and TEa T cells are stimulated by the 
same BMDC.  
These in vitro studies have been validated by three studies that showed that Exp 
human iNKT cells are able to suppress alloreactive T cells in vitro (408, 513, 514). 
However, these studies used unseparated T cells as responder cells and as such 
Treg may also have contributed the mechanism of suppression. One of these studies 
showed that the iNKT mediated suppression occurred through iNKT mediated lysis of 
the DCs (408). This would be an important experiment to carry out in future work. 
Interestingly, it was recently shown that in addition to suppressing alloreactive T cell 
responses Exp iNKT cells mounted a robust GVL response against HLA matched 
allogeneic leukaemia cells in vitro (514). It would be interesting to investigate whether 
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Exp iNKT cells could also mediated an anti-tumour effect. Nonetheless, as far as we 
are aware our study represents the first demonstration that murine iNKT cells can 
suppress alloreactive T cells in vitro, and that Exp iNKT cells are more potent 
suppressors than FI cells.   
 
7.1.4. Summary of Chapter 6 data  
In this chapter we aimed to use the model we established in Chapter 3 to investigate 
the ability of both FI and Exp iNKT cells to suppress GVHD. Our initial experiment set 
out to investigate the ability of FI iNKT cells with and without αGal to suppress 
GVHD. We found that even in the absence of alloreactive T cells iNKT cells activated 
with αGal exacerbated initial radiation-induced weight loss (Figure 6.1). In addition, 
TEa T cells administered with iNKT cells and αGal exacerbated GVHD in terms of 
clinical scores, weight loss and survival (Figure 6.1).  
As a result of these findings we next sought to investigate if activating iNKT cells with 
C20.2 which has been shown to lead to the inhibition of GVHD in a B6 to B6D2F1 
model would be a beneficial alternative to activation with αGal (528). However, we 
again found that the administration of C20.2 exacerbated the initial weight loss, which 
in some cases led to death. Furthermore, no significant increase in survival was 
observed (Figure 6.6).  
Intriguingly, the mice that survived the initial radiation induced weight loss went on to 
show a 2 day delay in GVHD related death (Figure 6.6). We went on to show that 
mice did not present with exacerbated weight loss following the administration of 
C20.2 in the absence of AT iNKT cells but still survived longer than controls (Figure 
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6.8). This suggests that the AT iNKT cells were mediating the initial weight loss and 
the host residual iNKT cells were responsible for the modest increase in survival. 
The observation that the AT iNKT cells exacerbated the initial weight loss after 
irradiation, led us to postulate that removing potentially pathogenic subsets of iNKT 
cells might prevent this exacerbated weight loss. However, transfer of either T-bet-/- 
or RORγT- iNKT cells exacerbated GVHD (Figure 6.9, 6.10). One potential 
explanation for this is as cells are being transferred into an inflammatory environment 
upon adoptive transfer, and it is possible that the absence of one pathogenic 
phenotype leads to the cells compensating by increasing the production of other 
proinflammatory cytokines. This could be investigated using fate-mapping mice. 
Another possibility is that the cells having a pathogenic phenotype that is not under 
the control of RORγT or T-bet, for example IL-2 production, to test this it would be 
necessary to block IL-2 using mAb. 
In Chapter 5 we observed that Exp iNKT cells were more potent suppressors of 
alloreactive T cell responses than FI iNKT cells in vitro. As a result of this observation 
and due to our lack of success suppressing GVHD using FI iNKT cells, we sought to 
test whether Exp iNKT cells would have a better outcome in GVHD. We found that 
anti-CD3 anti-CD28 Exp iNKT cells could survive following in vivo transfer (Figure 
6.11). A caveat is that it would have been useful to investigate the stability of their 
phenotype upon transfer. Mice that received TEa T cells + Exp iNKT cells +C20.2, 
showed extended survival compared to mice that received TEa T cells + Exp iNKT 
cells (Figure 6.12). However, neither group showed increased survival compared to 
mice that received TEa T cells + C20.2 alone, suggesting that any increase in 
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survival was primarily mediated by recipient iNKT cells and not the AT Exp iNKT cells 
(Figure 6.12). 
There could be several reasons why we did not observe GVHD suppression, despite 
the ability of these cells to suppress alloreactive T cells in vitro. As discussed at 
length in Chapter 6, despite our observation that Exp iNKT cells alone can suppress 
alloreactive T cells in vitro they may require other cells such as Treg to mediate 
suppression in an in vivo setting (238, 525). Another possibility is that due to the 
complex effector phenotype of Exp iNKT cells observed in chapter 4, any 
suppressive effect of a particular subset is masked by other proinflammatory 
properties. It is also possible that increasing the number of iNKT cells transferred 
might enable suppression to occur. However, in a previous study that saw increased 
survival in a B6 to DBA/2 model of GVHD due to transfer of Exp iNKT cells, mice lost 
30-35% of their original body weight (237). This would exceed the moderate severity 
limit in our licence. We also encountered this problem when testing the suppressive 
ability of the FI iNKT cells. In several previous studies in which transferring FI iNKT 
cells lead to a protective effect in GVHD, mice exceeded 20% weight loss but went 
on to recover from GVHD. It is likely that amending our licence to allow for more 
severe weight loss would provide us with a better opportunity to investigate the 
suppressive ability of iNKT cells in this model of GVHD.  
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7.2.  Potential factors in the therapeutic potential of iNKT cells 
7.2.1. The timing of infusion may influence the therapeutic potential of iNKT 
cells   
In all studies to date that have shown suppression of GVHD with the iNKT cells (FI or 
Exp) have either been co-infused with BM transplant and disease causing cells, or 
administered one day later (126, 234-238, 513). In the model of GVHD we employed 
we infused iNKT cells with the Tcon and an effect on GVHD was not observed. Our 
reasoning for the timing of infusion was that iNKT cells are rapidly activated and 
therefore pre-infusion might not be necessary and in fact it might be too early for 
them to have an effect on the Tcon.  
Many studies have examined the ability of AT Treg to suppress GVHD, and it has 
been reported that the timing of the Treg infusion has a profound influence on GVHD 
in that it can affect both GVHD and the GVT effect (546). Although the exact timing of 
Treg infusion is not likely to be directly translatable due to the differences in iNKT and 
Treg activation and response rates, it does emphasise that the timing of the delivery 
of immunomodulatory cells can impact their ability to control disease (546). nTreg 
infusion 2 days prior to the infusion of Tcon has been shown to lead to nTreg 
expansion and a ten-fold decrease in the number of Treg needed to suppress GVHD 
and infusing Treg prior to Tcon also lead to increase iTreg potency (547, 548). It 
would be interesting to investigate if injecting iNKT cells before, during and after Tcon 
injection impacted their ability to influence GVHD. 
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7.2.2. The disease setting and local microenvironment can influence the iNKT 
response  
In the model of GVHD that was used in the presented studies the adoptive transfer of 
iNKT cells caused exacerbated weight loss after irradiation. While there are many 
explanations as to why this may have occurred, including the absence of Treg 
transfer, iNKT cells can play a protective or pathogenic role in different models of the 
same disease. This has been shown to occur in Inflammatory Bowel disease (IBD) a 
disease in which iNKT cells have been shown to have both protective and pathogenic 
roles. For example, activating iNKT cells using either αGal or OCH has been shown 
to suppress Dextran sulfate sodium induced IBD (549, 550). While in contrast in the 
Oxazolone colitis model of IBD αGal activated iNKT cells have been shown to be 
detrimental, an effect mediated by IL-13 production (551). This may be due to 
differences in the disease microenvironment of the target organs such as the 
intestine in different models having an effect on the phenotype or function of the 
transferred iNKT cells.  
A hallmark of iNKT cells is their ability to rapidly secrete cytokines upon activation 
and this property is conferred by epigenetic regulation during development (326, 335, 
463, 552). However, iNKT cell phenotype is not fixed and can be altered peripherally 
as the phenotype of iNKT cells can be influenced by the microenvironment in which 
they are situated (334).  
Another study showed that the nature of the APC presenting glycolipid to the iNKT 
cell determines the polarity of the immune response (289). It goes on to suggest that 
the reason that iNKT cells respond differently to different glycolipids is because αGal 
requires presentation by DCs, while presentation of Th2-promoting glycolipid variants 
248 
 
is promiscuous and is not effected by the ablation of CD1d on DCs (289). Co-
stimulation has also been suggested to influence the polarity of the iNKT cell 
response with anti-CD28 and anti-CD40 promoting Th1 responses whereas Th2 
responses are only driven by anti-CD28 stimulation (553).  
There is precedence for iNKT cells behaving in a plastic manner in response to 
cytokines. For example iNKT cells capable of producing IL-17 are thought to originate 
in the thymus; however IL-17 production can be induced under inflammatory 
conditions such as in the presence of IL-1β and IL-23 with TGF-β (454, 475).  
Epigenetic changes are involved in human disease in addition to development; 
however the epigenetic regulation of peripheral iNKT cells has not been extensively 
studied. iNKT cells in the intestine are activated by lipid antigens from either 
pathogenic bacteria or indeed commensals presented by APCs. Whether iNKT cells 
are pathogenic or protective can be influenced by the nature of the lipid antigens, the 
cytokine milieu and the type of APC presenting glycolipid (554). In the steady state 
CD1d mediated lipid presentation by CD11c+ cells and intestinal epithelial cells have 
been shown to be import in the maintenance of intestinal homeostasis (555, 556).  
The intestinal microbiome has been shown to affect the phenotype and function of 
iNKT cells (557). Exposing germ-free mice to bacteria which carry iNKT cell specific 
antigens led to the iNKT cells maturing from less mature to fully mature iNKT cells 
(557). In this study we have observed an inflammatory infiltrate and signs of intestinal 
damage in GVHD (Figure 3.15). Given the propensity of the phenotype of iNKT cells 
to be altered in response to the intestinal microbiome, theoretically it would be 
possible for iNKT cells in a disease such as GVHD which causes epithelial damage 
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and hence weakens the integrity of the intestine to alter the phenotype of iNKT cells 
through releasing previously sequestered lipid antigens.   
iNKT cells have also been shown to be amenable to ex vivo reprogramming (558). 
Splenic iNKT cells were harvested from mice with 2,4,6-trinitrobenzenesulfonic acid 
colitis (oxazolone colitis) and were exposed to colitis extracted proteins which 
resulted in a shift away from NKT1 cytokines and towards NKT2 cytokines (558). 
Adoptive transfer of such cells alleviated colitis. Although the mechanism by which 
this occurred was not investigated it is likely that it occurred by means of epigenetic 
regulation. 
More research is required into the plasticity of peripheral iNKT cells and if indeed this 
plasticity is mediated by epigenetic regulation. Furthermore, it will be important in the 
context of therapeutically transferring iNKT cells to understand how the local and 
systemic disease microenvironment can potentially influence the phenotype of 
transferred iNKT cells.    
 
7.2.3. The site of infection or injury can influence the iNKT cell response 
iNKT cells can play paradoxical roles in organ transplantation depending on the 
anatomical location of the transplanted organ (Jones, unpublished observation). iNKT 
cells have been shown to be required for graft acceptance in vascularised cardiac 
transplant models in which tolerance was induced either by blocking co-stimulatory 
molecules, integrins or co-receptors (232, 399, 404). In contrast, iNKT cells produce 
IL-17 post skin transplantation and promote graft rejection (231). 
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In these models of heart transplantation the recipients were B6 and the hearts were 
vascularised and hence drained to the spleen (559-562). The majority of iNKT cells in 
the spleen of B6 mice are IFN-γ producing (310, 320, 330, 331). On the other hand 
skin transplants drain to the LNs and in B6 mice IL-17 is the predominant cytokine 
produced by iNKT cells in the skin and draining LNs (407). Therefore, it is likely that 
as a result of the dominance of different subtypes of iNKT cells at different locations, 
namely the draining secondary lymphoid organs, iNKT cells have the ability to both 
facilitate and impede allograft acceptance. iNKT cells also play diametrically 
opposing roles in various viral infections, which has been suggested to be influenced 
at least in part by the primary site of infection (563).   
In terms of GVHD, the skin, lungs, liver and intestine are affected, in addition to the 
iNKT cells potentially having an anti-tumour response against blood borne cancer 
cells. With multiple organs being affected by GVHD, iNKT cells may have to behave 
in the same suppressive manner against alloreactive T cells in multiple anatomical 
locations. However, the GI tract is thought to be particularly important in the initiation 
of GVHD and the perpetuation of the cytokine storm (172). Furthermore, intestinal 
damage has been shown to be important in the pathophysiology of GVHD (154). 
Therefore, as iNKT cells respond rapidly on activation, iNKT cells may mediate their 
effects early in disease before GVHD has progressed to multiple organs.  
In the model of GVHD characterised in Chapter 3, we observed the infiltration of 
immune cells, and damage to the liver and SI on day 8 which is prior to the onset of 
disease (Figure 3.15). Although we did not observe any clinical signs of skin GVHD, 
the damage that was present in the SI and Liver was sufficient for the animals to 
reach their severity limit in terms of either weight loss or clinical score. Given these 
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observations and the significant weight loss observed in disease mice, we 
hypothesise that in order to see suppression mediated by iNKT cells in this model it 
will be important for them to have a suppressive effect in the GI tract.  
 
7.2.4. The stage of disease can influence the iNKT cell response 
In the model of GVHD we employed, we have observed that activation of AT iNKT 
cells exacerbates initial weight loss after irradiation (Figure 6.6, 6.8). However, 
although the majority of mice that received AT iNKT cells and C20.2 had to be culled 
as a result of this exacerbated weight loss, those that survived did so for longer than 
control mice (Figure 6.6). While this effect was most likely mediated by recipient iNKT 
cells (Figure 6.8), it suggests that iNKT cells albeit from different origins had different 
roles depending on the stage of the disease. Due to project licence regulations we 
had to cull mice that reach 20% weight due to exacerbated weight loss post-
irradiation, however these mice appeared to be otherwise healthy and did not register 
a clinical score. Therefore, it is impossible to say if such mice would have also gone 
on to show improved survival.  
iNKT cells have previously been shown to have pathogenic and immunoregulatory 
roles even within the same disease depending on the disease stage. An example of 
this is in relapsing remitting MS, in which decreased peripheral blood iNKT cells 
correlated with onset of relapse (370). In contrast, remission periods have been 
associated with Th2 biased NKT cells (371).  
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NOD mice, which are frequently used to study diabetes, have significant defects in 
the frequency of iNKT cells and cytokines they produced (564). Adoptive transfer of 
WT iNKT cells, or restoration of iNKT cell function using αGal, or overexpression of 
CD1d or TCR can prevent the development of diabetes in NOD mice (564-566). This 
suggests that iNKT cells have a protective role during the development of diabetes. 
These observations led to investigation into the mechanism by which iNKT cells 
mediate this protective effect. As a result of this iNKT cells have been found to impair 
the development of autoreactive T cells into effector Th1 cells, by directly 
suppressing autoreactive CD4+ T cells via IFN-γ and by inducing the development of 
non-inflammatory DCs (567-569). 
In contrast, iNKT cells have also been shown to have a pathogenic role in diabetes 
through enhancing the activation, expansion and IFN-γ production of diabetogenic 
CD8+ T cells (570). This suggests that iNKT cells may have a different effect on CD4+ 
and CD8+ T cells and while they may act to prevent diabetes early in disease once 
autoreactive CD8+ T cells become activated they may exacerbate disease 
pathogenesis.  
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7.2.5. The type of glycolipid and route of administration can impact the 
response of iNKT cells  
As previously mentioned the nature of the glycolipids used to activate iNKT cells 
influences the polarity of the immune response. αGal leads to the production of 
predominantly Th1 type cytokines such as IFN-γ, while OCH and C20.2 lead to 
preferential production of IL-4 and other Th2 type cytokines (271, 277, 278).   
In Chapter 6 we observed no improved survival of mice which received AT iNKT cells 
and αGal i.p. Kuns et al. showed that αGal injection induced hyperacute disease 
induction and early mortality in B6 to B6D2F1 and BALB/c to B6 GVHD models while 
C20.2 failed to exacerbate GVHD in B6 to B6D2F1 and BALB/c to B6 GVHD models 
and in most settings inhibited it (528). Therefore we decided to use C20.2 to activate 
the AT iNKT cells. However, we found that this led to only a very modest increase in 
survival, which was most likely mediated by radio-resistant recipient iNKT cells 
(Figure 6.8). This observation is in agreement with a previous study which 
investigated the role of host residual cells upon adoptive transfer of Exp iNKT cells 
into a B6 to BALB/c mice model of GVHD (535). Using Jα18-/- recipient mice the 
authors demonstrated that host-residual iNKT cells play an important role in reducing 
the severity of GVHD, and are required for the prolongation of survival by AT Exp 
iNKT cells (535).   
The route by which the glycolipid is administered can also influence the nature of the 
immune response. For example type 3 innate lymphoid cells (ILC3s) express CD1d 
and can present glycolipids to iNKT cells (571). An increase in IL-22 production by 
ILC3s is observed when αGal is administered by oral gavage rather that i.v. injection 
(571).  
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In the model of GVHD we employed we administered αGal by i.p. injection. This was 
due to it being the mode of delivery employed in previous GVHD experiments, and 
the proximity of the intestine which is affected by GVHD (527, 528). However, given 
that one study has found that ILC3 derived IL-22 is critical for prevention of intestinal 
GVHD (468); it might be beneficial to investigate the influence of αGal delivery via 
oral gavage.  
 
7.2.6. The local animal facility or supplier and microbiota may influence the 
iNKT cell response 
The local animal facility and animal supplier has an impact on the microbiome of mice 
(572, 573). As previously discussed the intestinal microbiome has been shown to 
affect the phenotype and function of iNKT cells (557). iNKT cells can recognise 
intestinal glycolipids presented on CD1d expressed by CD11c+ cells and intestinal 
epithelial cells which has been shown to be importance in the maintenance of 
intestinal homeostasis (555, 556).  
In the model of GVHD we employed, Baytril (enrofloxacin) was given in drinking 
water for one week prior to and two weeks post BMT. Antibiotics are commonly 
administered prior to BMT as the immune system has been ablated by the irradiation 
which leaves the mice vulnerable to infection. However, interestingly in a model of 
collagen induced arthritis Baytril has been shown to aggravate the disease (574). It 
does this through partially depleting the intestinal microbiota when administered 
orally compared to positive control mice. In vitro, auxiliary LN and MLN cells from 
collagen induced arthritis mice show increased production of IFN-γ and IL-17 and a 
decrease in IL-4 production compared to controls (574). 
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Given this observation and the propensity of iNKT cells to respond to microflora lipid 
antigens in the intestine and hence maintain homeostasis it is conceivable that 
alterations in the microflora results in the AT iNKT cells having a detrimental impact 
in our experiments, in that they cause exacerbated weight loss after irradiation. This 
could theoretically be influenced by the microbiome present in the local animal facility 
or animal supplier (572, 573). Indeed in mice and humans, broad spectrum 
antibiotics have been shown to give rise to the dominance of families of bacteria 
which are usually subdominant and in some cases these bacteria are multi-drug 
resistant (575-580). Furthermore, decreased diversity is related to poor clinical 
outcomes in clinical GVHD calling into question which antibiotics should be used and 
the timing of antibiotic administration (575-580). One study showed that a decrease 
in the Lachnospiraceae and Ruminococcaceae families and increase in the 
Enterobacteriaceae family correlated with an imbalance in the ratio of Treg/Th17 
observed in GVHD patients compared to non-GVHD patients (579).  
Together these studies suggest that broad spectrum antibiotics can alter the 
microbiome and decrease diversity and this is associated with onset of GVHD and 
poor outcomes. In mice studies, the remaining microbiome post antibiotic treatment 
could be influenced by the type of antibiotic used as well as the timing of 
administration. It is also likely that the original microbiome present in a particular 
animal facility or supplier prior to antibiotic treatment could influence what bacteria 
are present after treatment which one might predict could impact the effect of the 
microbiome of GVHD, depending on the dominant family of bacteria present. It is 
possible that in our animal house treatment with broad-spectrum antibiotic Baytril 
leads to the dominance of bacteria that promote GVHD and the death of bacteria that 
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promote regulatory cells, similar to what has been shown to occur in collagen 
induced arthritis (574). Given the propensity of iNKT cells to recognise lipids, iNKT 
cells could have exacerbated this. Indeed in another disease setting (NOD mice) an 
increase in NKT17 cells has been observed in the intestine which was associated 
high Bacterioidales and low Clostridiales abundance (581). Of course only a detailed 
phenotyping of the microbiome of our recipient mice would enable us to examine this 
hypothesis. 
 
7.2.7. Summary of known and potential effects on the therapeutic potential of 
iNKT cells  
Multiple factors are known to influence the iNKT cells response, which may have a 
bearing on their ability to be used therapeutically to suppress GVHD. These include 
the timing of infusion, the microenvironment in which they are situated, the site of 
injury, the stage of disease and the type of glycolipid antigen and mode of delivery 
employed. Furthermore, other factors such as the influence of the local animal facility 
and supplier and antibiotic treatment and the timing of iNKT infusion for adoptive 
transfer based therapies have not been investigated in the context of iNKT cells but 
may impact their response none the less. Greater understanding of these factors in 
the context of GVHD would result in improved study design for investigating the 
ability of iNKT cells to suppress GVHD. Furthermore, this information would be useful 
in unravelling the ability of iNKT cells to maintain anti-tumour immunity following HSC 
transplantation.  
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7.3. Graft-versus-tumour effect.  
FI isolated CD4+ iNKT cells or DX5+ CD4+ NKT cells have been reported to be 
capable of suppressing GVHD while maintaining the anti-tumour effect (234, 238). 
Current therapies for GVHD involve blocking or depleting T cells in the graft and 
while this can reduce GVHD, it results in impaired engraftment and reduces the GVT 
effect (148, 532). The ultimate goal in the treatment of HSC transplantation is to 
prevent the GVHD response while still maintaining the anti-tumour effect. Exp iNKT 
cells have been shown to suppress GVHD, however these studies have not 
thoroughly investigated the impact of Exp iNKT cells on the tumour (236, 237, 513).  
Decreased GVHD and increased progression free survival has been observed in 
humans who received higher numbers and ratios of iNKT to Tcon (409, 410). 
Reduced conditioning regimes in patients have also been shown to preserve the 
GVT effect and patients showed a significant increase in the frequency of iNKT cells 
in the blood (534). Furthermore, iNKT cells were shown to mediate protection by 
preventing the tissue damage induced by donor T cells in a mouse model of GVHD, 
while simultaneously maintaining the GVT response of donor T cells against B cell 
lymphoma cells (533). In addition, although CD1d-/- or Jα18-/- recipient mice clear 
tumour cells they ultimately succumb to GVHD (533).  
The mechanism by which iNKT cells prevent GVHD while maintaining the anti-tumour 
response has not been demonstrated. As we observed in Chapter 4 iNKT cells are a 
heterogeneous population of cells (Figures 4.2, 4.3). It is possible that in studies 
where iNKT cells were observed to suppress GVHD while maintaining the GVT 
effect, different subsets were responsible for these two roles.  
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As discussed at length in the introduction, iNKT cells can have a different phenotype 
depending on their location and the type of disease. As GVHD occurs as a result of 
HSC transplantation to treat leukaemia or lymphoma, there are effectively two 
diseases being treated which may require dichotomous immune responses in order 
to restore immune homeostasis. The anatomical locations affected by GVHD and the 
cancer are different as leukaemia, lymphoma and myeloma mainly affect the blood, 
BM, LNs and lymphoid tissue and GVHD affects the skin, lung, liver and GI tract. 
Therefore, it is possible that the iNKT cell subsets are present in the different 
locations and are having different effects.  
iNKT cell derived IFN-γ produced as a result of stimulation with αGal, stimulates NK 
cells and CD8+ T cells which go on to lyse tumour cells and iNKT cell derived IL-12 
primes DCs and enhancing their ability to stimulated tumour specific CD8+ T cells 
(582). In contrast NKT cell derived IL-4 has been shown to be required for NKT cell 
mediated suppression of GVHD (234). Therefore, it is possible that different subsets 
of iNKT cells are responsible for suppressing GVHD and maintaining the anti-tumour 
response. 
While, is has been shown that iNKT cells can maintain the GVT response, whether or 
not iNKT cells can contribute directly to tumour clearance, or merely do not affect the 
anti-tumour effect of the T cells has not been definitely demonstrated. In humans and 
mouse models iNKT cells can mediate their effects directly by killing CD1d 
expressing tumour cells, as can occur in many forms of cancer including AML and 
acute lymphoblastic leukaemia, myelomas and myeloid leukaemias (390-392). 
Furthermore, it has been reported that iNKT cells play a role in anti-tumour immunity 
in leukaemia and lymphoma (386) and a decrease in the number of iNKT cells or 
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defects in their function has been observed in leukaemia, lymphoma and myeloma 
(583). 
There is some evidence that iNKT cell can mediate anti-tumour immunity in the 
context of HSC transplantation as they have been shown, using bioluminescence 
imaging, to have modest anti-tumour activity against A20 but not BCL-1 lymphoma 
cell lines, and such anti-tumour immunity lead to a significant survival benefit (238). 
However, B cell lymphoma lines are known to grow variably in vivo and to be 
particularly sensitive to anti-tumour immunity (538). Furthermore, the mechanism of 
killing used is dependent on the cell line (584) which is also likely to be the case in 
human leukaemia. Therefore, inducing leukaemia using retroviral insertion of 
oncogenes may be more clinically relevant (146, 585). Furthermore, this study does 
not make evident that iNKT cells are mediating this effect directly (238). Further 
evidence that iNKT cells can mediate anti-tumour immunity comes from a recent in 
vitro study that demonstrated that Exp human iNKT cells can suppress alloreactive T 
cells and the same cells Exp iNKT cells show a robust anti-tumour response against 
HLA matched allogeneic patient leukaemia cells in vitro (514).  
iNKT cells have also been shown to mediate anti-tumour immunity indirectly. Such 
cells have been shown to be required for CD8+ T cell mediated cytotoxicity upon 
administration of potent G-CSF analogues (586). iNKT cells may enhance tumour 
clearance indirectly via recruitment and activation of other cells or by regulating 
immunosuppressive cells in the tumour microenvironment or directly by tumour cell 
lysis (587). An example iNKT cells indirectly effecting tumours is via regulating the 
tumour microenvironment, for example by killing tumour-associated macrophages 
which suppress anti-tumour immunity (394, 588).   
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Similar to iNKT cells, Treg have been shown to suppress GVHD while allowing the 
anti-tumour effect to still occur in some mouse models (200-202). This is thought to 
be due to the fact that there is relatively high precursor frequency of allospecific T 
cells in many models of GVHD. Under such conditions, major expansion of CTLs 
may not be required for the anti-tumour effect. Effectively this means that is some 
models of GVHD, the maintenance of the anti-tumour effect is thought to be due to 
the fact that Treg inhibit proliferation, but not activation (589). It is possible that iNKT 
mediated suppression of GVHD and maintenance of the GVT response is occurring 
in a similar manner either directly by the iNKT cells, or indirectly via the Treg. Indeed, 
Treg have been shown to be required for iNKT cell mediated suppression in some 
models of GVHD (238, 525).  
 
7.4. Challenges in translation of cellular therapies to a clinical setting 
Cellular therapy has the potential to transform the treatments of many diseases; 
however several challenges exist in order for a therapy to be successfully translated 
into the clinic. The most important requirements are that the therapy is safe, 
consistent and cost effective and achieving these requirements is not trivial. 
Furthermore, as most preclinical studies are conducted in mice cell therapy faces the 
same challenges as any translational therapy in that results do not always translate 
to humans in terms of relative dose or efficacy. This is further complicated by the fact 
that the mechanism of action of cellular therapies often rely on the intrinsic properties 
of the cells, and therefore the success of the therapy in the clinic is dependent on 
whether human immune cells have the same phenotype and activity.  
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As many cells require expansion is order to obtain numbers capable of mediating 
their effect in vivo a manufacturing process that produces consistent numbers of cells 
of a consistent phenotype at a relatively low cost is required in order for the therapy 
to be financially viable. Cells are known to lose their therapeutic potential with 
increased time in culture, however sufficient numbers of cells have to be produced 
which can take time (590). Furthermore, even slight alterations in conditions can 
drastically alter the phenotype of the cells, for example changes in oxygen 
concentration in the culture media of embryonic stem cells can lead to changes in the 
phenotype of the cells (591, 592).   
Maintenance of the phenotype and function of the cells is of quintessential 
importance for the efficacy of the therapy (593). Maintaining such processing under 
Good Manufacturing practice (GMP) presents a unique challenge (594). Traditional 
production of biotherapeutics involves isolating products from cells but does not 
require recovery of the cells, whereas cell therapies require the cells to be re-
isolated. 
Pathogen transfer is also a concern especially as patients receiving the cell therapy 
are often immunocompromised. Potency assays have been suggested to be a useful 
means of determining the quality, stability and consistency of the cells and it has 
been suggested that they should be in place at an early stages of development and 
be validated prior to commencement of clinical trials (595).   
Variation in the expanded products can occur either as a result of variation in the 
cells being input (which may be genetic) or as a result of the conditions during the 
expansion (596). In some cases cells can come from a third party i.e. can be 
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allogeneic, which makes the process more straightforward as the cells for expansion 
can be carefully chosen and a single batch administered to multiple patients. 
Automating the expansion process can help decrease variability in the conditions 
(597-600). Manufacturing the cells in a closed process would also be preferable as it 
would reduce the risk of pathogen transfer. It would also allow for facilities in which 
multiple batches of cells could be produced in the same room, whereas a semi-
closed system needs to be separated or there would be a risk of cross-contamination 
(601).  
Existing expansion protocols require hands on labour intensive processes which may 
be difficult to automate and scale-up. For example mesenchymal stem cells (MSCs) 
which are currently in ongoing stage 3 clinical trials for steroid refractory GVHD. The 
maximum number of cells that can be generated per lot is currently ~21 billion cells 
(601). The steroid refractory GVHD therapy requires 100 million cells per dose, which 
would mean that 213 doses could be produced per lot and multiple infusions may be 
required per patient to treat GVHD (602). There are approximately 30,000 HSC 
transplants performed annually world-wide, where ~10 to 80% get GVHD depeding 
on the risk factors (603). Of those that develop GVHD, 50% develop steroid 
refractory GVHD (208). This means that even a single infusion per patient would 
present a significant challenge with current technologies.  
Given the difficulties which lead to expense in establishing closed and automated 
manufacturing processes, it has been proposed that for Phase 1 trials a semi-closed, 
manual process should be used which could be up-scaled to an automatic closed 
process if the therapy was successful in early stages.    
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Cell therapies that cannot utilize third party cells present additional challenges. One 
issue is the inability to choose the donor can lead to a variable starting population of 
cells to be expanded. Furthermore, this kind of therapy is a highly personalised 
medicine which is extremely expensive. For example Sipuleucel-T (Provenge), an 
individualised DC vaccine for prostate cancer, currently costs $93,000 for a course of 
three treatments (604). In addition, the shelf life of these therapies can be limited for 
Provenge it is only 18 h at 2-8°C (605). Furthermore, some potential therapies are 
ineffective after freezing and therefore need to be manufactured on site.  
 
7.5. Where do iNKT cells fit into potential cellular therapies? 
Existing cellular therapies in trials for GVHD consist of MSCs which are in ongoing 
stage 3 clinical trials and Treg which are in stage 1 clinical trials (206, 207, 602). 
Similarly to iNKT cells, Treg have been shown to be able to suppress GVHD while 
allowing the GVT effect to occur (206).  
In addition to being able to maintain the anti-tumour effect while suppressing GVHD 
iNKT cells have the advantage of being specifically activated by glycolipids, and 
studies in mice have shown that specific glycolipids can influence the polarity of the 
immune response (271, 277, 278). Furthermore, this means that the iNKT cells are 
effectively antigen specific as they respond to the same glycolipids, whereas Treg 
are polyclonal and the precursor frequency of antigen specific cells would not be as 
high. Depending the on the relative potency of iNKT cells and Treg this may mean 
that less iNKT cells are required in order to mediate an effect.  
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Several protocols exist for the in vitro expansion of human iNKT cells (462, 513, 543, 
544, 606-611). These protocols rely on combinations of αGal pulsed APCs, IL-2, IL-
12 and anti-CD3 and some of these protocols vary only slightly. Furthermore, these 
cells can be cryopreserved and have been deemed safe in two stage 1 clinical trials 
(396, 462). Exp iNKT cells have been successfully expanded for a stage 1 clinical 
trial for advanced melanoma based on scaled up versions of two of the 
aforementioned methods (396, 606, 607). Another clinical trial used Exp iNKT cells 
for advanced and recurrent Non-Small Cell Lung carcinoma (462).   
In Chapter 4, we saw Exp murine iNKT cells have a different phenotype than their FI 
counterparts. In addition, we observed the immergence of complex phenotype, with 
some Exp cells capable of making multiple cytokines, although we do not know the 
stability of this phenotype upon in vivo transfer. Several studies have investigated the 
phenotype of Exp human iNKT cells.  
Two studies investigated the capacity of Exp iNKT cells to produce cytokines using 
IC staining and found that following stimulation with PMA and Ionomycin that the Exp 
iNKT cells were capable of producing IFN-γ and IL-4, with IFN-γ production 
predominating (396, 513). One of the studies also reported that IL-10 was produced 
by iNKT cells in only one patient out of eight after 4 h stimulation. However, a recent 
study found that Exp human CD4+ iNKT cells produced predominantly IL-4 with lower 
frequencies in IFN-γ and IL-17 producing cells, these difference may be due to 
variations in the expansion protocols (514). Several other studies have stimulated 
Exp iNKT cells with αGal and measured cytokine levels being produced by enzyme-
linked immunosorbent assay (ELISA) after 24h or 48h incubation and generally found 
intermediate levels of IFN-γ, low levels of IL-4 and high levels of IL-13. (396, 462, 
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513, 544). Additionally, one study measured IL-10 production which was produced at 
a low level in the supernatants after 24 h (544). The stability of the phenotype of Exp 
cells upon administration has not been investigated although cytokine production by 
PBMCs has been shown to be IFN-γ dominant (396).   
We observed that Exp murine iNKT cells produce IL-10 (Figure 4.5, 4.6), while 
production of IL-10 in Exp human iNKT cells appears to be variable. While IL-10 
might be useful in the suppression of GVHD, it would not be preferable in terms of 
the anti-tumour response. However, if IL-10 or indeed another cytokine was found to 
be detrimental in the case of either GVHD or the GVT effect, gene editing techniques 
such as Clustered Regularly Interspaced Short Palindromic Repeats 
(Crispr)/CRISPR associated protein 9 (Cas9) or Transcription activator-like effector 
nucleases (TALENs) could be employed in order to knockout the expression of the 
implicated gene. Indeed these techniques have been shown to be feasible in primary 
isolated immune cells (612).  
It should be noted, that in the clinical trial for advanced melanoma the Exp iNKT cells 
were autologous and hence coming from patients with advanced melanoma. iNKT 
cells isolated from prostate cancer patients have previously been observed to have 
diminished capacity to proliferate as well as to have a decreased ability to produce 
IFN-γ compared to healthy controls (396, 613). However, cytokines levels were 
comparable to those from healthy donors in the case of advanced melanoma (126). 
Murine studies have indicated that third party iNKT cells can be used to suppress 
GVHD (126). Individuals have differences in the phenotype of peripheral blood iNKT 
cells even before expansion, for example there are differences in the cytokine 
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profiles of iNKT cells in both men and women as well as the profile of cytokines 
produced by bystander cells (610). Therefore, it is not surprising that the phenotype 
of human Exp iNKT cells seems to be variable in terms of cytokine production (396, 
462, 513, 544). If third party iNKT cells could be utilized in humans as has been 
shown in mice this would be useful as it would allow some control of the starting 
material. Additionally, as discussed in the previous section, non-autologous cellular 
therapies are easier to scale up and are therefore likely to be more cost effective.  
In addition to the safety and consistent phenotype of Exp cells, large number of iNKT 
cells would needed to be generated in order to make a potential therapy financially 
viable. In the clinical trial for advanced melanoma, iNKT cells were successfully 
expanded between to 1.1x107-12.26x109 from a starting number of ~1x106 cells per 
patient (396). Therefore, human iNKT cells expand well and if it were possible to use 
third party iNKT cells it may be possible to scale up production further and constantly 
manufacture these cells.  
Chimeric antigen receptor (CAR) or recombinant (r)iNKT cells would be an interesting 
area to explore for the treatment of GVHD. CAR and riNKT cells have been 
investigated in the context of cancers such as lymphoma, but to date their ability to 
suppress GVHD has not been investigated. As iNKT cells possess an endogenous 
TCR, they have been suggested to contribute to anti-tumour immunity directly as 
described previously, as well as through their CAR or rTCR. CAR-iNKT cells against 
B cell lymphomas have been shown to stably express CD19 CARs and to kill APCs 
expressing the relevant tumour antigen in vitro as well as exhibiting enhanced anti-
tumour activity in vivo (614). Interestingly, CD19 CAR-iNKT cells have been shown to 
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be more effective at killing tumour cells than CD19 CAR-T cells in vitro and in vivo 
(615). Given this enhanced anti-tumour effect and the propensity of iNKT cells to 
suppress GVHD while maintaining the anti-tumour effect, investigating the propensity 
of CAR-iNKT cells to suppress GVHD while maintaining the GVT effect would be an 
interesting area of future research.  
In conclusion, though a lot of additional research needs to be carried out before 
clinical translation, Exp iNKT cells present an attractive potential therapeutic for the 
treatment for GVHD as they have been shown to prevent GVHD while maintaining 
the GVT response in mice, they can be specifically activated and they are amenable 
to expansion. 
 
7.6. Conclusions/Future work  
The Holy Grail in the treatment of GVHD has long since been to supress GVHD 
without interfering with the GVT effect. Cellular therapy using Exp iNKT cells provides 
an attractive therapeutic prospect due to their ability to be activated with specific 
glycolipids and the fact that they are effectively antigen specific.  
In this study we have set up a model of GVHD using transgenic T cells, in which the 
mechanism by which iNKT cells suppress GVHD could be investigated. We 
extensively phenotyped Exp iNKT cells and found the emergence of complex effector 
phenotypes and such cells were potent suppressors of alloreactive T cell responses 
in vitro. Experiments thus far have not found these cells capable of suppressing 
GVHD. However, further investigation is warranted in order to determine if these Exp 
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iNKT cells can suppress GVHD in this model and if so to investigate the mechanism 
by which this occurs.  
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Appendix I Mice  
 
Breed  Origin  Age at initiation  
of experiment  
Allotype Haplotype 
B6.SJL-Ptprca 
Pepcb/BoyJ 
(BoyJ)  
Bred in house  8-12 weeks of age  CD45.1 b 
CB6F1 Charles River  8-12 weeks of age  CD45.2 b/d 
C57BL/6  Charles River  8-12 weeks of age  CD45.2 b 
IFN-γ reporter 
(C57BL/6) 
Bred in house 8-12 weeks of age CD45.2 b 
RORγT reporter mice 
(C57BL/6) 
Bred in house 8-12 weeks of age CD45.2 b 
TEa  
(C57BL/6 )  
Bred in house  
(Kind gift from Dr. W. 
Gao and Prof. T. Strom 
(Harvard Medical School, 
Boston, MA)  
8-12 weeks of age  CD45.1 or 
CD45.1+CD45.2+ 
b 
T-bet knockout 
(C57BL/6) 
Bred in house 8-12 weeks of age CD45.2 b 
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Clinical Scoring 
Criteria  Grade 0  Grade 1  Grade 2  
Posture  Normal  Slight hunching noted only at rest  Hunching only at rest  
Activity  Normal  Slightly decreased  Mild to moderate decrease in  
activity  
Fur texture  Normal  Slight Ruffling  Mild to moderate ruffling  
Hair loss  None  Slight loss  Severe loss  
Eye Integrity  Normal  Obvious pain  Eyes closed  
Skin Integrity  Normal  Erythema  Erythema +  
Scaling of paws/tail  
Diarrhoea  None  None  Anal staining  
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Appendix II Solutions 
 
 
cRPMI  
Penicillin-streptomycin 100 U ml-1 (Sigma Aldrich) 
L-glutamine 2mM (Sigma Aldrich) 
2-mercaptoethanol 5.5 μM  
FCS 10% (vol/vol)  
1X RPMI 1640 Sodium Bicarbonate without L-Glutamine (Sigma)  
FACS buffer  
Azide 0.02% (w/v) (Sigma Aldrich) 
1X PBS (See PBS)  
HBSS w/EDTA 
HBSS 500 ml 
EDTA 2mM  
 
HBSS w/FCS 
HBSS 500 ml 
FCS 2% v/v 
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iNKT cell medium  
non-essential amino acids 0.1 mM (Sigma Aldrich) 
Penicillin-streptomycin 100 U ml-1  
L-glutamine 2mM  
Hepes 10 nM (Sigma Aldrich) 
Sodium Pyruvate 1 nM (Sigma Aldrich) 
2-mercaptoethanol 5.5 μM (Sigma Aldrich) 
FCS 10% (vol/vol)  
1X RPMI-1640 Medium M/L-Glutamine (Sigma Aldrich)  
 
MACS buffer  
1X PBS (See PBS)  
EDTA 2 mM  
FCS 2 %(v/v)  
 
PBS (without calcium and magnesium)  
1 PBS tablet (Life technologies/Fisher)  
1L of ddH2O 
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Appendix III Cytometry antibodies/viability dyes 
 
Surface marker 
 
Fluorochrome Clone Antibody 
Subclass 
Company Stock 
Concentration 
Working 
Concentration 
Dilution 
7-
aminoactinomycin 
D 
 (7-AAD) 
PECy5 n/a n/a eBioscience 0.5 mg/ml 10 µg/ml 1/50 
CD11b APCy7 M1/70 Rat IgG2b, κ BD 
Biosciences 
0.2 mg/ml 0.5 µg/ml 1/400 
CD11c PECy7 HL3 Armenian 
Hamster 
IgG1, λ2 
BD 
Biosciences 
0.2 mg/ml  1 µg/ml 1/200 
CD19 PE 6D5 Rat IgG2a, κ Biolegend 0.2 mg/ml 1 µg/ml 1/200 
CD1d tetramer 
(PBS57) 
APC   NIH Tetramer 
Core Facility 
1.5 mg/ml 3.75 µg/ml 1/400 
CD1d tetramer 
(unloaded) 
APC   NIH Tetramer 
Core Facility 
1.5 mg/ml 3.75 µg/ml 1/400 
CD1d-αGal 
complex 
PE L363 Mouse 
IgG2a,k 
eBiosciences 0.2 mg/ml 2 µg/ml 1/100 
 
CD3ε 
 
PE/Cy7 
 
145-2C11 
 
Armenian 
Hamster IgG 
 
eBioscience 
 
0.2 mg/ml 
 
1 µg/ml 
 
1/200 
CD4 PerCP5.5 RM4-5 Rat IgG2aκ BD 0.2 mg/ml 0.5 µg/ml 1/400 
CD4 FITC       
CD5 PECy7 53-7.3 Rat-IgG2a,k Biolegend 0.5 mg/ml 2.5 µg/ml 1/200 
CD8α BV786 53-6.7 Rat-IgG2a,κ BD 0.2 mg/ml 0.25 µg/ml 1/800 
CD45.1 BV510 A20 IgG2a, κ Biolegend 0.2 mg/ml 2 µg/ml 1/100 
CD45.1 FITC A20 Mouse 
(A.SW) 
IgG2a, k 
Biolegend 0.5 mg/ml 1.25 µg/ml 1/400 
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CD45.2 APCy7 104 Mouse 
IgG2a, k 
eBiosciences 0.5 mg/mL 2.5 µg/ml 1/200 
CD45-bio n/a 30-F11 Rat LOU 
IgG2b, k 
BD 
Biosciences 
0.5 mg/ml 2.5 µg/ml 1/200 
CD25 BV605 PC61 Rat IgGa, 
ramda 
Biolegend 0.2 mg/ml 1 µg/ml 1/200 
DAPI BV421 n/a n/a Sigma Aldrich 0.1 mg/ml 1 µg/ml 1/100 
Gr1 APC RB6-8C5 Rat IgG2b, κ eBioscience 0.2 mg/ml 0.5 µg/ml 1/400 
H2 (IA-IE) V500 M5/114 
15.2 
Rat IgG2b, κ BD 
Biosciences 
0.2 mg/ml 1 µg/ml 1/200 
LAG-3 
(CD223) 
BV785 C9B7W Rat IgG1, κ Biolegend 0.2 mg/ml 1 µg/ml 1/200 
Ly6C BV421 AL-21 Rat IgM, κ BD 
Bioscience 
0.2 mg/ml 1 µg/ml 1/200 
Ly6G PerCp5.5 1A8 Rat IgG2a, κ Biolegend 0.2 mg/ml 0.5 µg/ml 1/400 
MHC class II V500      1/200 
NK1.1 BV605 PK136 Mouse 
IgG2a,κ 
BD 0.1 mg/ml 1 µg/ml 1/100 
PD-1 
(CD279) 
BV421 29F.1A12 Rat IgG2a, k Biolegend 0.2 mg/ml 1 µg/ml 1/200 
Streptavidin APC-
eFluor780 
n/a n/a eBioscience 0.2 mg/mL 1 µg/ml 1/200 
Streptavidin BV605 n/a n/a Biolegend 0.1 mg/ml .25 µg/ml 1/400 
TIGIT PE 1G9 Mouse 
IgG1, κ 
Biolegend 0.2 mg/mL 1 µg/ml 1/200 
TRC-β BV510 H57-597 Armenian 
Hamster IgG 
Biolegend 0.1 mg/ml 0.5 µg/ml 1/200 
TCR-β PE       
Vα2-biotin n/a B20.1 Rat IgG2a eBioscience 0.5 mg/ml 1.25 µg/ml 1/400 
TCR-Vα2 Pacific blue B20.1 Rat IgG2a, 
ramda 
Biolegend 0.5 mg/ml 5 µg/ml 1/100 
TCR-Vα2 PE-Cy7 B20.1 Rat-IgG2a eBioscience 0.2 mg/ml 0.25 µg/ml 1/800 
Zombie-dye PE-texas red n/a n/a Biolegend n/a n/a 1/1000 
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Intracellular antibodies 
Intracellular marker Fluorochrome Clone Antibody subclass Company Stock Concentration Working concentration Dilution 
E4BP4 PE S2M-E19 Rat IgG2a, κ eBioscience 0.2 mg/ml 4 µg/ml 1/50 
IFN-γ PE XMG1.2 Rat IgG1, κ eBioscience 0.2 mg/ml 2 µg/ml 1/100 
IL-4 Alexa488 11B11 Rat-IgG1k eBioscience 0.5 mg/ml 4 µg/ml 1/50 
IL-10 PE/Cy7 JES5-16E3 Rat-IgG2b,κ Biolegend 0.2 mg/ml 4 µg/ml 1/50 
IL-13 PE eBio13A Rat IgG1, k eBioscience 0.2 mg/ml 4 µg/ml 1/50 
IL-17 FITC eBio17B7 Rat-IgG2aκ eBioscience 0.5 mg/ml 10 µg/ml 1/50 
IL-17 BV711 TC11-18H10.1 Rat IgG1, k Biolegend 0.2 mg/ml 4 µg/ml 1/50 
FOXP3 APC FJK-16s Rat-IgG2a,k eBioscience 0.2 mg/ml 4 µg/ml 1/50 
RORγT PE B2D Rat IgG1k eBioscience 0.2 mg/ml 4 µg/ml 1/50 
T-bet PerCP5.5 4B10 Mouse IgG1,k Biolegend  0.2 mg/ml 4 µg/ml 1/50 
 
Isotype controls  
Isotype 
 
Fluorochrome Clone Antibody 
Subclass 
Company Stock 
Concentration 
Working 
Concentration 
Dilution 
Golden 
Syrian 
hamster 
IgG 
PerCP n/a Golden 
Syrian 
hamster 
IgG 
eBioscience 0.2 mg/mL 10 µg/ml 1/50 
Rat IgG 
2b 
PE/Cy7 RTK207
1 
Rat IgG1, 
κ 
Biolegend 0.2 mg/ml 10 µg/ml 1/50 
RatIgG1 PE eBRG1 Rat IgG1, 
κ 
eBioscience 0.2 mg/ml 2 µg/ml (IFN-γ), 
4 µg/ml 
(RORγT) 
1/100 
(IFN-γ) 
1/50 
(RORγT) 
RatIgG1, k BV711 RTK207
1 
Isotype 
Control 
RatIgG1, k 
Biolegend 0.2 mg/ml 10 µg/ml 1/50 
RatIgG1κ4
88 
FITC eBRG1 Rat IgG1, 
κ 
Biolegend  0.5 mg/ml 10 µg/ml 1/50 
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Appendix IV Confocal microscopy  
 
 
 
 
 
 
 
Surface 
marker 
 
Fluorochrome Clone Antibody Subclass Company Stock 
Concentration 
Working 
Concentration 
Dilution 
CD45.1 FITC A20 Mouse (A.SW) IgG2a, 
k 
Biolegend 0.5 mg/ml 5 µg/ml 1/100 
Gr-1 eFluor660 RB6-
8C5 
Rat IgG2b, κ eBioscience 0.2 mg/mL 0.4 µg/ml 1/500 
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Appendix V Purity checks and gating strategies  
 
Purity check iNKT cells post bead sort. Mean frequency post sort 85%±11%. n=43.  
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Purity check iNKT cells post bead and sorter sort. Mean frequency post sort 85%±0%. n=5. 
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Purity check TEa T cells. Mean frequency post sort 87%±0.08%. n=20. 
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Purity check T cell depletion of BM. Mean frequency post sort of contaminating CD4
+
 T cells 
0.4±0.7%. CD8
+
 T cells 0.2±0.1%. n=15.  
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Purity check IFN-γ
+
 iNKT cells post bead and sorter sort. Mean frequency post sort 94%±6%. 
n=5. 
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Purity check RORγT
-
 iNKT cells post bead and sorter sort. Mean frequency post sort 87%±12%. 
n=3. 
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Purity check B6 BMDCs 53%±10%. n=5.  
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Purity check CB6F1 BMDCs 38%±16%. n=5.  
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